text stringlengths 65 123k | url stringlengths 25 420 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 01:00:57 2022-09-19 04:34:04 |
|---|---|---|
Fla. prison guards accused of beating inmate to death
MIAMI (CNN) - Four Florida Department of Corrections officers are facing murder charges after authorities say they beat a 60-year-old inmate to death.
Officers Christopher Rolon, 29, Kirk Walton, 34, and Ronald Connor, 24, were arrested Thursday and charged with murder. Officer Jeremy Godbolt, 28, was arrested Friday in Los Angeles, according to Florida’s Department of Law Enforcement. He is also charged with murder.
The alleged incident took place Feb. 14 when 60-year-old Ronald Ingram was being moved from a mental health area of the Dade Correctional Institute to another facility.
The inmate reportedly threw urine on one of the officers before they moved him.
FDLE says the officers then handcuffed the man and beat him so badly he had to be carried to the transport van.
A press release from authorities indicates Ingram was complying with officers at the time.
The inmate was found dead in the back of the van several hundred miles away, near Ocala. The medical examiner says he died from a punctured lung leading to internal bleeding. He also suffered injuries to his face and torso.
A Miami-Dade judge ruled there is probable cause to hold Rolon, Walton and Connor without bond until their next hearing.
Copyright 2022 CNN Newsource. All rights reserved. Gray News contributed to this report. | https://www.whsv.com/2022/05/02/fla-prison-guards-accused-beating-inmate-death/ | 2022-05-02T04:03:17Z |
- Wayne Taylor Racing duo drive the #10 Acura ARX-05 to victory for the second consecutive year at WeatherTech Raceway Laguna Seca
- Acura completes 1-2 sweep with second-place finish for #60 Meyer Shank Racing
- Fourth consecutive win at Laguna Seca for Acura in IMSA competition
MONTEREY, Calif., May 1, 2022 /PRNewswire/ -- Ricky Taylor and Filipe Albuquerque scored Acura's fourth consecutive win at WeatherTech Raceway Laguna Seca, today, leading an Acura 1-2 finish in their #10 ARX-05 prototype and recording their second straight victory at the classic California race circuit.
Starting from the pole in a front-row lockout for Acura, Taylor and co-driver Albuquerque combined to lead for 111 laps in the 117-lap race. The only time the pair lost the lead was to the Meyer Shank Racing #60 Acura ARX-05 driven by Tom Blomqvist and Oliver Jarvis. Jarvis and Blomqvist challenged their fellow Acura team throughout the day, with the #60 leading briefly following the second round of pit stops in the two-hour, 40-minute contest.
However, Albuquerque and Wayne Taylor Racing would take the lead back through an aggressive move in traffic. At the finish, Meyer Shank Racing would take the checkers just one second behind the #10 Wayne Taylor machine, giving Acura their second 1-2 finish of the year—the first being January's triumph at the Rolex 24 at Daytona, where Meyer Shank Racing led the Wayne Taylor Acura to the winning sweep.
After four of 10 races, the two Acura teams are tied for the lead in the 2022 IMSA WeatherTech SportsCar Championship points standings.
Acura NSX GT3 Evo22
In the production-based GTD class, the #51 Rick Ware Racing Acura NSX GT3 Evo22 driven by Aidan Read and Ryan Eversley, despite showing speed all weekend and making great strides at Laguna Seca, were thwarted by an improper pass-around during a caution period. The resulting penalty left them sitting on pit lane for several minutes as the field circulated. The team used the opportunity to make up for the very limited test time they had and made adjustments on the car to better prepare for the remainder of the season. The duo were ultimately classified 12th.
Monterey Sports Car Championship Acura Race Results
- 1st overall - #10 Ricky Taylor and Filipe Albuquerque, Wayne Taylor Racing Acura ARX-05 DPi
- 2nd overall - #60 Tom Blomqvist and Oliver Jarvis, Meyer Shank Racing Acura ARX-05 DPi
- 12th GTD - #51 Aidan Read and Ryan Eversely, Rick Ware Racing Acura NSX GT3 Evo22
Quotes
Ricky Taylor (#10 Wayne Taylor Racing ARX-05) Race winner: "A great day for Acura, first of all. It's their second one-two finish of the season and their fourth straight win at Laguna Seca. We knew it would be a strong one for us and we knew that having Acura finish one-two and maximize the points was the goal. It's nice that we had the Konica Minolta Acura leading the charge. I can't say enough about the team executing. All we needed to do this weekend was execute and do what we knew the car was capable of. To come away with maximum points and really close the gap in the championship was good."
Filipe Albuquerque (#10 Wayne Taylor Racing Acura ARX-05) Race winner: "I'm happy and relieved at the same time. We came to Laguna with a sense of duty. This is our best race track and it suits our car the best. We needed maximum points. It's always easy to say, but knowing that we have that responsibility, doing it is a different thing. There was a weight of a lot of pressure on top of us. I was just happy that Ricky did an amazing job in qualifying, securing pole by eight one-hundredths of a second. Taking off, it seemed like we were in control, but whenever I was pulling away, traffic was pushing me back. I was frustrated for a good portion of the race. When I was P2, I was really mad. I couldn't believe it. I'm happy that I found a little gap to put the car through and get the position back. Again, I was managing the race with the following car in my mirrors, but he never had a move to make on me. I'm glad those laps are over, but the car was great and the team did an amazing job."
Oliver Jarvis (#60 Meyer Shank Racing Acura ARX-05) Finished second: "It's been a really strong weekend. The team did a fantastic job and we made a lot of progress with the car. But, you know, when you take the lead in the race like that, and then to come away short, I can't help to feel a little bit disappointed. But Tom [Blomqvist, co-driver] was racing hard and did a fantastic job. The team has been superb all weekend and this is great for the points. I think we're in the lead of the championship or joint lead with the #10. A long way to go still, but you know if we can keep progressing I think we got a good chance the rest of the season."
David Salters (President and Technical Director, Honda Performance Development) on today's 1-2 finish for Acura at WeatherTech Raceway Laguna Seca: "Just a fantastic day! Congratulations to both of our Acura DPi teams. They certainly showed some 'Precision Crafted Performance', in true Acura style. Laguna Seca is a very special race track, so it's extremely rewarding to see our cars do well here. The Rick Ware Racing team made great progress with the Acura NSX this weekend, we appreciate their massive efforts. We can't wait to see what they are able to do at Mid-Ohio. Well done to everyone at Acura and HPD for working hard, it's great to see the fruit of their hard work in victory lane."
Fast Facts
- Acura Motorsports and HPD have a long, successful history at WeatherTech Raceway Laguna Seca, and now has recording 19 victories – more than at any other racing circuit – in Camel Lights, LMP1, LMP2, Prototype, GTD and DPi competition from 1992-2022.
- Acura's victory today is the fourth consecutive DPi win for the manufacturer, and the second in a row for Wayne Taylor Racing's Filipe Albuquerque and Ricky Taylor at this legendary road course.
- 2020 Helio and Ricky Taylor led a 1-2 sweep in DPi, with teammates Dane Cameron and Juan Pablo Montoya finishing second in their Acura ARX-05 prototype. In 2019, Cameron and Montoya claimed victory at Laguna Seca.
Next
Having completed its annual west coast swing with the Acura Grand Prix of Long Beach and Laguna Seca, the IMSA WeatherTech SportsCar Championship now heads back to America's heartland, resuming May 13-15 at the Mid-Ohio Sports Car Course.
Acura Motorsports social media content and video links from the WeatherTech Raceway Laguna Seca can be found on Instagram (www.instagram.com/hondaracing_hpd), Twitter (twitter.com/HondaRacing_HPD) and Facebook (www.facebook.com/HondaRacingHPD). Additional features and long-form videos can be found on the Honda Racing/HPD YouTube channel (https://www.youtube.com/HondaRacingHPDTV).
View original content to download multimedia:
SOURCE Acura Motorsports | https://www.whsv.com/prnewswire/2022/05/02/acura-dominates-with-1-2-finish-laguna-seca/ | 2022-05-02T04:03:23Z |
BANGALORE, India, May 2, 2022 /PRNewswire/ --South India's diversified Sona Group has forged a 50:50 joint venture with Australia's Mycelium Biotechnology Group to set up a state-of-the art Mycelium research and production facility in Salem.
Mycelium Biotechnology is an Australian group known for pioneering innovative solutions to optimise human and planetary health, using mycelium and other extracts from Mushrooms, an abundantly available and sustainable natural resource. As a global mushroom biotechnology group, Mycelium Biotechnology is engaged in mushroom growing, global distribution and offering biotechnology and nutraceuticals solutions through global partners.
According to Mr Chocko Valliappa, Vice Chairman of The Sona group, "We are happy to forge the Mycelium Sona Biotech joint venture with Australia's Mycelium Biotechnology, a research focused world leader in Mycelium based products and solution provider. The partnership will leverage Sona Group's research and innovation framework to add to the vast range of IP and patentable technologies."
The JV named as Mycelium Sona Biotech (MSB) has set up a research facility at Salem to focus on Nanotech Research, IP development, Extract Manufacturing, Milling, Bottling and eCommerce. Billed as one of the largest mushrooms laboratories in India at Salem with best Global Manufacturing Practices, MSB laboratory will research and grow high end mushrooms, extract Mushroom and Mycelium compounds, produce nutraceuticals that conform to FSSAI and FDA certification.
"We see great opportunity in the Indian market moving forward. Sona's background in health tech and research development is a perfect partnership for us to further advance our nano compound extraction IP. The launch of the first MSB facility in Salem comes at the most opportune time soon after signing of the Free Trade Agreement between Australia and India" says Mr William Scott, Chairman of Mycelium Biotechnology group.
With R&D, Business and Distribution centres located across Australia's East Coast as well as manufacturing facilities in Wisconsin (USA), Mycelium Biotechnology owns scores of IP. The bulk of this IP relates to cultivation methods and associated medium formulations for nearly 20 mushroom species, extraction processes of mushroom and mycelium biomass and formulations of mushroom extracts.
Some of the key portfolio companies expanding through the joint-venture include the following:
- REMbiotics, one of the divisions of Mycelium Biotechnology, addresses the global issue of depression (MDD, TRD, PTSD) using specific mushroom mycelium bioactive compounds combined with Australian native bush foods for a beneficial and synergistic effect.
- Shroompac focuses on mushroom and mycelium-derived sustainable eco-packaging materials for industrial and consumer applications.
- Preotica is an evolutionary life sciences company that has been focusing on enhancing animal immunity and microbial health. Utilising mycelium biotechnology extraction processes, the Preotica product has been able to produce some remarkable results, specifically in the poultry industry, aquaculture industry and for beekeepers across Australia.
The medicinal mushroom industry is expected to grow exponentially as more and more of the 5.1 million mushroom species are researched. The global fungi industry is forecast to exceed USD $86B by 2025, up from $53.7B in 2019. Growth will be powered in part by culinary demand, but an even larger driver will be rising adoption by the pharmaceutical industry. Varieties such as Chaga, not ever seen on a dinner plate, are now in the supplement spotlight.[1]
References
1 https://trends.co/signal/mushrooms-moment/
View original content:
SOURCE Mycelium Sona Biotech Pte Ltd | https://www.whsv.com/prnewswire/2022/05/02/india-embraces-shroom-boom-with-new-nano-laboratories-jv-salem/ | 2022-05-02T04:03:30Z |
Clay Township presses pause on rezoning Harsens Island property owned by Champion's operation
Clay Township officials are taking more time to weigh the rezoning of property on Harsens Island owned by the Champion’s ferry operation after neighbors aired concerns over what impact the business would have nearby.
The property at 1682 North Channel Drive is owned by Champion's Marine Inc., is zoned residential. Jacob Bryson, vice president at Champion’s Auto Ferry and a representative for Champion's Marine Inc., is asking the township to rezone the site for general business use.
“We’re planning on using this possibly for one building, possibly two for replacing our office building, as well as for enhancing and expanding our maintenance facility,” Bryson told planning commissioners this week. “We also currently use this property for loading and unloading of the DTE equipment to get those pieces of equipment to the out islands on Harsens Island. It’s the only piece of property we have where we can do that.”
He said he understood concerns about how the rezoning may affect the neighboring residential property, adding, “We actually are under land contract to purchase that property to use specifically for a buffer zone.” It was a four-year contract that, he said, began in 2020.
Bryson said the structure already on the property has been “vacant for decades” and that the home next door was also not occupied.
However, several residents and officials during a public hearing last week said the property seemed to be used for commercial purposes already.
Mark Kapanowski said he lives in the first-occupied home next to the ferry and was against the rezoning.
“To me the rezoning request does not make any sense,” he said. “There are two existing ferry company commercial properties that have larger, vacant land that is more suitable for an office and maintenance building.”
Kapanowski added he thought the rezoning would have “significant negative impacts of my property values and my way of life” with any Champion’s expansion resulting in “possible blight and unpleasant views.”
Others agreed — with one resident questioning the language of the request to “legitimately” use the property for office and storage use.
Planning commissioners asked Bryson why Champion’s was changing the site now after running ferry operations for decades, and Bryson said he was attempting to bring the property into compliance “as opposed to just willy-nilly doing what we want.”
Additionally, if they want to build on the property in the future, he said the rezoning would be needed.
“I want to get the zoning correct first, and I certainly don’t want to spend money on an architect to design buildings and site plans before I know if the zoning’s going to get changed,” Bryson said.
Commissioner Chris Hiltunen said it was also “a little concerning to me” that Champion’s already treated it as a commercial lot and was “coming to planning after the fact.”
“I personally don’t think it’s the biggest blight,” Hiltunen said, pointing to an area Champion’s operates he thought was a bigger blight. “… But it’s an eyesore, and I think it’s concerning to the citizens that you would want to expand a business and not take care of what you currently have.”
Kapanowski said he was also concerned about a rise in noise levels if a maintenance facility was located at 1682 North Channel Drive. He said he could already hear repair activity, playing a loud example recorded this month from his phone.
“I currently hear work being done on the ferry and in the maintenance buildings when the doors are open on a somewhat daily basis, whether it’s grinding of the ferries, grinding of metal in the maintenance building, hammering, whatever’s going on,” Kapanowski said. “… Imagine sitting out with your family out enjoying the weather, on your deck, in your pool, In your yard, and you hear noises coming from the ferry.”
Commissioners agreed to continue the public hearing to a future meeting, tabling the subject while they fact-find and get clarification about the issue. The planning commission typically meets at 7 p.m. on the fourth Wednesday of each month. Agenda materials are posted ahead of time at www.claytownship.org.
Contact Jackie Smith at (810) 989-6270 or jssmith@gannett.com. Follow her on Twitter @Jackie20Smith. | https://www.thetimesherald.com/story/news/2022/05/02/clay-township-presses-pause-rezoning-property-owned-champions-operation/9562651002/ | 2022-05-02T04:46:18Z |
Bluefield State soars past Alice Lloyd for senior day win
Big Blue leads whole way
Published: May. 2, 2022 at 12:44 AM EDT|Updated: 7 minutes ago
BLUEFIELD, Va. (WVVA) -Bluefield State notched its eighth win in nine games behind 4 RBI from Cole Cote.
The Big Blue scored three runs in the first inning and countered every Alice Lloyd attempted comeback.
Bluefield State won 10-8 and improved to 21-24 on the season.
Copyright 2022 WVVA. All rights reserved. | https://www.wvva.com/2022/05/02/bluefield-state-soars-past-alice-lloyd-senior-day-win/ | 2022-05-02T04:52:10Z |
Fla. prison guards accused of beating inmate to death
MIAMI (CNN) - Four Florida Department of Corrections officers are facing murder charges after authorities say they beat a 60-year-old inmate to death.
Officers Christopher Rolon, 29, Kirk Walton, 34, and Ronald Connor, 24, were arrested Thursday and charged with murder. Officer Jeremy Godbolt, 28, was arrested Friday in Los Angeles, according to Florida’s Department of Law Enforcement. He is also charged with murder.
The alleged incident took place Feb. 14 when 60-year-old Ronald Ingram was being moved from a mental health area of the Dade Correctional Institute to another facility.
The inmate reportedly threw urine on one of the officers before they moved him.
FDLE says the officers then handcuffed the man and beat him so badly he had to be carried to the transport van.
A press release from authorities indicates Ingram was complying with officers at the time.
The inmate was found dead in the back of the van several hundred miles away, near Ocala. The medical examiner says he died from a punctured lung leading to internal bleeding. He also suffered injuries to his face and torso.
A Miami-Dade judge ruled there is probable cause to hold Rolon, Walton and Connor without bond until their next hearing.
Copyright 2022 CNN Newsource. All rights reserved. Gray News contributed to this report. | https://www.wvva.com/2022/05/02/fla-prison-guards-accused-beating-inmate-death/ | 2022-05-02T04:52:16Z |
BASEL, Switzerland, May 2, 2022 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributor of the Eversense® continuous glucose monitoring (CGM) system, announces a new study demonstrating that people who use the connected CONTOUR® BGM systems (BGMS) and CONTOUR®DIABETES App (CDA) for at least six months can see a reduced frequency of hypoglycaemic and hyperglycaemic blood glucose readings (BGRs). BGRs in these out-of-target ranges can lead to serious health complications, suggesting a key benefit of using Ascensia's connected CONTOUR® BGMS and CDA together (the CDA system). Real-world data from this study were presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2022.
The study, which assessed data from 7,047 CDA system users in Australia, demonstrated a reduction in frequency of BGRs within both hypoglycaemic (low) and hyperglycaemic (high) ranges. After six months, the estimated frequency of BGRs in high and very high ranges in people using the CDA system fell by more than 6.5-times and 5.6-times, respectively, compared to baseline. This decrease was more prominent among users who reported the use of oral antidiabetic medications, at 7.37-times less than baseline. The decrease of BGRs in the low range was modest at 1.2-times in the entire assessed population, and at 1.38-times in CDA system users who were treated with insulin and are more prone to hypoglycaemic events. These data suggest improved glycaemic control when using the CDA system for at least six months and, more generally, a key benefit in using connected BGMS, including apps, to support the management of diabetes.
The majority of CDA system users in the assessed group were people with type 2 diabetes (66.9%), for whom improvement of glycaemic control is associated with the reduced progression of diabetes-related complications[1]. As diabetes apps continue to permeate clinical care, these findings offer the potential to explore how connected BGMS with visibility and accessibility of blood glucose readings can support self-management for people with type 1 and type 2 diabetes.
Frank Held, Head BGM Marketing and Strategy at Ascensia Diabetes Care, said: "We're pleased to see results from the study showcasing that our CDA system is helping people with diabetes to manage their condition. While many diabetes apps support people with diabetes in managing their condition, they don't all provide alerts or guidance for hypoglycaemic or hyperglycaemic events, like the CONTOUR®DIABETES App does. Failure to properly address these events can result in serious health complications, so it is crucial that monitoring systems and connected apps facilitate the detection of high and low blood glucose levels."
Before this study, there were limited data assessing the impact of diabetes apps in Australia, particularly in a 'real world' setting. In addition, while evidence suggests that there are hundreds of diabetes apps that support people with diabetes in managing their blood glucose, only a third of these apps have alerts or guidance for hypoglycaemic and or hyperglycaemic events[2]. If these events are not addressed, they can become severe and lead to serious complications[3], so it is of utmost importance that monitoring tools help people with diabetes to manage these events.
The poster featuring this research, titled 'Assessment of Blood Glucose Readings of People with Diabetes in Australia who were using the connected CONTOUR®BGMS and CONTOUR®DIABETES App,' was presented from a study led by Wendy Mak PhD, Scott Pardo PhD, PStat®, and Rimma Shaginian, MD, MPH. ATTD 2022 took place in Barcelona, Spain from April 27-30, 2022.
1. Stratton, IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPD 35); prospective observational study. BMJ 2000; 321: 205-412.
2. Lum E, Jimenez G, Huang Z et al (2019) Decision support and alerts of apps for self-management of blood glucose for type 2 diabetes. JAMA 321(15):1530 1530–1532. https://doi.org/10.1001/jama.2019.1644.
3. Mayo Clinic. 2022. Hyperglycemia in diabetes - Symptoms and causes. [online] Available at: https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631 [Accessed April 2022].
Logo - https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg
View original content:
SOURCE Ascensia Diabetes Care | https://www.whsv.com/prnewswire/2022/05/02/ascensia-diabetes-care-presents-new-research-showing-that-people-using-contour-blood-glucose-monitoring-system-app-experience-fewer-out-of-target-blood-glucose-levels/ | 2022-05-02T05:37:49Z |
The Texan firm is offering *72-month no-interest financing on their bathroom remodels.
HOUSTON , May 2, 2022 /PRNewswire/ -- Homeowners in Houston and surrounding areas of the Lone Star State who are struggling to finance their bathroom renovations due to increased living costs and gas prices can now capitalize on the best financing plan that the industry has ever seen courtesy of EZ Bath.
An Unprecedented Finance Plan for Unprecedented Times
With millions of Americans still struggling from the fallout of the pandemic, inflation and increased living costs have caused many households to think twice before committing to their intended home upgrade projects, including much-needed bathroom updates. EZ Bath's new *72-month zero-interest plan gives homeowners an opportunity to combat inflation by facilitating renovations that are more affordable than ever.
Unprecedented times call for unprecedented action and the six-year no interest plans enable homeowners to spread the costs and avoid compounding interest rates while additionally receiving a world-class service from a professional team of designers and builders that was awarded the Angie's List Super Service Award in 2021 to go alongside its BBB accreditation and Home Advisor Elite Service Award.
The best financing product for new bathrooms in Texas, which is immediately available, allows homeowners to upgrade their properties right away while also supporting cash flow for short-term financial challenges such as handling the high gas prices and other forms of inflation.
Modern Bathroom Upgrades For Modern Living
For many families, updating the bathroom isn't just an aesthetic upgrade. It's a matter of necessity to fix broken items or adapt to changing life circumstances. EZ Bath offers an extensive range of products to complete the perfect transition. The list includes tub to shower conversions, shower remodels, walk-in bathtubs, frameless glass shower upgrades, bathtub remodels, and tub shower combos for both full and small bathroom remodeling projects.
While many of those updates are built with accessibility and function in mind, EZ Bath also delivers versatile design options across many styles. From traditional to modern looks, or earth tones to black and white, the options are plentiful and can be tailored to match the needs of the family as well as the bathroom's spatial limitations.
All remodels and products, extending to faucets and Karndean flooring, can be included in the *72-month zero-interest plan while the offer is open to clients across all of the company's service areas.
About EZ Bath
We are a bathroom remodeling company that specializes in using solid surface walls for the tub and shower area. The company serves clients throughout Houston, Cypress, Kingwood, The Woodlands, Tomball, Katy, Spring, Sugar Land, and the surrounding areas while also offering free consultations and quotes.
*Subject to credit approval, for current information about this financing program, call us at 1-800-431-5921. More information can be found by visiting https://www.ezbathremodel.com. Alternatively, EZ Bath press contact Mitchell Clay can be reached at 281-968-3000, Mail queries may be addressed to 11246 Timber Tech, Tomball TX 77375.
View original content to download multimedia:
SOURCE EZ Bath | https://www.whsv.com/prnewswire/2022/05/02/ez-bath-is-helping-their-customers-combat-inflation-high-gas-prices/ | 2022-05-02T05:37:55Z |
GENEVA, May 2, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, today announces that it has increased its equity stake in strategic partner ArtSci Biology Technologies (Hangzhou) Co., Ltd ("ArtSci") moving to majority ownership, subject to registration by local authorities. ArtSci and Firmenich have been strategic partners since 2019, when Firmenich took a minority equity stake. This move will further strengthen Firmenich's ability to serve the rapidly growing Chinese local market and extend its geographic reach across China. ArtSci will continue to operate as normal, with its management team remaining in place and fully committed to serving ArtSci customers.
"Firmenich is committed to investing and growing in China following our decades' long commitment to this key market," said Gilbert Ghostine, CEO, Firmenich. "I am delighted to announce that we have moved to majority ownership of ArtSci in our established strategic partnership, which will open up new avenues of growth as we continue to combine ArtSci's intimate understanding of Chinese customers, geographic reach and agility, with Firmenich's innovation capabilities, consumer insights and unparalleled product quality."
"We are proud of the achievements of our strategic partnership with ArtSci, which combines their local expertise and agile business model with our industry-leading technology, creation and manufacturing," said Paul Andersson, President, Firmenich China, "ArtSci is a dynamic and entrepreneurial company, and we are excited to move to the next phase of our partnership to better serve the rapidly growing Chinese market."
"Firmenich is a highly valued strategic partner, and we look forward to the next step in our journey, as we continue to work with them and combine our passion for innovation and customer service, to meet the evolving needs of consumers in China," said Wang Ying, Chairman, ArtSci.
China is a key strategic market for Firmenich, with compelling structural dynamics that will drive future growth opportunities for the Group. Firmenich has been investing consistently for more than 30 years to expand its footprint and capabilities in China. Recent investments include Firmenich's largest flavor manufacturing plant in the world, opened in Zhangjiagang in 2019, and the company's first sensorial co-creation center in Guangzhou, opened in 2021, to respond with agility to local customer demands for tailored fragrance and health-conscious taste solutions. Firmenich has a nationwide presence of commercial facilities, with application laboratories in Shanghai, Beijing, and Guangzhou, manufacturing facilities in Shanghai, Kunming and Zhangjiagang, and a major research center in Shanghai.
About Firmenich
Firmenich, the world's largest privately-owned fragrance and taste company, was founded in Geneva, Switzerland, in 1895, and has been family-owned for 126 years. Firmenich is a leading business-to-business company specialized in the research, creation, manufacture and sale of perfumes, flavors and ingredients. Renowned for its world-class research and creativity, as well as its leadership in sustainability, Firmenich offers its customers superior innovation in formulation, a broad and high-quality palette of ingredients, and proprietary technologies including biotechnology, encapsulation, olfactory science and taste modulation. Firmenich had an annual turnover of 4.3 billion Swiss Francs at end June 2021. More information about Firmenich is available at www.firmenich.com.
About ArtSci
Founded in 2005 and headquartered in Hangzhou, Zhejiang Province, ArtSci is a Chinese taste company specialized in dairy and beverages, as well as bakery and confectionery. With more than 130 employees, it serves China's middle market with a broad distribution network across China.
Logo - https://mma.prnewswire.com/media/798187/Firmenich_Logo.jpg
View original content:
SOURCE Firmenich | https://www.whsv.com/prnewswire/2022/05/02/firmenich-moves-majority-ownership-artsci-capitalize-high-growth-chinese-taste-market/ | 2022-05-02T05:38:02Z |
- Winning companies are turbo-charging performance with digital-enabled "machinery as a service," Bain & Company finds. But intensifying competition is leaving laggards' products commoditized
- Win-win opportunity from sweeping changes is reinforced by a "Great Retooling" as industries worldwide move to meet sustainability challenge of global push for net-zero carbon emissions
- M&A and PE dealmaking surges as digital transformation drives jump in returns and valuations, while firms and investors respond to challenge from Chinese competitors in the vanguard of change
BOSTON and MUNICH, May 2, 2022 /PRNewswire/ -- The global machinery and equipment industry stands at a critical moment as it confronts a whirlwind of disruptive forces, facing its leaders with fundamental and accelerating change over the next decade. In its first Global Machinery & Equipment Report, Bain & Company analyses the wave of digital-driven transformation sweeping the sector.
The report explains how the emerging winners from these powerful trends are embracing "machinery beyond the machine," experimenting aggressively beyond the industry's traditional boundaries. It reveals how this strategic approach is propelling winning companies past competitors in a high-stakes race that is turbocharging sales growth and profits—as well as fueling a surge in mergers and acquisitions (M&A) activity and private equity (PE) dealmaking. And it maps out the key moves that machinery and equipment players can make over the next two to three years to tackle this transformational agenda.
"The tectonic shifts reshaping the entire machinery sector are being driven by rapidly intensifying competition, a slowdown in hardware-centered innovation, and the power of digitalization to radically change virtually every aspect of the business," Michael Staebe, leader of Bain & Company's Global Machinery and Equipment practice, said. "The industry's traditional focus on smarter, faster, cheaper machines as the key to drive growth no longer gives any guarantee of success. Even the most technologically advanced machines, and their makers, are not immune from disruption."
Instead, the report shows that the fundamental transition now happening takes the industry "beyond the machine" to "machinery as a service." This means combining makers' hardware with software, automation and services developed around the machines. It means delivering tightly integrated solutions that are precisely tailored to customers' needs—and within dramatically altered new business models.
Services-based solutions are "shape of things to come" for machinery
The report sets out how this critical shift to a digitally-enabled and services-based 'bundled solutions' model is already developing at pace. Bain & Company's research projects that in the industrial automation sector, where this shift is well underway, the share of profits coming from hardware will fall from 31% today to just 23% by the end of the decade. The rest of the profit will come from bundled software, services and solutions. In some sectors, companies already generate more than half of sales and 100% of their profits from services.
"This trend is accelerating and will become the norm—the shape of things to come—for the industry in the next few years," Thomas Lustgarten, leader of Bain & Company's Global Advanced Manufacturing & Services practice, said. "By 2030, Bain projects that the leading machinery companies will sell most equipment as only a part of bundled solutions that include software and services, further cutting hardware's contribution to profits. In many cases, companies making this shift have the chance to capture market growth rates several times those of their current businesses."
Among the top machinery companies, Bain & Company found that the average annualized total shareholder return was 32% from 2019 to 2021, compared with a mere 4% among the industry's laggards. But most machinery and equipment companies have so far been slow to act. Bain finds that fewer than 5% of industrial companies have successfully executed a technologically or digitally based transformation.
"Industrials that put effort into digital are four-times more likely to outperform the competition—but two out of three digital laggards are worse performers than the competition, according to Bain & Co.'s 2019 survey of 205 industrial businesses," Lustgarten adds.
"Great Retooling" for global sustainability and net-zero creates multi-decade opportunity
The sweeping machinery sector transformations triggered by the forces of digitalization and "Industry 4.0" are only part of the story for the machinery and equipment sector, however. The reshaping of the industry also presents an enormous opportunity for its companies to give a powerful response to the global push for businesses of all kinds to meet and master the challenges of sustainability and environmental responsibility: to become more energy efficient, less wasteful, and to tailor operations to improve the circularity and recyclability of machinery products.
As in other industries, machinery makers are already changing operations and supply chains to reduce greenhouse gas and carbon emissions and pursue net-zero goals. But for this sector, the implications go deeper. Because every industry is changing, a "Great Retooling" is underway as nearly every industrial and manufacturing company rethinks its operations. Machinery businesses that quickly grasp the potential and develop the products and services to allow customers to meet decarbonization goals, are likely to gain first-mover advantage in a huge transition set to last decades rather than years, the report finds.
Spate of supply chain shocks fuel retooling for resilience
The global opportunities of rising to sustainability goals, as well as from this Great Retooling trend, are closely tied to the challenge posed by a new era of supply chain vulnerability. Over the past two years, a spate of major supply chain disruptions has battered the machinery sector, from materials shortages and price fluctuations sparked by the global pandemic to, most recently, the consequences of the war in Ukraine. These and future unexpected disruptions reinforce and extend the market for machinery makers to equip customers for the future with the equipment that ensures more resilient and sustainable supply chains.
Bain & Company's research shows that supply chain executives across all industries have shifted investments to prioritize resilience and flexibility over cost and speed. Machinery companies are on the front line to provide the tools and equipment to meet these objectives while simultaneously meeting the urgent aim of greater resilience for their own operations. Digital tools are important here, too, and can help firms manage supply chain risks, improve efficiency and measure environmental impact and cost in real time.
Companies at the forefront of this evolution have a head start in building competitive advantage in the markets of 2030 and beyond. They are building new capabilities, such as supply risk assessments, to bolster their customers and their own operations. As such, they will also bounce back faster in times of supply disruption and gain from a tailwind of support from customers, investors and regulators.
China's industry vanguard of innovative insurgents drives imperative for strategic change
While the machinery sector's winners over the coming decade will move aggressively to expand their business ecosystem beyond machinery, other companies will struggle to keep up. Those that fail to climb the software and automation ladder, focus on tailored solutions for "verticals" specific sectors, and adapt to the new business models, will be at risk from the growing commoditization of machines sold purely as hardware. Chinese manufacturers are rapidly developing competing, lower-cost hardware.
The competitive challenge is underscored by the reality that China is also in the vanguard of the broader industry trends examined in the report, with Chinese tech start-ups and other insurgents introducing a new generation of innovative service offerings. The cloud service Machine Commander, offered by the Chinese start-up Zeaho, offering real-time monitoring of construction sites to improve equipment efficiency is one example: it has 135,000 units of equipment connected to its cloud-based platform just seven years since it was founded.
To defend their turf, equipment markets are increasing investments in digital technologies and accelerating the rollout of advanced services. For example, 100% of original equipment manufacturers (OEMs) surveyed by Bain & Company plan to offer "predictive maintenance" of machines by 2024. 95% will provide remote maintenance, and new services geared to operational efficiency.
M&A jumps to decade-highs as companies accelerating moves to buy in capabilities
The wave of change across the machinery sector is also stimulating a surge in dealmaking as many companies and their investors reshape business portfolios in the face of the evolving industry dynamics. Industrial machinery manufacturers have a growing appetite for big deals as they accelerate these strategies.
The jump in M&A activity means that the average deal size in the sector shot up to an average of $179 million in 2020 and $161 million in 2021 breaking the prior downward trend seen up to 2017. Last year's $63 billion global deal value was the sector's second highest annual total in the past decade, only exceeded by 2020's $72 billion tally.
"For machinery executives, M&A provides access to higher-growth and strategically-critical markets. These leaders are leaning-in to acquire new capabilities around software, the Internet of Things (IoT), artificial intelligence and connectivity – and at higher valuations, as they move to meet the challenge from the sector's digitalization and move to service-driven, solutions-based business models," Michael Staebe said. "We don't expect momentum to slow for large M&A deals in the machinery sector."
PE drives faster pulse of machinery dealmaking on rising valuations and returns
As in M&A, the machinery industry is now among the most active industrial sectors for global PE dealmaking—and machinery and equipment deals are outperforming those in other industrial sectors.
Some of the largest industrial PE deals have been in machinery, such as Advent and Cinven's €17.2 billion ($20.2 billion) purchase of Thyssenkrupp Elevators in 2020. Over the past decade, Bain & Company finds that such deals produced returns 10% higher than for industrials as whole, as shown by a median multiple on invested capital (MOIC) of 2.5. Over the same period, the enterprise value of machinery companies grew 1.9-fold.
Winning PE firms are spotting opportunities to reposition traditional machinery businesses amid the broad trends reshaping the sector. Top performing funds are taking a holistic approach to value creation, looking well beyond cost structures to tap all areas of potential improvements, including commercial and service excellence, pricing, and M&A potential.
Media contacts:
For more information, or to arrange an interview with one of the report's expert authors, please contact
Gary Duncan, Head of Public Relations (EMEA)
gary.duncan@bain.com Tel: +44 (0)7788 163 791 (mobile/cell) (London)
About Bain & Company
Bain & Company is a global consultancy that helps the world's most ambitious change makers define the future.
Across 63 offices in 38 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition, and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster, and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise, and insight to organizations tackling today's urgent challenges in education, racial equity, social justice, economic development, and the environment. We earned a gold rating from EcoVadis, the leading platform for environmental, social, and ethical performance ratings for global supply chains, putting us in the top 2% of all companies. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.
View original content to download multimedia:
SOURCE Bain & Company | https://www.whsv.com/prnewswire/2022/05/02/machinery-enters-brave-new-world-beyond-machine-digital-drives-high-stakes-race-growth-bain-amp-company/ | 2022-05-02T05:38:08Z |
Collaboration brings a new, exclusive line of high-quality dog supplies, apparel, toys and travel gear made for the outdoors to Petco pet care centers, petco.com, the Petco app and Backcountry.com
SAN DIEGO, May 2, 2022 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (Nasdaq: WOOF) and Backcountry, the premier outdoor specialty retailer, today announced the launch of "Backcountry x Petco," an exclusive collection of pet gear designed for outdoor enthusiasts and active dogs. Backcountry and Petco collaborated on the premium, innovative assortment, including dog supplies, apparel, accessories, toys and travel products for summer, plus a subsequent line launching in the fall. The summer line is now available exclusively at most Petco pet care centers nationally, as well as at petco.com/backcountry, the Petco app and backcountry.com/petco.
"84% of Backcountry customers have dogs in the household and consider their furry friends important members of the family," says Backcountry CEO, Melanie Cox. "Backcountry has always cherished adventure pets, so our partnership with Petco couldn't be a more natural fit. When you bring together outdoor experts and the best in pet care, you end up with a thoughtfully crafted product line for pets at the same quality we expect as humans. We're proud to offer premium products built to connect family members to the outdoors, whether they have two legs or four."
"Backcountry x Petco" features easy to clean, water- and stain-resistant fabrics, as well as a variety of apparel and accessory styles to accommodate dogs of all shapes and sizes. The collection provides pets and pet parents with durable, trustworthy products that help keep pets happy and healthy as they accompany their humans on every outing.
"With more pets in homes than ever before and continued interest in shared outdoor experiences, there's a whole new generation of pet parents eager to explore the outdoors – and bring their pets along for the ride," said Aaron Weiss, Senior Vice President, Owned Brands at Petco. "Our customers are looking for functional solutions, tailored to the changing seasons, that really hold up and offer protection against the elements for outdoor activities like camping and hiking. Our partnership with Backcountry has allowed us to combine our more than 55 years' worth of expertise in designing pet products with their top-notch experience in all things outdoors for a premier line of pet gear that helps active pets thrive and meets the evolving needs of our customers."
Designed to help pets remain safe and protected during outdoor activities, the collection ranges from apparel and accessories such as dog t-shirts, jackets and bandanas and supplies like collars, harnesses, leashes and flotation devices, to sturdy toys for physical and mental stimulation and travel necessities including collapsible food and water bowls, foldable crates, and portable sleeping bags and travel mats.
For more information on the "Backcountry x Petco" collection, visit petco.com/backcountry and backcountry.com/petco.
About Petco, The Health + Wellness Co.:
Petco is a category-defining health and wellness company focused on improving the lives of pets, pet parents and our own Petco partners. Since 1965, we've consistently set new standards in pet care while delivering comprehensive pet wellness products, services and solutions, and creating communities that deepen the pet-pet parent bond. We operate more than 1,500 pet care centers across the U.S., Mexico and Puerto Rico, which offer merchandise, companion animals, grooming, training and a growing network of on-site veterinary hospitals and mobile veterinary clinics. Our complete pet health and wellness ecosystem is accessible through our pet care centers and digitally at petco.com and on the Petco app. In tandem with Petco Love (formerly the Petco Foundation), an independent nonprofit organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we've helped find homes for more than 6.5 million animals.
About Backcountry
From the one-on-one expertise of our Gearheads to our epic selection of the best in both style and performance, Backcountry has been a leading outdoor retailer since 1996. Dialing in your gear closet, exploring your backcountry, recharging with après—Backcountry elevates the entire outdoor experience. In 2018, Backcountry began building its own Gearhead-inspired products; the fast-growing Built By Backcountry ski, MTB, climb, hike, fly fish, and après lines include collabs with brands like GORE-TEX Technology, Burton, and Simms. Seek it, find it, send it—the Goat takes you further.
Media Contacts:
For Petco:
Yvonne Tarrab
yvonne.tarrab@petco.com
For Backcountry:
Katie Hostetler
katie.hostetler@rygr.us
970-924-0704 ext: 2108
View original content to download multimedia:
SOURCE Petco Health and Wellness Company, Inc. | https://www.whsv.com/prnewswire/2022/05/02/petco-backcountry-team-up-outdoor-pet-gear-collection/ | 2022-05-02T05:38:14Z |
...SMALL CRAFT ADVISORY NOW IN EFFECT UNTIL 6 PM HST MONDAY...
* WHAT...East to northeast winds 20 to 25 knots.
* WHERE...All Hawaiian Coastal Waters.
* WHEN...Until 6 PM HST Monday.
* IMPACTS...Conditions will be hazardous to small craft.
PRECAUTIONARY/PREPAREDNESS ACTIONS...
Inexperienced mariners, especially those operating smaller
vessels, should avoid navigating in these conditions.
&&
During National Small Business Week, business owners in Hawaii want to get the word out that supporting local shops is the easiest and most affordable way to support the economy.
“Death by Scrapbooking” is a pop shop in Windward Mall selling locally-made cards and crafts. Owner, Stefanie Ontai says she supports local artists by allowing them to share their products in her store.
“Being a small business in Hawaii, not everything can be made here. We do have to outsource some products but at the same time, when you shop local, you know where your money is going,” said Ontai.
After Ohana Hale Marketplace was shut down to build a luxury condo, Genova Hawaiian Jewelry relocated to Ala Moana. Owner, Diana Genova, said she views the move as a positive but says business is currently slow.
"When we were in Ohana, it was a really nice concept because all locals are shopping with us. Our prices are low. It was a community we had over there but unfortunately because of big corporations, we were forced to move out,” said Genova.
Genova says it’s crucial to support local business now more than ever.
“Some of us are fortunate enough to find a location like we did, but some of them had to be shut down. We feel blessed that we are here. we don’t know anybody yet and a lot of our customers don’t know we’re out here. However, we are trying our best to stay afloat,” said Genova.
Both business owners say they go out of their way to keep prices affordable which includes only partnering with local vendors that will also build community.
Do you have a story idea? Email news tips to news@kitv.com | https://www.kitv.com/multimedia/national-small-business-week-kicks-off/article_d99beba4-c9ce-11ec-bf04-f7fd83f1a604.html | 2022-05-02T05:38:15Z |
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe | https://www.kitv.com/news/local/after-a-two-year-hiatus-kapiolani-park-welcomes-back-lei-day/article_d4db8872-c9ce-11ec-9662-0bc37b9d565e.html | 2022-05-02T05:38:21Z |
HELSINKI, May 2, 2022 /PRNewswire/ -- Dual Miners (www.dualminers.com/) have crossed the $20million USD mark in pre-orders and sales. Dual Miners has announced the official introduction of three mining rigs that have the potential to change the worldwide crypto industry. They have recently earned the distinction of becoming the first company to ever produce an extraordinary range of endothermic cryptocurrency mining rigs.
Image:
https://s3-ap-southeast-2.amazonaws.com/mnr-s3-prod/0029/000481_dualpremium.jpg
Dual Miners has used ASIC chip technology to create three solutions that are pre-configured for ease of use and promise a return on investment in as little as one month, led by some of the most experienced specialists in the Cryptocurrency mining industry.
DualPro, DualPro Max, and the most recent DualPremium are the company's current products, which support profitable operations on the blockchain of choice, according to a statement.
Dual Miners is a chip design and manufacturing firm established in London, with offices in Finland, South Korea, and Australia. It has a number of teams with in-depth understanding of, among other things, Blockchain technology and technological design.
The company provides graphics processing units to consumers in addition to providing crypto wallet development services. On three continents, the company has offices. Due to its extensive experience in the market, Dual Miners has acquired a solid name in the Blockchain industry.
As a result, Dual Miners will cover both shipping and import duties, allowing consumers to spend no more than the cost of the device and obtain everything they need to get started without incurring additional fees.
About Dual Miners
Dual miners, which bills itself as the world's first dual-mining firm, was founded in 2015 with the goal of developing and selling the world's first leading dual Cryptocurrency miners that use either SHA-256 or Scrypt technology, respectively. With the DualPro, we set out to provide more power at a lower cost than had previously been available. Dual Miners is headquartered in London, United Kingdom, and maintains offices in other locations throughout the globe. On the website www.dualminers.com, you may find out more about the company.
More details at www.dualminers.com
View original content:
SOURCE Dual Miners | https://www.whsv.com/prnewswire/2022/05/02/rise-new-dual-miners-technology/ | 2022-05-02T05:38:21Z |
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe | https://www.kitv.com/news/local/celebrate-national-pet-month-with-kitv4-and-share-your-photos/article_9025fbbc-c993-11ec-a0be-2bd6fec4cd58.html | 2022-05-02T05:38:27Z |
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe | https://www.kitv.com/news/local/hfd-extinguishes-two-story-building-fire-on-varsity-circle/article_5dfa9268-c9a9-11ec-aa65-53cc11c5afc9.html | 2022-05-02T05:38:33Z |
HONOLULU (KITV) -- More than 50% of over 100-million requested medical specialist referrals are not completed each year in the United States.
That is according to the Institute of Healthcare Improvement, which says 20% of those incomplete referrals have resulted in a misdiagnosis.
It's those statistics that are the driving force for Hawai'i digital health startup, TeleMedicX, focused on making access to care faster by streamlining the referral process.
Currently, the referral process can be frustrating and often time consuming. Taking weeks or even months for patients to be connected to a medical specialist for the care they need.
"Access to care now is currently very slow because of fax, manual phone calls, manual insurance check, so the focus is automating the referral process from PCP to a specialty doctor," explained Nour Lababidi.
33-year-old Lababidi got the idea for TeleMedicX in 2020. The idea came to him after an excellent recovery experience from a paragliding accident in Annecy, France 4-years-ago.
You can watch the video of that accident below:
Lababidi was in France practicing for a Red Bull paragliding competition when he crashed into a house. He says he thought his life was over.
Lababidi now fully recovered, credits quick access to care, but a friend of his who suffered a similar accident wasn't as lucky.
"Same similar accident happened to my friend John in Hawaii, also paragliding accident and with different care resulted in very different outcome. He’s handicap for rest of his life," said Lababidi.
Lababidi went to the University of Hawai'i at Manoa to study entrepreneurship and learn how to launch his startup.
And now, less than two years from when the idea was born, TeleMedicX is about to be piloted by the Pacific Vascular Institute located in Aiea.
"I think what Nour is trying to do is really a game changer," said Amr El-Sergany.
El-Sergany is the Medical Director at PVI.
"Vascular disease in Hawai’i and around the world is overwhelming specialists and there is no way to create more doctors. All we can do is make access to care more efficient and more effective."
TeleMedicX works by connecting primary care doctors directly to specialists.
"It’s really nice when medical health records communicate with each other, but what do we do when they don’t," said Dr. Delaram Taghipour.
Taghipour is the Veinous and Lymphatic medicine specialist and PVI.
"We still want to be able to communicate provider to provider and this really provides us that touch point where we can talk to our colleagues and really have a way to share HIPAA compliant information, get access, and get questions for our patients answered really quickly which is awesome."
When it comes to vascular care, how quickly a patient is seen can mean the difference between saving or amputating a limb.
"What this system allows us to do is we can go into that referral and see if this is something we need to see right away or is this something less urgent on the list," said El-Sergany.
Funding
"Their innovation is about improving the experience for patients, but in particular cancer patients and the ability to get these patients to see specialists because timing is important and timing is going to save lives," said Dr. Mona Jhaveri.
"There are so many people that don’t receive the proper treatment because the path wasn’t paved for them."
Jhaveri is a cancer researcher by training as well as the Founder and Director of Music Beats Cancer, a non-profit organization, with a mission to raise funds for cancer research and innovation.
According to the Music Beats Cancer website:
A severe funding gap remains for innovators who are developing promising technologies for fighting cancer. Most of these technologies will fail before they get a chance to prove their possibility – this is not always because the science is bad – but rather, because they lack the funding to succeed.
This funding breakdown, known as the “Valley of Death,” where great ideas go to die, fully impedes progress in reducing the cancer burden.
Music Beats Cancer wants to change this by leveraging the power and passion of people and music to help raise funds and awareness of promising cancer innovations that would otherwise linger in the Valley of Death.
"What they have is real, implementable and possible, what they need is money," said Jhaveri.
TeleMedicX has a campaign on Music Beats Cancer, check it out here.
"When people get behind something and they share that with their doctor the people become part of the ecosystem to make something happen," said Jhaveri. "Their donated dollar is a vote for an innovation to move forward."
Get started with TeleMedicX
"I see great value for the referral process to be fixed, streamlined, easy, and cost effective. I would say its almost a no brainer to implement this," said Jhaveri.
TeleMedicX's customers are doctors offices with patients benefiting through the connection.
Lababidi's plan is to do a full launch and on-boarding of other customers by July 1, 2022.
TeleMedicX is taking limited preorders now, click here to learn more. | https://www.kitv.com/news/local/improving-access-to-health-care-new-hawaii-digital-startup-telemedicx/article_999e48c6-c9b5-11ec-86a0-6fd16893f9fb.html | 2022-05-02T05:38:39Z |
ROCK SPRINGS – The 7th annual Power of the Purse auction fundraiser gave new meaning to ‘girls’ night out’ on Saturday, April 30 at Holiday Inn in Rock Springs.
Deer Trail Assisted Living sponsored the event.
“The event benefits services such as Hospice of Sweetwater County and VIRS to fill the financial gap for families to have the medical care they deserve,” said Kolbi McKenzie, owner of Elements Integrative Wellness and coordinator for Power of the Purse. “We wanted to honor those who didn’t quit no matter what. This includes doctors, nurses, first responders, teachers, our local garbage collectors – everyone on the front-line.
“Whether you give a little or a lot, when we come together, it’s powerful.”
The dress attire for this year’s sold-out event was white. A few attendees and volunteers even showed up wearing angel wings.
Executive Director of Hospice Nicole Mandros pointed out that as a non-profit organization, they help provide services to those who don’t have insurance.
“I like the work we do and the team we have,” said Mandros. “It’s a wonderful program.”
Rock Springs resident Sandy DaRif has served as the committee chairwoman for Walk to End Alzheimer’s for several years.
“You see hospice go hand-in-hand with the Alzheimer’s patients,” DaRif mentioned. “It’s tough on those who have loved ones with this disease and it comforts them when they can get help from groups like hospice and respite care.”
She added, “When the women here are bidding their hearts out, they are making a difference for those families and individuals.
“It takes a special person to do the job of hospice.”
Robin Fife, clinical administrative assistant at Memorial Hospital of Sweetwater County was looking at which purse she should bid on with her daughter, Jessi.
“It’s always fun to come together for a cause,” said Fife. “And I get to bring my daughter with me – that's the best!”
Melissa Searle, executive director of Respite Care, expressed the importance of relief time for personal caregivers.
“They can’t continue to care for their loved ones if they don’t take care of themselves,” Searle shared. “That’s why we’re here.
“Since the seventies, we’ve been fulfilling the needs of our community. There are representatives who have been with us for decades.”
Pam Nebeker Tolman, author and hypnotherapist, was the keynote speaker. She discussed her struggles with multiple sclerosis.
The evening, according to McKenzie, was about healing.
“Even if you haven’t lost someone due to 2020, you know someone who has been affected by the loss of someone they love in 2020,” she said.
Volunteers from the Rock Springs High School Health Academy assisted with the event.
“These students are the generation that will provide health care,” McKenzie revealed.
According to the Hospice of Sweetwater County’s website, the organization’s mission is to provide high quality, individualized care to patients who are facing an end of life journey. They extend their support and services to the patient’s family and caregivers from admission through the bereavement.
Go to myhsc.org for more information. | https://www.wyomingnews.com/rocketminer/when-times-are-difficult-angels-are-among-us/article_60097b78-d618-54a8-8e93-c2dd0ccecfb6.html | 2022-05-02T05:51:33Z |
Kenny Osborne retires after 22 seasons as Concord WBB Head Coach
Osborne won 306 games with Lady Mountain Lions
Published: May. 2, 2022 at 1:04 AM EDT|Updated: 1 hour ago
ATHENS, W.Va. (WVVA) -Kenny Osborne has called it a career after 22 seasons on the sideline for the Lady Mountain Lions.
He led Concord to six 20-win seasons and coached 13 1,000-point scorers among other accolades.
Copyright 2022 WVVA. All rights reserved. | https://www.wvva.com/2022/05/02/kenny-osborne-retires-after-22-seasons-concord-wbb-head-coach/ | 2022-05-02T06:27:26Z |
Suspect arrested in fatal shooting of man walking his dog
LOS ANGELES (KCAL/KCBS) - Police in Texas arrested a man suspected of randomly shooting a man who was walking his dog in Los Angeles and leaving him on the street to die.
A single red rose marks the spot where 52-year-old Marcos Sandoval’s life came to an unnecessary and violent end. The March 12 shooting, which investigators believe was random and unprovoked, was caught on camera in his Mid-City neighborhood in Los Angeles.
Surveillance footage shows a vehicle pull up next to Sandoval before a couple shouts are heard, followed by shots fired.
The accused shooter, who fled in a Ford Fusion, was arrested Wednesday in San Marcos, Texas, with the help of the FBI’s Fugitive Task Force. Detectives have filed a murder charge against 21-year-old Cliffton Kamal Styles.
Authorities say Styles went on a cross-county road trip before arriving in Los Angeles and allegedly killing Sandoval. Afterward, he traveled to San Diego then back to Texas.
Though Styles may be in custody, Sandoval’s family is left with plenty of questions, mainly trying to answer why their beloved patriarch was killed.
“He would always put me and my sister first, before anyone,” said one of Sandoval’s daughters at a vigil shortly after the shooting.
Police haven’t determined a motivation in the crime but say Styles may have been suffering from mental illness.
Raymond walks his dog in the same neighborhood where Sandoval was killed. He says he’s been shaken up about his safety ever since.
“It’s kind of scary that this close and something so cold-blooded occurred,” he said. “I’m just astounded by that. I mean, the reasoning behind that, as to the why he would drive all the way here to do some kind of crazy mess like that.”
Police believe Styles may have been involved in other acts of predatory violence during his extensive trip. They are asking anyone who knows anything about other crimes Styles may have committed to contact them.
Styles is awaiting extradition back to Los Angeles.
Copyright 2022 KCAL/KCBS via CNN Newsource. All rights reserved. | https://www.wvva.com/2022/05/02/suspect-arrested-fatal-shooting-man-walking-his-dog/ | 2022-05-02T06:27:32Z |
Suspect arrested in fatal shooting of man walking his dog
LOS ANGELES (KCAL/KCBS) - Police in Texas arrested a man suspected of randomly shooting a man who was walking his dog in Los Angeles and leaving him on the street to die.
A single red rose marks the spot where 52-year-old Marcos Sandoval’s life came to an unnecessary and violent end. The March 12 shooting, which investigators believe was random and unprovoked, was caught on camera in his Mid-City neighborhood in Los Angeles.
Surveillance footage shows a vehicle pull up next to Sandoval before a couple shouts are heard, followed by shots fired.
The accused shooter, who fled in a Ford Fusion, was arrested Wednesday in San Marcos, Texas, with the help of the FBI’s Fugitive Task Force. Detectives have filed a murder charge against 21-year-old Cliffton Kamal Styles.
Authorities say Styles went on a cross-county road trip before arriving in Los Angeles and allegedly killing Sandoval. Afterward, he traveled to San Diego then back to Texas.
Though Styles may be in custody, Sandoval’s family is left with plenty of questions, mainly trying to answer why their beloved patriarch was killed.
“He would always put me and my sister first, before anyone,” said one of Sandoval’s daughters at a vigil shortly after the shooting.
Police haven’t determined a motivation in the crime but say Styles may have been suffering from mental illness.
Raymond walks his dog in the same neighborhood where Sandoval was killed. He says he’s been shaken up about his safety ever since.
“It’s kind of scary that this close and something so cold-blooded occurred,” he said. “I’m just astounded by that. I mean, the reasoning behind that, as to the why he would drive all the way here to do some kind of crazy mess like that.”
Police believe Styles may have been involved in other acts of predatory violence during his extensive trip. They are asking anyone who knows anything about other crimes Styles may have committed to contact them.
Styles is awaiting extradition back to Los Angeles.
Copyright 2022 KCAL/KCBS via CNN Newsource. All rights reserved. | https://www.whsv.com/2022/05/02/suspect-arrested-fatal-shooting-man-walking-his-dog/ | 2022-05-02T07:09:27Z |
LOD, Israel, May 2, 2022 /PRNewswire/ --
First Quarter Highlights
- Quarterly revenues increased by 12.8% year-over-year to $66.4 million.
- Quarterly service revenues increased by 26.2% year-over-year to $27.5 million.
- GAAP results:
- Quarterly GAAP gross margin was 66.9%;
- Quarterly GAAP operating margin was 12.1%; and
- Quarterly GAAP net income was $8.6 million, or $0.26 per diluted share. - Non-GAAP results:
- Quarterly Non-GAAP gross margin was 67.2%;
- Quarterly Non-GAAP operating margin was 18.0%; and
- Quarterly Non-GAAP net income was $11.2 million, or $0.33 per diluted share. - Net cash provided by operating activities was $938,000 for the quarter.
- AudioCodes declared a cash dividend of 18 cents per share. The dividend, in the aggregate amount of $5.8 million, was paid on March 1, 2022 to shareholders of record on February 15, 2022.
- AudioCodes repurchased 720,124 of its ordinary shares during the quarter at an aggregate cost of $20.9 million.
Details
AudioCodes (NASDAQ: AUDC), a leading vendor of advanced communications software, products and productivity solutions for the digital workplace, today announced its financial results for the first quarter ended March 31, 2022.
Revenues for the first quarter of 2022 were $66.4 million compared to $58.8 million for the first quarter of 2021.
Net income was $8.6 million, or $0.26 per diluted share, for the first quarter of 2022 compared to $10.0 million, or $0.29 per diluted share, for the first quarter of 2021.
On a Non-GAAP basis, net income was $11.2 million, or $0.33 per diluted share, for the first quarter of 2022 compared to $12.7 million, or $0.37 per diluted share, for the first quarter of 2021.
Non-GAAP net income excludes: (i) share-based compensation expenses; (ii) amortization expenses related to intangible assets; (iii) expenses related to deferred payments in connection with the acquisition of Callverso Ltd; (iv) other income related to a payment made by the landlord to AudioCodes Inc., a subsidiary of the Company, in connection with the termination of a lease agreement for its offices in New Jersey; (v) financial income related to exchange rate differences in connection with revaluation of assets and liabilities in non-dollar denominated currencies; and (vi) non-cash deferred tax expenses (income). A reconciliation of net income on a GAAP basis to a non-GAAP basis is provided in the tables that accompany the condensed consolidated financial statements contained in this press release.
Net cash provided by operating activities was $938,000 for the first quarter of 2022. Cash and cash equivalents, long and short-term bank deposits, long and short-term marketable securities and long-term financial investments were $144.1 million as of March 31, 2022 compared to $174.8 million as of December 31, 2021. The decrease in cash and cash equivalents, long and short-term bank deposits long and short-term marketable securities and long-term financial investments was the result of the use of cash for the continued repurchasing of the Company's ordinary shares pursuant to its share repurchase program and the payment of a cash dividends during the first quarter of 2022.
"We are pleased to report solid top-line financial results for the first quarter of 2022, growing 12.8% year-over-year," said Shabtai Adlersberg, President and Chief Executive Officer of AudioCodes.
"Strong sales in the Unified Communications and Collaboration (UCC) business were the key driver for our continued growth in the first quarter of 2022. Revenue growth acceleration was reflected mainly in enterprise sales in the Microsoft Teams Voice and the Zoom Phone environments which grew each above 50% year-over-year. Microsoft business as a whole grew above 25% year over year. AudioCodes Live for Microsoft Teams managed services continue to grow at a nice clip. We now forecast Live for Teams ARR to double in 2022 and reach a level of above $30 million. The second important driver of growth is attributed to service revenues which grew above 25% year-over-year. The services business growth was driven primarily by professional services and AudioCodes Live managed services. Exiting the first quarter of 2022, services revenue reached a level of 41.5% of total company revenue. We regard this momentum as an important indicator of our ongoing successful transformation to cloud services and recurring revenue model.
"In our customer experience market business (CX), we continue to see great progress with our conversational AI business where total contract value (TCV) signed during the quarter grew 40% year-over-year. We are now confident that we are well on track to grow our conversational AI business more than 50% in 2022. We are glad to report that the acquisition of Callverso at the end of 2021 started to bear fruit with a growing number of new opportunities for intelligent virtual agent (IVA) solutions for the CX market. Following our success in the Israeli market with IVA applications, we have plans to start addressing the global market in the second half of 2022. Finally, our Voice.ai Connect platform which powers voice interactions for the growing market of chatbots, our conversational IVR for contact centers, and AI-powered call recording in enterprise applications, performed well above our expectations. As such, we strongly believe in our ability to develop a new meaningful growth engine to fuel further success in our core markets," continued Mr. Adlersberg.
"On the operational front, first quarter 2022 non-GAAP operating margin came in at 18%, 240 basis points below last quarter's, nearly all of which was attributable to $1.4 million higher components costs affecting our gross margins. The higher non-GAAP operating expenses and change in non-GAAP operating margin on an annual basis was the result of increase of 17% in headcount and related budget to support our business expansion and higher components costs, both of which are expected to continue throughout this year but subside in 2023 and beyond," concluded Mr. Adlersberg.
Share Buy Back Program and Cash Dividend
In December 2021, the Company received court approval in Israel to purchase up to an aggregate amount of $35 million of additional ordinary shares. The court approval also permits AudioCodes to declare a dividend of any part of this amount. The approval is valid through June 19, 2022.
On February 1, 2022, the Company declared a cash dividend of 18 cents per share. The dividend, in the aggregate amount of approximately $5.8 million, was paid on March 1, 2022 to all of the Company's shareholders of record on February 15, 2022.
During the quarter ended March 31, 2022, the Company acquired 720,124 of its ordinary shares under its share repurchase program for a total consideration of $20.9 million.
As of March 31, 2022, the Company had $8.3 million available under this approval for the repurchase of shares and/or declaration of cash dividends.
Conference Call & Web Cast Information
AudioCodes will conduct a conference call at 8:30 A.M., Eastern Time today to discuss the Company's first quarter of 2022 operating performance, financial results and outlook. Interested parties may participate in the conference call by dialing one the following numbers:
United States Participants: 888-506-0062
International Participants: +1 (973) 528-0011
The conference call will also be simultaneously webcast. Investors are invited to listen to the call live via webcast at the AudioCodes investor website at http://www.audiocodes.com/investors-lobby
First quarter of 2022 earnings call supplementary slides are available at AudioCodes investor website at http://www.audiocodes.com/investors-lobby
Follow AudioCodes' social media channels:
AudioCodes invites you to join our online community and follow us on: AudioCodes Voice Blog, LinkedIn, Twitter, Facebook, and YouTube.
About AudioCodes
AudioCodes Ltd. (NASDAQ, TASE: AUDC) is a leading vendor of advanced communications software, products and productivity solutions for the digital workplace. AudioCodes enables enterprises and service providers to build and operate all-IP voice networks for unified communications, contact centers, and hosted business services. AudioCodes offers a broad range of innovative products, solutions and services that are used by large multi-national enterprises and leading tier-1 operators around the world.
For more information on AudioCodes, visit http://www.audiocodes.com.
Statements concerning AudioCodes' business outlook or future economic performance; product introductions and plans and objectives related thereto; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements'' as that term is defined under U.S. Federal securities laws. Forward-looking statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. These risks, uncertainties and factors include, but are not limited to: the effect of global economic conditions in general and conditions in AudioCodes' industry and target markets in particular; shifts in supply and demand; market acceptance of new products and the demand for existing products; the impact of competitive products and pricing on AudioCodes' and its customers' products and markets; timely product and technology development, upgrades and the ability to manage changes in market conditions as needed; possible need for additional financing; the ability to satisfy covenants in the Company's loan agreements; possible disruptions from acquisitions; the ability of AudioCodes to successfully integrate the products and operations of acquired companies into AudioCodes' business; possible adverse impact of the COVID-19 pandemic on our business and results of operations; and other factors detailed in AudioCodes' filings with the U.S. Securities and Exchange Commission. AudioCodes assumes no obligation to update the information in this release.
©2022 AudioCodes Ltd. All rights reserved. AudioCodes, AC, HD VoIP, HD VoIP Sounds Better, IPmedia, Mediant, MediaPack, What's Inside Matters, OSN, SmartTAP, User Management Pack, VMAS, VoIPerfect, VoIPerfectHD, Your Gateway To VoIP, 3GX, VocaNom, AudioCodes One Voice, AudioCodes Meeting Insights, AudioCodes Room Experience and CloudBond are trademarks or registered trademarks of AudioCodes Limited. All other products or trademarks are property of their respective owners. Product specifications are subject to change without notice.
Summary financial data follows
(1) Share-based compensation expenses related to options and restricted share units granted to employees and others.
(2) Amortization expenses related to intangible assets.
(3) Expenses related to deferred payments in connection with the acquisition of Callverso Ltd.
(4) Other income related to a payment made to AudioCodes Inc. in connection with the termination of a lease agreement for its offices in New Jersey.
(5) Financial income related to exchange rate differences in connection with revaluation of assets and liabilities in non-dollar denominated currencies.
(6) Non-cash deferred tax expenses (income).
Note: Non-GAAP measures should be considered in addition to, and not as a substitute for, the results prepared in accordance with GAAP. The Company believes that non-GAAP information is useful because it can enhance the understanding of its ongoing economic performance and therefore uses internally this non-GAAP information to evaluate and manage its operations. The Company has chosen to provide this information to investors to enable them to perform comparisons of operating results in a manner similar to how the Company analyzes its operating results and because many comparable companies report this type of information.
View original content:
SOURCE AudioCodes | https://www.whsv.com/prnewswire/2022/05/02/audiocodes-reports-first-quarter-2022-results/ | 2022-05-02T07:09:34Z |
Continuing our success and growth in digital gaming, MGM Resorts is expanding internationally with the acquisition of LeoVegas
LeoVegas' global presence, strong team and technology capabilities to drive MGM Resorts' digital gaming and sports betting international development
LAS VEGAS, May 2, 2022 /PRNewswire/ -- MGM Resorts International (NYSE: MGM) ("MGM Resorts" or the "Company") today announced that it has commenced a recommended public tender offer for 100% of the shares of LeoVegas AB (publ) ("LeoVegas") at a price of SEK 61.00 in cash per share, equivalent to a total tender value of approximately $607 millioni. The acquisition will be financed with existing cash and is expected to be accretive to MGM Resorts' earnings and cash flow per share.
"Our vision is to be the world's premier gaming entertainment company, and this strategic opportunity with LeoVegas will allow us to continue to grow our reach throughout the world," said MGM Resorts' CEO & President Bill Hornbuckle. "We have achieved remarkable success with BetMGM in the U.S., and with the acquisition of LeoVegas in Europe we will expand our online gaming presence globally. We believe that this offer creates a compelling opportunity that allows the combined teams of MGM Resorts and LeoVegas to accelerate our global digital gaming growth and fully realize the potential of our omnichannel strategy. We look forward to being able to welcome the LeoVegas team to our MGM Resorts family."
Founded in 2011 by Gustaf Hagman and Robin Ramm-Ericson, LeoVegas is a leading global online gaming company with licenses in eight jurisdictions primarily in the Nordics and rest of Europe. LeoVegas generated EUR 393 million in revenue and EUR 48 million in Adjusted EBITDAii during the last twelve months ended March 31, 2022. The business is headquartered in Stockholm with offices in Malta, United Kingdom and Milan.
MGM Resorts believes the acquisition of LeoVegas will provide a unique opportunity for the Company to create a scaled global online gaming business with the following attributes:
- Strategic Opportunities to Accelerate Growth and Product Offerings – LeoVegas' online casino and sports betting capabilities and strong customer base outside of the U.S. is expected to further expand MGM Resorts' presence around the world.
- Experienced Online Gaming Management Team and Superior Technology Capabilities – LeoVegas' management team has demonstrated the ability to develop a robust and scalable technology platform with advanced product offerings.
- Commitment to Continued Profitable Growth – LeoVegas has operated profitably as a high-growth platform since 2014. From 2017 to 2021, LeoVegas' revenues compounded annual growth rate was 16%, while maintaining strong profitability. MGM Resorts' scale, brands and expertise will allow the combined businesses to expand within existing gaming segments and provide incremental opportunities to enter new areas.
The acceptance period of the offer is expected to commence on or around June 2022 and expire on or around August 2022. An offer document regarding the offer is expected to be made public shortly before the commencement of the acceptance period. Assuming that the offer is declared unconditional no later than around end of August 2022, settlement is expected to begin around early September 2022.
The offer is subject to certain regulatory approvals, the receipt of valid tenders of more than 90% of LeoVegas' shares and customary closing conditions. It is expected to be completed during the second half of fiscal year 2022.
Advisors
MGM Resorts has retained Goldman Sachs & Co. LLC. as financial advisor, Advokatfirman Vinge KB and Weil, Gotshal & Manges LLP as legal counsel and Fox Rothschild as gaming counsel in connection with the offer.
About MGM Resorts International
MGM Resorts International (NYSE: MGM) is an S&P 500® global entertainment company with national and international locations featuring best-in-class hotels and casinos, state-of-the-art meetings and conference spaces, incredible live and theatrical entertainment experiences, and an extensive array of restaurant, nightlife and retail offerings. MGM Resorts creates immersive, iconic experiences through its suite of Las Vegas-inspired brands. The MGM Resorts portfolio encompasses 32 unique hotel and gaming destinations globally, including some of the most recognizable resort brands in the industry. The Company's 50/50 venture, BetMGM, LLC, offers U.S. sports betting and online gaming through market-leading brands, including BetMGM and partypoker. The Company is currently pursuing targeted expansion in Asia through the integrated resort opportunity in Japan. Through its "Focused on What Matters: Embracing Humanity and Protecting the Planet" philosophy, MGM Resorts commits to creating a more sustainable future, while striving to make a bigger difference in the lives of its employees, guests, and in the communities where it operates. The global employees of MGM Resorts are proud of their company for being recognized as one of FORTUNE® Magazine's World's Most Admired Companies®. For more information, please visit us at www.mgmresorts.com. Please also connect with us @MGMResortsIntl on Twitter as well as Facebook and Instagram.
Forward-Looking Statements
Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and other effects of the offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as "anticipates", "intends", "expects", "believes", "estimates", "plans", "will be" or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Actual results and developments may differ materially from those expressed in, or implied or projected by these forward-looking statements due to many factors, many of which are outside the control of MGM Resorts. Forward-looking statements appear in a number of places throughout this announcement and the information incorporated by reference into this announcement and may include statements regarding the expectations on the closing of the offering and the intentions, beliefs or current expectations of MGM Resorts or LeoVegas concerning, amongst other things: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies, the expansion and growth of MGM Resorts' or LeoVegas' business operations and potential synergies resulting from the offer; and (iii) the effects of government regulation and industry changes on the business of MGM Resorts or LeoVegas. Any forward-looking statements made herein speak only as of the date on which they are announced. Except as required by the Takeover Rules or applicable law or regulations, MGM Resorts expressly disclaims any obligation or undertaking to publicly announce updates or revisions to any forward-looking statements contained in the offer document to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. The reader should, however, consult any additional disclosures that MGM Resorts or LeoVegas have made or may make.
A long form of this release and further information is available at: http://investors.mgmresorts.com/investors/leovegas
MGM RESORTS CONTACTS
Investment Community:
ANDREW CHAPMAN, Director of Investor Relations
(702) 693-8711, achapman@mgmresorts.com
News Media:
BRIAN AHERN, Executive Director of Communications
media@mgmresorts.com
i Based upon 97,652,970 outstanding shares of LeoVegas and a USD/SEK exchange rate of 9.814.
ii Definition of Adjusted EBITDA per LeoVegas' financial reports. The amount has been calculated as the sum of the Adjusted EBITDA figures in LeoVegas' financial reports for the second, third and fourth quarters 2021 and the first quarter 2022.
View original content to download multimedia:
SOURCE MGM Resorts International | https://www.whsv.com/prnewswire/2022/05/02/mgm-resorts-international-announces-offer-acquire-global-online-gaming-company-leovegas/ | 2022-05-02T07:09:41Z |
Global technology leader reaffirms commitment to the future of manufacturing in European region
JACKSONVILLE, Fla. and KARLSRHUE, Germany, May 2, 2022 /PRNewswire/ -- Revalize, the worldwide leader in revenue operations software for manufacturers, their distributors, and their specifiers, announced today that Marc Maurer will join the organization as the Managing Director for EMEA. In this role, he will be responsible for all revenue-related activities, leading the EMEA team, and driving overall culture and productivity.
Revalize is growing at an accelerated pace, and supporting a global market of more than 15,000 customers worldwide. With the expanded offerings and reach, Revalize aims to enhance its market position as the worldwide leader in Design, PLM, and CPQ solutions for manufacturers, and the only global, at-scale provider of manufacturing software solutions.
"I am thrilled to be joining the Revalize team," states Marc Maurer. "The company has already proven itself as the premier revenue platform for thousands of organizations across the globe. Moreover, Revalize has significantly expanded and strengthened its portfolio in Europe through several large acquisitions that build on our capabilities to address the challenges our customers are facing. The rapid uptake on digitalization by manufacturers makes this an exciting time in our industry, and I'm looking forward to leading the EMEA team to further growth and our customers to success."
Maurer has a strong technology background, and experience implementing software best practices to professionalize operations of European-based software companies so that they can better serve their customers. His appointment further expands Revalize's capabilities to support end-to-end, idea-to-cash workflows and strengthens the brand's operational presence in Europe at a critical time for the company.
"Europe now accounts for nearly half of our business worldwide and by appointing Marc as our Managing Director EMEA, we aim to further strengthen our position," says Jim Contardi, CEO of Revalize. "Thanks to his leadership capabilities and extensive experience in enterprise software, Marc is the right person to bring our brand to the next level and make us an even better partner for our European customers."
In his previous role as Portfolio Manager for Constellation Software Inc., Maurer acquired, integrated, and operated several highly specialized B2B software companies in the DACH region. Prior to Constellation, he held sales leadership positions at SAP, SAS Institute, and Nokia. Marc earned a PhD from the University of Zurich and enjoys hiking in the Swiss mountains.
Learn more about Revalize and its solutions, as well as employment opportunities globally, at www.revalizesoftware.com.
About Revalize
Revalize is the global leader in sector-specific software that helps manufacturers optimize revenue operations through design applications, engineering simulations, product selection, CPQ, PLM, visualization, and data analytics. Headquartered in Jacksonville, FL, the company serves over 15,000 customers across the globe. Revalize is a portfolio company of TA Associates and Hg. Learn more at www.revalizesoftware.com.
Contact: RevalizePR@teamlewis.com
View original content to download multimedia:
SOURCE Revalize | https://www.whsv.com/prnewswire/2022/05/02/revalize-appoints-marc-maurer-managing-director-emea/ | 2022-05-02T07:09:47Z |
DoorDash driver saves unconscious customer’s life during delivery
FAIRHAVEN, Mass. (Gray News) - A DoorDash delivery driver rushed into action when she found her customer unconscious and bleeding on the ground outside her house. Police say she saved the woman’s life.
The Fairhaven Police Department honored Sophia Furtado with a Life Saving Award for “her courageous actions that directly resulted in a life saved” on April 20, according to a department Facebook post.
While working for DoorDash in February, Furtado found a woman, later identified as Caryn Sullivan, on the ground and alone outside a house she was delivering to around 10 p.m., CNN reports. Sullivan was unconscious and bleeding from her head, police say.
Sullivan told CNN that while waiting for her order, she fell and hit her head on the way down.
“I just remember laying on my driveway, thinking, ‘This is pretty much over,’” she said. “I was laying there and saw a lot of white clouds.”
But when Furtado arrived, she sprang into action. She had previously spent time training as an emergency medical technician, according to CNN.
After calling 911, police say Furtado wrapped a blanket around Sullivan’s head and applied direct pressure to the bleeding wound. She kept Sullivan stable and updated dispatchers on her condition.
When first responders arrived, Furtado continued helping until Sullivan was taken to the hospital.
Police say Sullivan went into emergency surgery at 2 a.m. for severe brain bleeds. Her doctor says if there had been any delay in her care, she would have died.
“Any first responder can tell you, what Sophia did that night was not something anyone would just do,” wrote police on Facebook. “She saved a life.”
Sullivan spent weeks in the hospital after the incident and months recovering. She credits Furtado with saving her life.
“I am so thankful for her. She’s my guardian angel,” Sullivan told CNN. “Thank God, she was there. If she wasn’t there, I’d be dead.”
DoorDash awarded Furtado a $1,000 educational grant. She hopes to use the money toward more EMT school, CNN reports.
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.wvva.com/2022/05/02/doordash-driver-saves-unconscious-customers-life-during-delivery/ | 2022-05-02T07:58:41Z |
DoorDash driver saves unconscious customer’s life during delivery
FAIRHAVEN, Mass. (Gray News) - A DoorDash delivery driver rushed into action when she found her customer unconscious and bleeding on the ground outside her house. Police say she saved the woman’s life.
The Fairhaven Police Department honored Sophia Furtado with a Life Saving Award for “her courageous actions that directly resulted in a life saved” on April 20, according to a department Facebook post.
While working for DoorDash in February, Furtado found a woman, later identified as Caryn Sullivan, on the ground and alone outside a house she was delivering to around 10 p.m., CNN reports. Sullivan was unconscious and bleeding from her head, police say.
Sullivan told CNN that while waiting for her order, she fell and hit her head on the way down.
“I just remember laying on my driveway, thinking, ‘This is pretty much over,’” she said. “I was laying there and saw a lot of white clouds.”
But when Furtado arrived, she sprang into action. She had previously spent time training as an emergency medical technician, according to CNN.
After calling 911, police say Furtado wrapped a blanket around Sullivan’s head and applied direct pressure to the bleeding wound. She kept Sullivan stable and updated dispatchers on her condition.
When first responders arrived, Furtado continued helping until Sullivan was taken to the hospital.
Police say Sullivan went into emergency surgery at 2 a.m. for severe brain bleeds. Her doctor says if there had been any delay in her care, she would have died.
“Any first responder can tell you, what Sophia did that night was not something anyone would just do,” wrote police on Facebook. “She saved a life.”
Sullivan spent weeks in the hospital after the incident and months recovering. She credits Furtado with saving her life.
“I am so thankful for her. She’s my guardian angel,” Sullivan told CNN. “Thank God, she was there. If she wasn’t there, I’d be dead.”
DoorDash awarded Furtado a $1,000 educational grant. She hopes to use the money toward more EMT school, CNN reports.
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.whsv.com/2022/05/02/doordash-driver-saves-unconscious-customers-life-during-delivery/ | 2022-05-02T08:41:05Z |
- Valour approved by Finansinspektionen, the Swedish Financial Supervisory Authority (SFSA), to extend its single digital asset distribution from Top 75 to Top 125 by market capitalisation.
- The extension opens the door for greater diversification for Valour's clients.
TORONTO, May 2, 2022 /PRNewswire/ - DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (NEO: DEFI) (GR: RMJR) (OTCQB: DEFTF), a technology company bridging the gap between traditional capital markets and decentralized finance, announced today that Valour Inc. ("Valour"), its wholly owned subsidiary and a pioneer in digital asset exchange traded products ("ETPs"), has received approval to extend its distribution from the Top 75 single digital assets by market capitalisation to the Top 125.
The approval from Finansinspektionen, the Swedish Financial Supervisory Authority ("SFSA"), supplements Valour's base prospectus and will enable Valour to distribute ETPs across the Swedish and EU markets involving the Top 125 single digital assets.
The criteria for the Top 125 are based on data regarding market capitalisation and price per unit in USD as published on coinmarketcap.com.
"With this extension we are opening the door for our clients to access more digital assets and a greater range of innovative technologies. Demand for our ETPs has been tremendous in the first months of 2022 and we're pleased to be able to bring our clients increased diversity with ease and in a cost-effective way," said Tommy Fransson, CEO of Valour. "We see this as a natural development as we continue to develop our products and make digital asset investment exposure secure and accessible."
Valour offers fully hedged digital asset ETPs with low to zero management fees, with product listings across four European exchanges. Valour's existing product range includes Valour Uniswap (UNI), Cardano (ADA), Polkadot (DOT), Solana (SOL), Avalanche (AVAX) and Terra Luna (LUNA) ETPs – as well as Valour's flagship Bitcoin Zero and Valour Ethereum Zero products, the first fully hedged, passive investment product with Bitcoin (BTC) and Ethereum (ETH) as underlyings which are completely fee-free, with competitors charging up to 2.5% in management fees.
Learn more about DeFi Technologies and Valour at defi.tech and valour.com.
Valour Inc. issues exchange-listed financial products that enable retail and institutional investors to access investment in disruptive innovations, such as digital assets, in a simple and secure way. Established in 2019 and based in Zug, Switzerland, Valour is a wholly owned subsidiary of DeFi Technologies Inc. (NEO: DEFI, GR: RMJ.F, OTCQB: DEFTF). For more information on Valour, visit www.valour.com.
DeFi Technologies Inc. is a technology company bridging the gap between traditional capital markets and decentralized finance. Our mission is to expand investor access to industry-leading decentralized technologies which we believe lie at the heart of the future of finance. On behalf of our shareholders and investors, we identify opportunities and areas of innovation, and build and invest in new technologies and ventures in order to provide trusted, diversified exposure across the decentralized finance ecosystem. For more information or to subscribe to receive company updates and financial information, visit https://defi.tech/.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to: the approval by SFSA of Valour's distribution of ETPs; the growth and adoption of decentralized finance; the pursuit by DeFi Technologies of business opportunities; the development of future ETPs and the merits or potential returns of any such opportunities. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited to, the growth and development of the DeFi and cryptocurrency sector; rules and regulations with respect to DeFi; regulatory approval of ETPs and future adoption of Valour's ETPs. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
THE NEO STOCK EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
View original content to download multimedia:
SOURCE DeFi Technologies, Inc. | https://www.whsv.com/prnewswire/2022/05/02/defi-technologies-subsidiary-valour-gains-approval-extend-distribution-single-digital-assets-top-75-top-125/ | 2022-05-02T08:41:11Z |
Conference Call Scheduled for May 24, 2022 at 9:00am ET
HAIFA, Israel, May 2, 2022 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it will be releasing its first quarter 2022 financial results on Tuesday, May 24, 2022.
Results Conference Call
The Company will also be hosting a conference call on that same day at 9:00am Eastern Time. On the call, management will review and discuss the results and will be available to answer questions. To participate, please call one of the teleconferencing numbers that follow:
US Dial-in Numbers: 1-866-744-5399
Canada Dial-in Numbers: 1-866-485-2399
ISRAEL Dial-in Number: +972-3-918-0644
INTERNATIONAL Dial-in Number: +972-3-918-0644
at 9:00am Eastern Time; 6:00am Pacific Time; 4:00pm Israel Time
This call will also be transmitted live on Elbit Systems' website at http://www.elbitsystems.com. An online replay will be available from 24 hours after the call ends.
Alternatively, for two days following the call, investors will be able to dial a replay number to listen to the call. The dial-in numbers are: 1-888-782-4291 (US and Canada) or +972-3-925-5900 (Israel and International).
About Elbit Systems
Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance ("C4ISR"), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios, cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems.
For additional information, visit: https://elbitsystems.com, follow us on Twitter or visit our official Facebook, Youtube and LinkedIn Channels.
Company Contact:
Joseph Gaspar, Senior Executive VP – Business Management
Tel: +972-77-2948661
j.gaspar@elbitsystems.com
Dr. Yaacov (Kobi) Kagan, Executive VP - CFO
Tel: +972-77-2946663
kobi.kagan@elbitsystems.com
Rami Myerson, Director, Investor Relations
Tel: +972-77-2948984
rami.myerson@elbitsystems.com
David Vaaknin, VP, Head of Corporate Communications
Tel: +972-77-2946691
david.vaaknin@elbitsystems.com
IR Contact:
Ehud Helft
Kenny Green
GK Investor Relations Tel: 1-646-201-9246
elbitsystems@gkir.com
This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management's current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies and anticipated trends in its business. Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings. The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.'s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.
Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies. All other brand, product, service and process names appearing are the trademarks of their respective holders. Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.
View original content:
SOURCE Elbit Systems Ltd. | https://www.whsv.com/prnewswire/2022/05/02/elbit-systems-schedules-first-quarter-2022-results-release-may-24-2022/ | 2022-05-02T08:41:18Z |
Leveraging accurate and up-to-date on-street and off-street parking data and driving behaviors,
Parking Demand helps predict parking usage, reduce last-mile congestion, and cut emissions
KIRKLAND, Wash., May 2, 2022 /PRNewswire/ -- Today, INRIX, Inc., a world leader in mobility analytics and connected car services, announced INRIX Parking Demand, a first-of-its-kind innovation to identify exact areas in each city experiencing high parking demand and predict future needs. By combining up-to-date parking and vehicle data, automakers, businesses, and cities now have access to accurate parking predictions to help reduce congestion, stress, and tail pipe emissions.
INRIX Parking Demand combines insights from INRIX Parking and INRIX Trips to better understand driving behavior by incorporating historical, real-time, and predictive parking availability information along with trip insights to provide a complete picture of the local parking demand. Automakers, public sector, and businesses can integrate Parking Demand into existing systems and easily scale to meet evolving needs, unlike alternative solutions that require hardware and are expensive to purchase, install, and maintain.
"Parking is a complex equation and historically it's challenging to provide drivers with an accurate prediction of parking availability at their destination," said Greg Corley, senior vice president of automotive at INRIX. "INRIX Parking Demand improves the driver experience by identifying the parking hot spots near their destination. We help our customers tap into reliable, high-quality data to optimize parking operations from end-to-end without new costly hardware."
Automakers, businesses, and cities can tap into Parking Demand to identify parking hot spots, improve product experience and address parking pain for customers, for example:
- Automakers can now direct drivers to the most appropriate parking lots, even in high-demand areas
- Urban planners can accurately predict parking demand in congested areas to manage availability, improve traffic flow, and make routing decisions
- Curbside management solutions can create data-driven models to predict parking trends and understand patterns and behaviors that enable effective decision making
"The unique combination of our Trips and Parking data allows us to more accurately predict demand and deliver the best experience for drivers," added Corley. "It's not just being able to list a number of parking spots in a city but it's about leveraging real intelligence to know where the highest parking need is in order to ensure the best coverage and guide the driver to the right location."
INRIX leverages big data and innovative technologies to provide a future-proof parking management solution, with customers having access to both on-street and off-street parking data that covers over 312,000 locations, in nearly 20,000 cities and over 150 countries.
To learn more about INRIX Parking solutions, visit www.inrix.com/products/parking-data-software/.
About INRIX
Founded in 2004, INRIX pioneered intelligent mobility solutions by transforming big data from connected devices and vehicles into mobility insights. This revolutionary approach enabled INRIX to become one of the leading providers of data and analytics into how people move. By empowering cities, businesses and people with valuable insights, INRIX is helping to make the world smarter, safer, and greener. With partners and solutions spanning across the entire mobility ecosystem, INRIX is uniquely positioned at the intersection of technology and transportation – whether its keeping road users safe, improving traffic signal timing to reduce delay and greenhouse gasses, optimizing last mile delivery, or helping uncover market insights. Learn more at INRIX.com.
View original content:
SOURCE INRIX | https://www.whsv.com/prnewswire/2022/05/02/inrix-parking-delivers-new-innovative-solutions-automakers-businesses-urban-city-planners-understand-parking-demand/ | 2022-05-02T08:41:24Z |
Ukraine city awaits 1st evacuees from Mariupol steel plant
ZAPORIZHZHIA, Ukraine (AP) - A first group of civilians trapped for weeks inside a steel plant in Mariupol under Russian siege was expected to reach a Ukrainian-controlled city on Monday, as a new attempt was launched to allow people sheltering elsewhere in the city to leave.
Video posted online Sunday by Ukrainian forces showed elderly women and mothers with small children climbing over a steep pile of rubble from the sprawling Azovstal steel plant and eventually boarding a bus.
The evacuation, if successful, would represent rare progress in easing the human cost of the almost 10-week war, which has caused particular suffering in Mariupol. Previous attempts to open safe corridors out of the port city on the Sea of Azov and other places have broken down. People fleeing Russian-occupied areas in the past have said their vehicles were fired on, and Ukrainian officials have repeatedly accused Russian forces of shelling agreed-upon evacuation routes.
At least some of the people evacuated from the plant were apparently taken to a village controlled by Moscow-backed separatists, though Russian state media reported they would be allowed to continue on to Ukrainian-held territory if they wanted to. In the past, Ukrainian officials have accused Moscow’s troops of forcibly relocating civilians from areas they have captured to Russia; Moscow has said the people wanted to go to Russia.
More than 100 civilians were expected to arrive in Zaporizhzhia on Monday, Ukrainian President Volodymyr Zelenskyy said Sunday.
“Today, for the first time in all the days of the war, this vitally needed green corridor has started working,” Zelenskyy said in a pre-recorded address published on his Telegram messaging channel.
While official evacuations have often faltered, many people have managed to flee Mariupol under their own steam. Anastasiia Dembytska took advantage of the brief cease-fire around the evacuation of civilians from the steel plant to leave with her daughter, nephew and dog.
She told The Associated Press she could see the steel plant from her window, when she dared to look out.
“We could see the rockets flying” and clouds of smoke over the plant, she said.
She said she had to navigate many checkpoints on the journey to Zaporizhzhia and waited 18 hours near the city before being allowed to pass.
Like many Mariupol residents, Dembytska and her family survived by cooking on a makeshift stove and drinking well water under near-constant bombardment.
“I was scared, then I got used to it,” her 14-year-old daughter Vladyslava said.
A defender of the steel plant said Russian forces resumed shelling the plant Sunday as soon as the civilians were evacuated.
Denys Shlega, commander of the 12th Operational Brigade of Ukraine’s National Guard, said in a televised interview Sunday night that several hundred civilians are still trapped alongside nearly 500 wounded soldiers and “numerous” dead bodies.
“Several dozen small children are still in the bunkers underneath the plant,” Shlega said.
As many as 100,000 people may still be in Mariupol, including an estimated 2,000 Ukrainian fighters beneath the sprawling, Soviet-era steel plant — the only part of the city not occupied by the Russians.
A siege of Mariupol since the early days of the war has trapped civilians with scarce access to food, water, medicine and electricity. A Russian airstrike hit a maternity hospital early in the conflict, and hundreds of people were reported killed when a theater was bombed.
The city, which had a pre-war population of more than 400,000, is a key Russian target because its capture would deprive Ukraine of a vital port, allow Moscow to establish a land corridor to the Crimean Peninsula, which it seized from Ukraine in 2014, and free up troops for fighting elsewhere in the Donbas, now Russia’s main focus.
A Ukrainian officer at the steel plant urged groups like the U.N. and the Red Cross to also ensure the evacuation of wounded fighters at the plant, though he acknowledged that reaching some of the injured is difficult.
“There’s rubble. We have no special equipment. It’s hard for soldiers to pick up slabs weighing tons only with their arms,” Sviatoslav Palamar, deputy commander of the Azov Regiment, told the AP in an interview. “We hear voices of people who are still alive” inside shattered buildings.
U.N. humanitarian spokesman Saviano Abreu said civilians arriving in Zaporizhzhia, about 140 miles (230 kilometers) northwest of Mariupol, would get immediate support, including psychological services. A Doctors Without Borders team was waiting for the U.N. convoy at a reception center for displaced people in the city.
In his nightly address Sunday, Zelenskyy accused Moscow of waging “a war of extermination,” saying Russian shelling had hit food, grain and fertilizer warehouses, and residential neighborhoods in the city of Kharkiv, in the Donbas and other regions.
More than 350,000 people have been evacuated from combat zones thanks to humanitarian corridors pre-agreed with Moscow, he said, adding the “organization of humanitarian corridors is one of the elements of the negotiation process which is ongoing.”
In Zaporizhzhia, residents ignored air raid sirens to visit cemeteries on Sunday, the Orthodox Christian day of the dead.
“If our dead could rise and see this, they would say, ‘It’s not possible, they’re worse than the Germans,’” Hennadiy Bondarenko, 61, said while marking the day with his family at a picnic table among the graves. “All our dead would join the fighting, including the Cossacks.”
Meanwhile, Russian forces embarked on a major military operation to seize the Donbas, Ukraine’s eastern industrial heartland, after failing to capture Kyiv.
A full picture of battle unfolding in eastern Ukraine is hard to capture. The fighting makes it dangerous for reporters to move around, and both sides have introduced tight restrictions on reporting from the combat zone.
Western officials say Russia is advancing slowly in its eastern offensive and has captured some villages, but is inflicting heavy civilian casualties through indiscriminate bombing. Ukrainian forces are fighting their offensive village-by-village while civilians flee airstrikes and artillery shelling.
The British Defense Ministry said in a daily briefing Monday that it believes more than a quarter of all the fighting units Russia has deployed in Ukraine are now “combat ineffective” — unable to fight because of loss of troops or equipment.
The British military believes Russia committed over 120 so-called “battalion tactical groups” into the war since February, which represents 65% of all of Moscow’s combat strength.
Ukraine’s military claimed Monday to have destroyed two small Russian patrol boats in the Black Sea. Drone footage posted online showed what the Ukrainians described as two Russian Raptor boats exploding after being struck by missiles.
The AP could not immediately independently confirm the strikes.
Hundreds of millions of dollars in military assistance has flowed into Ukraine during the war, but Russia’s vast armories mean Ukraine still needs massive support. Zelenskyy has appealed to the West for more weapons, and tougher economic sanctions on Russia.
U.S. House Speaker Nancy Pelosi and other U.S. lawmakers visited Zelenskyy on Saturday to show American support.
European Union energy ministers were meeting Monday to discuss a new set of sanctions, which could include restrictions on Russian oil — though Russia-dependent members of the 27-nation bloc including Hungary and Slovakia are wary of taking tough action.
___
Varenytsia reported from Kyiv, Ukraine. Associated Press journalists Yesica Fisch in Sloviansk, Jon Gambrell and Yuras Karmanau in Lviv, Mstyslav Chernov in Kharkiv, and AP staff around the world contributed to this report.
___
Follow AP’s coverage of the war in Ukraine: https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.wvva.com/2022/05/02/ukraine-city-awaits-1st-evacuees-mariupol-steel-plant/ | 2022-05-02T09:30:38Z |
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe | https://www.kitv.com/news/local/hfd-extinguishes-two-story-apartment-building-fire-on-varsity-circle/article_5dfa9268-c9a9-11ec-aa65-53cc11c5afc9.html | 2022-05-02T09:46:09Z |
...SMALL CRAFT ADVISORY NOW IN EFFECT UNTIL 6 PM HST MONDAY...
* WHAT...East to northeast winds 20 to 25 knots.
* WHERE...All Hawaiian Coastal Waters.
* WHEN...Until 6 PM HST Monday.
* IMPACTS...Conditions will be hazardous to small craft.
PRECAUTIONARY/PREPAREDNESS ACTIONS...
Inexperienced mariners, especially those operating smaller
vessels, should avoid navigating in these conditions.
&&
HONOLULU (KITV)- An apartment building fire forced eight residents from their homes, sent one man to the hospital, and a woman who lived next door is recovering from smoke inhalation. Residents of that building tell us they've lost what cannot be replaced.
"My uncle passed away. We had one photo of him. He just passed away 2 years ago. And we always had the photo by the door. And we always like blessed his photo, watching him as we left. I didn't even remember about it until a minute ago. Like oh my god I lost that," said Sarah Hickey who is a resident who was displaced by the fire.
Hours after a fire ripped through the second floor of apartment complex on Varsity Place, Sarah Hickey is still brought to tears. The Honolulu Fire Department says the call came in at 10:53 am. "The first unit arrived at 11:01 am to find smoke and flames coming from the second story," said Honolulu Fire Department Captain Randall Lindsey.
Only 9 minutes later, the second story started to collapse. So too did the hearts of those who once lived there. Two dogs did not make it out alive. "I think what really hurts is the loss of our fur family. That's what is really difficult. But I'm glad everyone is safe," said displaced resident Don farmer.
Hickey herself had a scare when she was notified of the fire. A neighbor was concerned her brother was inside at the time. "It was scary because I didn't know where he was. And I didn't know if he was a sleep at the time. So at the moment I was devastated thinking he might have been home. But luckily he wasn't," said Hickey.
No human fatalities. That's the good news. The bad news is the second floor is gutted by the fire, the first floor has water damage, and 4 families need a new place to sleep. They don't know what tomorrow brings. " I'm just going to try and find a new apartment to live in. Luck I have the support of neighbors and friends here, as well as my boyfriend. We're going to be OK for a few days as we try to get it together," said Hickey.
Meanwhile the Red Cross, a local church, and neighbors have stepped up to offer different kinds of support whether it was something to drink or a chair to sit and recover. But it's going to be an uphill battle after losing all their things, and pets. We're told a Gofundme account is being set up for the victims.
The Honolulu fire departments tells us an electrical arc from an outlet on the second floor caused this accidental fire, which caused an estimated $620,000 in damage. | https://www.kitv.com/news/local/new-details-come-out-about-varsity-circle-fire/article_453f94f4-c9f8-11ec-9648-cf3e2c567f0f.html | 2022-05-02T09:46:15Z |
Airbnb’s COVID refund policy is ending
Published: May. 2, 2022 at 6:06 AM EDT|Updated: 6 minutes ago
(CNN) - Airbnb has announced its popular COVID-19 refund policy is ending as of May 31.
After that date, guests will have to cover short-term rental costs, even if their reason for canceling was due to the coronavirus.
For much of the pandemic, guests who had to cancel an Airbnb reservation could do so without a penalty.
Starting at the end of May, cancellation policies will return to the discretion of the individual host property. Some Airbnb rentals only require 24 hours of advance notice, while others may require cancellation five days in advance for a full refund.
Airbnb is promising to offer guests travel insurance in the near future, which will provide another refund option for customers.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.whsv.com/2022/05/02/airbnbs-covid-refund-policy-is-ending/ | 2022-05-02T10:14:04Z |
Community Spotlight: New Bridges Immigrant Resources Center
HARRISONBURG, Va. (WHSV) - New Bridges Immigrant Resource Center has been working to build a community where everyone can thrive for more than 20 years.
Each year it has helped more and more people find their place in the Friendly City.
Especially now, with the conflicts in Ukraine and Afghanistan there has been an influx of people looking to start a new life.
With Harrisonburg being a refugee relocation center, the city has welcomed them with open arms.
“Being a Friendly City means having friendly people, and that’s who everyone is in Harrisonburg,” Russell Leary, Executive Director of NewBridges Immigrant Resource Center, said.
But starting over in a new country and city, even a friendly one, comes with several challenges and needs.
“I think the primary need we see is just language access, and helping people who maybe don’t have strong English skills just know what’s going on and how they can access information,” Leary explained.
A lot of NewBridges’ staff is bilingual and have the skills to support those who need help.
“We have an immigration legal program, and we offer low-cost, but really reliable and dependable legal representation for people going through legal processes,” Leary said.
Those services are offered with compassion and understanding, letting people know NewBridges is an organization they can trust, which the nonprofit said makes all the difference.
“The immigrations story in the U.S. goes way, way back, and it will continue too. Harrisonburg is a place that has decided to make a commitment to welcoming people, so we are just one piece, I think, in the larger puzzle of making Harrisonburg that welcoming, friendly city that it is.”
NewBridges’ main focus for this year is working to expand its immigration legal program. So, if you’d like to help, you can donate and stay up to date by going to its website newbridgesirc.org.
Copyright 2022 WHSV. All rights reserved. | https://www.whsv.com/2022/05/02/community-spotlight-new-bridges-immigrant-resources-center/ | 2022-05-02T10:14:10Z |
Librarian creates peacemaking circle with chairs
SHENANDOAH COUNTY, Va. (WHSV) -
At Signal Knob Middle School in Strasburg, a librarian and her assistant are both set to retire at the end of the school year. Jacqueline Weitmen and her assistant Brenda James, decided to create a legacy project called the “Peacemaking Circle.”
Instead of getting rid of some of the old oak chairs in the library, they asked local artists, students and teachers to paint them something that brought them peace. The ultimate goal is to create a place where people can sit in a peaceful setting and dive into conversation.
“You’ll see Chincoteague, you’ll see butterflies, you’ll see lots of different things even a Mother Theresa quote. Something as simple as that,” said Jacqueline Weitman.
One of the artists, known as the butterfly lady around the community, created her chair with lots of butterflies and other forms of nature.
”I’m just so excited that the current students and hopefully they will pass it on to their younger siblings will step out and have the conversations that are sometimes difficult, but make the most progress,” said Barbara Plitt, a local artist.
Among the artists were a few students and teachers. Two of the students talked about their favorite parts of their chairs and their hope for the project going forward.
”I hope that they will see that the sunflowers...sun kind of gives like a smile to everyone’s face, so the sunflowers should say something to people and give them a smile,” said Emily Davis, a student.
“It’s blue and it has aliens on it. It’s my favorite thing,” said Trevor Baker, a student.
Both librarians say they hope the chairs will leave a lasting impact on the school and community.
The formal celebration of the peacemaking circle is happening on Monday, May 2nd in the middle school’s library from 6 to 7 pm.
Copyright 2022 WHSV. All rights reserved. | https://www.whsv.com/2022/05/02/librarian-creates-peacemaking-circle-with-chairs/ | 2022-05-02T10:14:16Z |
Ukraine city awaits 1st evacuees from Mariupol steel plant
ZAPORIZHZHIA, Ukraine (AP) - A first group of civilians trapped for weeks inside a steel plant in Mariupol under Russian siege was expected to reach a Ukrainian-controlled city on Monday, as a new attempt was launched to allow people sheltering elsewhere in the city to leave.
Video posted online Sunday by Ukrainian forces showed elderly women and mothers with small children climbing over a steep pile of rubble from the sprawling Azovstal steel plant and eventually boarding a bus.
The evacuation, if successful, would represent rare progress in easing the human cost of the almost 10-week war, which has caused particular suffering in Mariupol. Previous attempts to open safe corridors out of the port city on the Sea of Azov and other places have broken down. People fleeing Russian-occupied areas in the past have said their vehicles were fired on, and Ukrainian officials have repeatedly accused Russian forces of shelling agreed-upon evacuation routes.
At least some of the people evacuated from the plant were apparently taken to a village controlled by Moscow-backed separatists, though Russian state media reported they would be allowed to continue on to Ukrainian-held territory if they wanted to. In the past, Ukrainian officials have accused Moscow’s troops of forcibly relocating civilians from areas they have captured to Russia; Moscow has said the people wanted to go to Russia.
More than 100 civilians were expected to arrive in Zaporizhzhia on Monday, Ukrainian President Volodymyr Zelenskyy said Sunday.
“Today, for the first time in all the days of the war, this vitally needed green corridor has started working,” Zelenskyy said in a pre-recorded address published on his Telegram messaging channel.
While official evacuations have often faltered, many people have managed to flee Mariupol under their own steam. Anastasiia Dembytska took advantage of the brief cease-fire around the evacuation of civilians from the steel plant to leave with her daughter, nephew and dog.
She told The Associated Press she could see the steel plant from her window, when she dared to look out.
“We could see the rockets flying” and clouds of smoke over the plant, she said.
She said she had to navigate many checkpoints on the journey to Zaporizhzhia and waited 18 hours near the city before being allowed to pass.
Like many Mariupol residents, Dembytska and her family survived by cooking on a makeshift stove and drinking well water under near-constant bombardment.
“I was scared, then I got used to it,” her 14-year-old daughter Vladyslava said.
A defender of the steel plant said Russian forces resumed shelling the plant Sunday as soon as the civilians were evacuated.
Denys Shlega, commander of the 12th Operational Brigade of Ukraine’s National Guard, said in a televised interview Sunday night that several hundred civilians are still trapped alongside nearly 500 wounded soldiers and “numerous” dead bodies.
“Several dozen small children are still in the bunkers underneath the plant,” Shlega said.
As many as 100,000 people may still be in Mariupol, including an estimated 2,000 Ukrainian fighters beneath the sprawling, Soviet-era steel plant — the only part of the city not occupied by the Russians.
A siege of Mariupol since the early days of the war has trapped civilians with scarce access to food, water, medicine and electricity. A Russian airstrike hit a maternity hospital early in the conflict, and hundreds of people were reported killed when a theater was bombed.
The city, which had a pre-war population of more than 400,000, is a key Russian target because its capture would deprive Ukraine of a vital port, allow Moscow to establish a land corridor to the Crimean Peninsula, which it seized from Ukraine in 2014, and free up troops for fighting elsewhere in the Donbas, now Russia’s main focus.
A Ukrainian officer at the steel plant urged groups like the U.N. and the Red Cross to also ensure the evacuation of wounded fighters at the plant, though he acknowledged that reaching some of the injured is difficult.
“There’s rubble. We have no special equipment. It’s hard for soldiers to pick up slabs weighing tons only with their arms,” Sviatoslav Palamar, deputy commander of the Azov Regiment, told the AP in an interview. “We hear voices of people who are still alive” inside shattered buildings.
U.N. humanitarian spokesman Saviano Abreu said civilians arriving in Zaporizhzhia, about 140 miles (230 kilometers) northwest of Mariupol, would get immediate support, including psychological services. A Doctors Without Borders team was waiting for the U.N. convoy at a reception center for displaced people in the city.
In his nightly address Sunday, Zelenskyy accused Moscow of waging “a war of extermination,” saying Russian shelling had hit food, grain and fertilizer warehouses, and residential neighborhoods in the city of Kharkiv, in the Donbas and other regions.
More than 350,000 people have been evacuated from combat zones thanks to humanitarian corridors pre-agreed with Moscow, he said, adding the “organization of humanitarian corridors is one of the elements of the negotiation process which is ongoing.”
In Zaporizhzhia, residents ignored air raid sirens to visit cemeteries on Sunday, the Orthodox Christian day of the dead.
“If our dead could rise and see this, they would say, ‘It’s not possible, they’re worse than the Germans,’” Hennadiy Bondarenko, 61, said while marking the day with his family at a picnic table among the graves. “All our dead would join the fighting, including the Cossacks.”
Meanwhile, Russian forces embarked on a major military operation to seize the Donbas, Ukraine’s eastern industrial heartland, after failing to capture Kyiv.
A full picture of battle unfolding in eastern Ukraine is hard to capture. The fighting makes it dangerous for reporters to move around, and both sides have introduced tight restrictions on reporting from the combat zone.
Western officials say Russia is advancing slowly in its eastern offensive and has captured some villages, but is inflicting heavy civilian casualties through indiscriminate bombing. Ukrainian forces are fighting their offensive village-by-village while civilians flee airstrikes and artillery shelling.
The British Defense Ministry said in a daily briefing Monday that it believes more than a quarter of all the fighting units Russia has deployed in Ukraine are now “combat ineffective” — unable to fight because of loss of troops or equipment.
The British military believes Russia committed over 120 so-called “battalion tactical groups” into the war since February, which represents 65% of all of Moscow’s combat strength.
Ukraine’s military claimed Monday to have destroyed two small Russian patrol boats in the Black Sea. Drone footage posted online showed what the Ukrainians described as two Russian Raptor boats exploding after being struck by missiles.
The AP could not immediately independently confirm the strikes.
Hundreds of millions of dollars in military assistance has flowed into Ukraine during the war, but Russia’s vast armories mean Ukraine still needs massive support. Zelenskyy has appealed to the West for more weapons, and tougher economic sanctions on Russia.
U.S. House Speaker Nancy Pelosi and other U.S. lawmakers visited Zelenskyy on Saturday to show American support.
European Union energy ministers were meeting Monday to discuss a new set of sanctions, which could include restrictions on Russian oil — though Russia-dependent members of the 27-nation bloc including Hungary and Slovakia are wary of taking tough action.
___
Varenytsia reported from Kyiv, Ukraine. Associated Press journalists Yesica Fisch in Sloviansk, Jon Gambrell and Yuras Karmanau in Lviv, Mstyslav Chernov in Kharkiv, and AP staff around the world contributed to this report.
___
Follow AP’s coverage of the war in Ukraine: https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/05/02/ukraine-city-awaits-1st-evacuees-mariupol-steel-plant/ | 2022-05-02T10:14:23Z |
MAUMEE, Ohio, May 2, 2022 /PRNewswire/ -- Aktion Associates, Inc., a national software reseller and IT infrastructure provider focused on the Architectural Engineering & Construction, Distribution and Manufacturing industries, announced today the acquisition of United Solutions, a Massachusetts based Sage CRE software reseller. This transaction is the continuation of a series of strategic Aktion investments recently made to improve its offerings in the Construction industry vertical.
"This acquisition expands our customer base in the Construction & Real Estate (CRE) markets in North America," said Aktion CEO Scott Irwin. "A key to this acquisition was onboarding the talented group of industry-focused consultants with deep-rooted Sage expertise experienced in servicing their customer base. He added, "With the new combined Sage customer base and the addition of the 2021 acquisition of Central Consulting Group's Architecture and Engineering (A&E) Deltek customer base, this is a continuation of the strategic focus to develop Aktion as the largest Value Added Reseller (VAR) in the Architecture Engineer and Construction (AEC) industry."
Aktion Associates has been helping companies develop cloud and managed service IT strategies for well over a decade. Its Cloud and Managed Services programs are designed specifically for the industry applications that they support, including the Architectural & Engineering, Construction, Distribution, and Manufacturing industries.
United Solutions customers now have access to a full-service IT consulting team and a robust portfolio of services, including network engineering, software engineering, and application and industry consulting.
ADD ONE- Aktion Associates Acquires United Solutions
"On behalf of the team at United Solutions and our Sage CRE customer base, I am thrilled to be joining forces with one of the most respected Sage Business Partners in North America, Aktion Associates," said United Solutions Owner, Greg Kirshe. "I have known Scott Irwin for over 25 years and have admired the way he managed and grew his business, but most importantly was always impressed with the quality of the people with whom he surrounded himself. I am excited for our New England based clients. They will continue to benefit from the same high level of service they have come to expect from United Solutions, while benefiting from the wider array of services (cloud hosting, managed services, level one support, etc.) and depth of talent (over 200 employees) that Aktion Associates offers to the marketplace. After 37 years of running United Solutions, I look forward to becoming a member of a larger team, continuing to serve our clients and finding new construction companies in search of improving their company through our technology, services and expertise."
About Aktion
Aktion Associates is a national ERP software reseller and IT infrastructure provider focused on the Architectural Engineering & Construction, Distribution and Manufacturing industries. Since 1979, more than 6,500 customers have chosen Aktion as their technology advisor. With a workforce of 220 professionals in application consulting, network and software engineering, these teams utilize proprietary lean implementation processes to help customers realize the value of their IT investment. Company-owned data centers provide secure cloud hosting, disaster recovery and backup services, and the Network Operations Center (NOC) monitors managed services clients. Aktion is an IT infrastructure provider for IBM, HP, Lenovo, Cisco, VMware and Microsoft technologies. Other deliverables include network engineering, software engineering, and on-premise IT support.
Visit www.aktion.com.
About United Solutions
For over 37 years, United Solutions delivered expert service and advice to thousands of construction companies. United Solutions was a leading reseller and partner with Sage, the premier solution for Construction and Real Estate businesses, and offered tools for business development, estimating, project management, financial accounting, service operations and business intelligence, as well as mobile and paperless solutions.
View original content to download multimedia:
SOURCE Aktion Associates, Inc. | https://www.whsv.com/prnewswire/2022/05/02/aktion-associates-acquires-united-solutions-inc-making-aktion-largest-value-added-reseller-serving-aec-industry/ | 2022-05-02T10:14:30Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on May 16, 2022.
BrainStorm's Chief Executive Officer, Chaim Lebovits, will present a corporate update after which participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, Stacy Lindborg, PhD, Executive Vice President and Chief Development Officer, David Setboun, PharmD, MBA, Executive Vice President and Chief Operating Officer, and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.
Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. Eastern Time on Sunday, May 15, 2022.
The investment community may participate in the conference call by dialing the following numbers:
Participant Numbers:
Toll Free: 888-506-0062
International: 973-528-0011
Entry Code: 476792
Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/45459
Those interested in listening to the conference call live via the internet may do so by using the webcast link above or by visiting the "Investors & Media" page of BrainStorm's website at
https://ir.brainstorm-cell.com/events-and-presentations and clicking on the conference call link.
Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.
Replay Numbers:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 45459
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).
CONTACTS
Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-429-3548
jmullaly@lifesciadvisors.com
Media:
Uri Yablonka
uri@brainstorm-cell.com
View original content:
SOURCE BrainStorm Cell Therapeutics Inc | https://www.whsv.com/prnewswire/2022/05/02/brainstorm-announce-first-quarter-2022-financial-results-provide-corporate-update/ | 2022-05-02T10:14:36Z |
Lower breakpoints expected to save over $20 million for investors in first year
LOS ANGELES, May 2, 2022 /PRNewswire/ -- Capital Group, home of American Funds, is reducing fees on 18 funds by revising initial fee breakpoints. The change applies to funds with current assets of less than $15 billion, resulting in a potential for over $20 million in savings for investors within the first year of the change.
Capital Group has a history of being a low-cost active manager. As of May 1, 93 percent of the company's fund management fees are expected to sit in the lowest quintile of fees within its peer group, versus 84 percent as of March 31, 2022¹.
"Over the past several years, our business has continued to grow as more and more investors appreciate the value our global team of investment professionals brings to our strategies," said Mike Gitlin, member, Capital Group management committee. "At Capital, we have a long history of sharing the benefits of scale with our fund shareholders through lower fees. Small differences in investment outcomes – just a few basis points – can compound over a lifetime and drive vastly different experiences for people."
Many of the funds positively affected by this change are Capital Group's fixed income funds. Fixed income continues to be a strong growth area for Capital Group with assets under management more than doubling in the last five years and now just shy of $500B. Of the 11 fixed income funds with five year track records that will see lower fees, 9 are in the top two quartiles for results (or 82%). American Funds Multi-sector Income Fund, Capital Group's newest bond fund which will also see lower fees, has a three year track record with results in the highest quartile. A total of 12 bond funds will experience reduced fees.
Funds affected by this change include:
"Every day we think about how we can achieve superior investment results for our clients over the long-term," said Gitlin. "Consistent active management and lowering fees on our smaller mutual funds both help us deliver on our commitment."
About Capital Group
Capital Group, home of the American Funds, has been singularly focused on delivering superior results for long-term investors using high-conviction portfolios, rigorous research and individual accountability since 1931.
As of December 31, 2021, Capital Group manages more than $2.7 trillion in equity and fixed income assets for millions of individual and institutional investors around the world. Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organization; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.
For more information, visit capitalgroup.com.
Media Contact:
Hannah Coan, Capital Group
Hannah.Coan@capgroup.com
Tel: (213) 615-5199
Sarah Christiansen, Capital Group
Sarah.Christiansen@capgroup.com
Tel: (213) 615-3052
Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.
Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and should not be considered advice, an endorsement or a recommendation.
All Capital Group trademarks mentioned are owned by The Capital Group Companies, Inc., an affiliated company or fund. All other company and product names mentioned are the property of their respective companies.
Use of this website is intended for U.S. residents only.
American Funds Distributors, Inc., member FINRA
This content, developed by Capital Group, home of American Funds, should not be used as a primary basis for investment decisions and is not intended to serve as impartial investment or fiduciary advice.
Your privacy and security are important to us. See our privacy policy (Canada | Europe & Asia | United States).
© 2022 Capital Group. All rights reserved.
333 S. Hope Street, Los Angeles, CA 90071 USA
- Management fee rank totals are for American Funds, American Funds Insurance Series Funds, and Capital Group Emerging Markets Growth Fund. Fee rank totals are based on each fund's Morningstar category; exclude index funds and funds of funds; and are filtered for the least expensive share class per offering as of 3/31/2022. American Funds Insurance Series Funds ranks utilize the net management fee, including any disclosed management fee waivers in the prospectus. For more information on each fund's fees, see the latest prospectus.
- As of May 1, 2022.
- As of each fund's prospectus available at the time of publication.
View original content to download multimedia:
SOURCE Capital Group Companies | https://www.whsv.com/prnewswire/2022/05/02/capital-group-lowers-fees-18-funds/ | 2022-05-02T10:14:42Z |
DEI officer for leading down payment assistance provider
succeeds outgoing chair Lola Oyewole
CEDAR CITY, Utah, May 2, 2022 /PRNewswire/ -- CBC Mortgage Agency (CBCMA), a nationally chartered housing finance agency and a leading source of down payment assistance for first-time homebuyers, announced that Tai Christensen, the company's director of government affairs and diversity, equity and inclusion (DEI) officer, has been named chair of the American Mortgage Diversity Council (AMDC). Christensen, who succeeds outgoing chair Lola Oyewole, will lead the Dallas-based organization's efforts to promote DEI throughout the mortgage industry.
Christensen, who was installed as AMDC chair on Thursday during the Five Star 2022 Diversity & Inclusion Symposium in Washington, D.C., originally joined the organization's advisory board in April 2021. She has two decades of real estate finance experience and has been with CBCMA since January 2018.
"When it came time to choose our next chair, it was clear to everyone that Tai was the best and obvious choice," said Gina Gallutia, executive director of AMDC. "We are thrilled for her to lead the council as we tackle the key DEI issues in our industry this year."
"Working for a company that aligns closely with my desire to erase racial disparity in homeownership has been so gratifying," Christensen said. "So, when the opportunity to support the American Mortgage Diversity Council arose last year, I jumped at the chance. Little did I know I would be given the opportunity to help guide the council as chair just a year later. I am honored to have the opportunity."
During Oyewole's leadership, AMDC has worked with business leaders to make the mortgage sector a more diverse and inclusive industry. Over the past year in particular, several Black women have been appointed to senior level housing positions in the Biden Administration.
In addition to her work with AMDC, Oyewole serves as vice president human resources and chief diversity and inclusion officer for Ocwen Financial Corp., where she has worked for nearly seven years.
"My time as AMDC chair has been very fulfilling, but there is more work ahead to maintain progress in the diversification of real estate finance," Oyewole stated. "I look forward to continuing to serve the organization in other capacities to help it achieve its mission of expanding diversity in the mortgage industry."
Oyewole will remain on the AMDC board of advisors as chair pro-tem for the next year and will help Christensen transition into her new role.
Christensen added, "I look forward to building on Lola's accomplishments to help make the mortgage industry more inclusive and representative of the communities we serve."
Founded in 2013, CBC Mortgage Agency is a nationally chartered housing finance agency. As a leading source of down payment assistance, the company helps low-to-moderate income consumers, often in minority neighborhoods, achieve the dream of homeownership. CBCMA, which was recognized as one of the Top 25 Companies in Mortgage & Servicing by MReport, is a wholly owned subsidiary of Cedar Band Corp., a federally chartered tribal corporation founded by the Cedar Band of Paiute Indians. More information can be found at chenoafund.org.
The American Mortgage Diversity Council (AMDC) promotes diversity and inclusion throughout the mortgage industry. The organization provides a platform for the collaboration of mortgage industry leaders for the advancement of diversity and inclusion dialogue. The organization develops and provides tools and strategies to create an understanding and appreciation of individual differences in thought, experience, race, ethnicity, culture, religion, style, sexual orientation and gender identity. Move business practices forward to embrace diversity and inclusion as essential to innovation and optimal business results. Read more about the AMDC at https://mortgagediversitycouncil.com/.
Press Contact:
Sam Garcia, Publicist
Strategic Vantage Marketing & Public Relations
214.762.4457 | SamGarcia@StrategicVantage.com
View original content:
SOURCE CBC Mortgage Agency | https://www.whsv.com/prnewswire/2022/05/02/cbc-mortgage-agencys-tai-christensen-named-chair-american-mortgage-diversity-council/ | 2022-05-02T10:14:48Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention AbbVie Inc. ("AbbVie") (NYSE: ABBV) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 30, 2021 and August 31, 2021.
If you suffered a loss on your investment in AbbVie, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against AbbVie includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
DEADLINE: June 6, 2022
Aggrieved AbbVie investors only have until June 6, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-abbvie-investors-lead-plaintiff-deadline-june-6-2022/ | 2022-05-02T10:14:54Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 28, 2018 and September 2, 2020.
If you suffered a loss on your investment in Akebia, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Akebia includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: May 13, 2022
Aggrieved Akebia investors only have until May 13, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-akebia-investors-lead-plaintiff-deadline-may-13-2022/ | 2022-05-02T10:15:00Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc.") (NASDAQ: AUPH) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 7, 2021 and February 25, 2022.
If you suffered a loss on your investment in Aurinia Pharmaceuticals Inc., contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Aurinia Pharmaceuticals Inc. includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: June 14, 2022
Aggrieved Aurinia Pharmaceuticals Inc. investors only have until June 14, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-aurinia-pharmaceuticals-inc-investors-lead-plaintiff-deadline-june-14-2022/ | 2022-05-02T10:15:07Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings ("Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings") (NYSE: BKKT) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Bakkt securities between March 31, 2021 and November 19, 2021, both dates inclusive; and/or (b) Bakkt Class A common stock pursuant and/or traceable to documents issued in connection with the business combination between the Company and Bakkt Holdings, LLC completed on or about October 15, 2021.
If you suffered a loss on your investment in Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/bakkt-holdings-inc-f-k-a-vpc-impact-acquisition-holdings-
loss-submission-form?prid=26537&wire=4
ABOUT THE ACTION: The class action against Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had defective financial controls; (ii) as a result, there were errors in the Company's financial statements related to the misclassification of certain shares issued prior to the business combination between the Company and Bakkt Holdings, LLC; (iii) accordingly, the Company would need to restate certain of its financial statements; (iv) the Company downplayed the true scope and severity of these issues; (v) the Company overstated its remediation of its defective financial controls; and (vi) as a result, the documents issued in connection with the business combination and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
DEADLINE: June 20, 2022
Aggrieved Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings investors only have until June 20, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-bakkt-holdings-inc-fka-vpc-impact-acquisition-holdings-investors-lead-plaintiff-deadline-june-20-2022/ | 2022-05-02T10:15:13Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention C3.ai, Inc. ("C3.ai, Inc.") (NYSE: AI) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) C3.ai Class A common stock pursuant and/or traceable to the documents issued in connection with the Company's initial public offering conducted on or about December 9, 2020; and/or (b) C3.ai securities between December 9, 2020 and February 15, 2022, both dates inclusive.
If you suffered a loss on your investment in C3.ai, Inc., contact us about potential recovery by
using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/c3-ai-inc-loss-submission-form?prid=26521&wire=4
ABOUT THE ACTION: The class action against C3.ai, Inc. includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) C3.ai's partnership with Baker Hughes was deteriorating; (ii) C3.ai was employing a flawed accounting methodology to conceal the deterioration of its Baker Hughes partnership; (iii) C3.ai faced challenges in product adoption and significant salesforce turnover; (iv) the Company overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its market growth, and the scale of alliances with its major business partners; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: May 3, 2022
Aggrieved C3.ai, Inc. investors only have until May 3, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-c3ai-inc-investors-lead-plaintiff-deadline-may-3-2022/ | 2022-05-02T10:15:19Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Celsius Holdings, Inc. ("Celsius") (NASDAQ: CELH) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 12, 2021 and March 1, 2022.
If you suffered a loss on your investment in Celsius, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/celsius-holdings-inc-loss-submission-form?prid=26525&wire=4
ABOUT THE ACTION: The class action against Celsius includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly recorded expenses for non-cash share-based compensation for second and third quarters of 2021; (2) as a result, the Company's financial statements for those periods would be restated, including to report a net loss for the third quarter of 2021; (3) there was a material weakness in Celsius's internal controls over financial reporting; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: May 16, 2022
Aggrieved Celsius investors only have until May 16, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-celsius-investors-lead-plaintiff-deadline-may-16-2022/ | 2022-05-02T10:15:25Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Grab Holdings Limited ("Grab Holdings") (NASDAQ: GRAB) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between November 12, 2021 and March 2, 2022.
If you suffered a loss on your investment in Grab Holdings, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Grab Holdings includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Grab's driver supply declined during the third quarter; (2) as a result, Grab continued to invest heavily in driver and consumer incentives to "preemptively recalibrate driver supply"; (3) as a result, the Company's financial results would be adversely impacted, including, among other things, a significant decline in revenue; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: May 16, 2022
Aggrieved Grab Holdings investors only have until May 16, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-grab-holdings-investors-lead-plaintiff-deadline-may-16-2022/ | 2022-05-02T10:15:31Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Homology Medicines, Inc. ("Homology") (NASDAQ: FIXX) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 10, 2019 and February 18, 2022.
If you suffered a loss on your investment in Homology, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Homology includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: May 24, 2022
Aggrieved Homology investors only have until May 24, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-homology-investors-lead-plaintiff-deadline-may-24-2022/ | 2022-05-02T10:15:37Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention International Business Machines Corporation ("IBM") (NYSE: IBM) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 4, 2017 and October 20, 2021.
If you suffered a loss on your investment in IBM, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against IBM includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.
DEADLINE: June 6, 2022
Aggrieved IBM investors only have until June 6, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-ibm-investors-lead-plaintiff-deadline-june-6-2022/ | 2022-05-02T10:15:43Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Innovative Industrial Properties, Inc. ("Innovative Industrial Properties") (NYSE: IIPR) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 7, 2020 and April 13, 2022.
If you suffered a loss on your investment in Innovative Industrial Properties, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Innovative Industrial Properties includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Innovative Industrial Properties' focus is to be a cannabis company lender rather than a REIT; (2) that the true values of the Company's properties are significantly lower than Innovative Industrial Properties represents; (3) there are existential issues in its top customers; (4) as a result, its top customers may not be able to continue making payments to Innovative Industrial Properties and the Company would face significant issues replacing these customers; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: June 24, 2022
Aggrieved Innovative Industrial Properties investors only have until June 24, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-innovative-industrial-properties-investors-lead-plaintiff-deadline-june-24-2022/ | 2022-05-02T10:15:49Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Ironnet, Inc. ("Ironnet") (NYSE: IRNT) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between September 15, 2021 and December 15, 2021.
If you suffered a loss on your investment in Ironnet, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/ironnet-inc-loss-submission-form?prid=26539&wire=4
ABOUT THE ACTION: The class action against Ironnet includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had materially overstated its business and financial prospects; (ii) the Company was unable to predict the timing of significant customer opportunities which constituted a substantial portion of its publicly- issued FY 2022 financial guidance; (iii) the Company had not established effective disclosure controls and procedures to reasonably ensure its public disclosures were timely, accurate, complete, and not otherwise misleading; and (iv) as a result, the Company's public statements were materially false, misleading, and/or lacked any reasonable basis in fact at all relevant times.
DEADLINE: June 21, 2022
Aggrieved Ironnet investors only have until June 21, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-ironnet-investors-lead-plaintiff-deadline-june-21-2022/ | 2022-05-02T10:15:55Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. ("Li-Cycle") (NYSE: LICY) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between February 16, 2021 and March 23, 2022.
If you suffered a loss on your investment in Li-Cycle, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Li-Cycle includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Li-Cycle's largest customer, Traxys, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li-Cycle's product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company's mark-to-model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company's reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company's gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
DEADLINE: June 20, 2022
Aggrieved Li-Cycle investors only have until June 20, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-li-cycle-investors-lead-plaintiff-deadline-june-20-2022/ | 2022-05-02T10:16:02Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Lilium N.V. f/k/a Qell Acquisition Corp. ("Lilium N.V. f/k/a Qell Acquisition Corp.") (NASDAQ: LILM) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 30, 2021 and March 14, 2022.
If you suffered a loss on your investment in Lilium N.V. f/k/a Qell Acquisition Corp., contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Lilium N.V. f/k/a Qell Acquisition Corp. includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Lilium materially overstates the design and capabilities of the Lilium Jet, an electric vertical take-off-and-landing aircraft for use in a new type of high-speed air transport system for people and goods; (2) Lilium materially overstates the likelihood for the Lilium Jet's timely certification; (3) Lilium misrepresents its ability to obtain or create the necessary batteries for the Lilium Jet; (4) the special purpose acquisition company merger would not and did not generate enough cash to commercially launch the Lilium Jet; (5) Qell Acquisition Corp. did not engage in proper due diligence regarding its merger with Lilium GmbH; and (6) as a result, Defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.
DEADLINE: June 17, 2022
Aggrieved Lilium N.V. f/k/a Qell Acquisition Corp. investors only have until June 17, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-lilium-nv-fka-qell-acquisition-corp-investors-lead-plaintiff-deadline-june-17-2022/ | 2022-05-02T10:16:08Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Lucid Group, Inc. ("Lucid") (NASDAQ: LCID) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Lucid common stock between November 15, 2021, and February 28, 2022, inclusive.
If you suffered a loss on your investment in Lucid, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid's business and operations. Specifically, the Company overstated its production capabilities while concealing that "extraordinary supply chain and logistics challenges" were hampering Lucid's operations. As a result of the defendants' wrongful acts and omissions, and the significant decline in the market value of Lucid's common stock, Lucid investors have suffered significant damages.
DEADLINE: May 31, 2022
Aggrieved Lucid investors only have until May 31, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-lucid-investors-lead-plaintiff-deadline-may-31-2022/ | 2022-05-02T10:16:14Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Meta Platforms, Inc. ("Meta Platforms, Inc.") (NASDAQ: FB) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 2, 2021 and February 2, 2022.
If you suffered a loss on your investment in Meta Platforms, Inc., contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Meta Platforms, Inc. includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Apple's iOS privacy changes were having a material impact on Meta's ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta's mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
DEADLINE: May 9, 2022
Aggrieved Meta Platforms, Inc. investors only have until May 9, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-meta-platforms-inc-investors-lead-plaintiff-deadline-may-9-2022/ | 2022-05-02T10:16:20Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Natera, Inc. ("Natera") (NASDAQ: NTRA) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.
If you suffered a loss on your investment in Natera, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Natera includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
DEADLINE: June 27, 2022
Aggrieved Natera investors only have until June 27, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-natera-investors-lead-plaintiff-deadline-june-27-2022/ | 2022-05-02T10:16:26Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Playstudios, Inc. ("Playstudios, Inc.") (NASDAQ: MYPS) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of all persons and entities other than defendants who: (a) purchased, or otherwise acquired securities of Playstudios between June 22, 2021 and March 1, 2022, both dates inclusive, including, but not limited to, those who purchased or acquired Playstudios securities pursuant to the offering of the private investment in public equity; (b) held common stock of Acies as of May 25, 2021, and were eligible to vote at Acies' June 16, 2021 special meeting who exchanged their shares of Acies stock for shares of Playstudios stock pursuant to the merger of Acies and Old Playstudios; and/or (c) purchased or otherwise acquired Playstudios common stock pursuant to or traceable to Acies' documents issued in connection with the June 2021 merger.
If you suffered a loss on your investment in Playstudios, Inc., contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Playstudios, Inc. includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Playstudios was having significant problems with its flagship game, Kingdom Boss; (ii) Playstudios would not be releasing Kingdom Boss as expected; and (iii) Playstudios had not revised its financial projections to account for the problems it had encountered with Kingdom Boss. As a result of defendants' wrongful conduct, Class members paid artificially inflated prices for their Playstudios securities and suffered substantial losses and damages.
DEADLINE: June 6, 2022
Aggrieved Playstudios, Inc. investors only have until June 6, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-playstudios-inc-investors-lead-plaintiff-deadline-june-6-2022/ | 2022-05-02T10:16:33Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Rivian Automotive, Inc. ("Rivian Automotive, Inc.") (NASDAQ: RIVN) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of investors that purchased or otherwise acquired Rivian common stock pursuant and/or traceable to Rivian's initial public offering on November 10, 2021 and/or between November 10, 2021, and March 10, 2022.
If you suffered a loss on your investment in Rivian Automotive, Inc., contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: Documents issued in connection with the initial public offering contained representations that were materially inaccurate, misleading, and/or incomplete because they failed to disclose, among other things, that the R1T electric pickup truck and R1S electric SUV were underpriced to such a degree that Rivian would have to raise prices shortly after the IPO and that these price increases would tarnish Rivian's reputation as a trustworthy and transparent company and would put a significant number of the existing backlog of 55,400 preorders, along with future preorders, in jeopardy of cancellation.
DEADLINE: May 6, 2022
Aggrieved Rivian Automotive, Inc. investors only have until May 6, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-rivian-automotive-inc-investors-lead-plaintiff-deadline-may-6-2022/ | 2022-05-02T10:16:39Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Stronghold Digital Mining, Inc. ("Stronghold Digital Mining, Inc.") (NASDAQ: SDIG) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Stronghold Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2021 initial public offering.
If you suffered a loss on your investment in Stronghold Digital Mining, Inc., contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/stronghold-digital-mining-inc-loss-submission-form?prid=26534&wire=4
ABOUT THE ACTION: The class action against Stronghold Digital Mining, Inc. includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) contracted suppliers, including MinerVa Semiconductor Corp., were reasonably likely to miss anticipated delivery quantities and deadlines; (2) due to strong demand and pre-sold supply of mining equipment in the industry, Stronghold would experience difficulties obtaining miners outside of confirmed purchase orders; (3) as a result of the foregoing, there was a significant risk that Stronghold could not expand its mining capacity as expected; (4) as a result, Stronghold would likely experience significant losses; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: June 13, 2022
Aggrieved Stronghold Digital Mining, Inc. investors only have until June 13, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-stronghold-digital-mining-inc-investors-lead-plaintiff-deadline-june-13-2022/ | 2022-05-02T10:16:45Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Telefonaktiebolaget LM Ericsson ("Telefonaktiebolaget LM Ericsson") (NASDAQ: ERIC) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 27, 2017 and February 25, 2022.
If you suffered a loss on your investment in Telefonaktiebolaget LM Ericsson, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Telefonaktiebolaget LM Ericsson includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Ericsson overstated the extent to which it had reformed its business practices to eliminate the use of bribes to secure business in foreign countries; (ii) Ericsson had paid bribes to the terrorist group the Islamic State in Iraq and Syria to gain access to certain transport routes in Iraq; (iii) accordingly, the Company's revenues derived from its operations in Iraq were, in at least substantial part, derived from unlawful conduct and thus unsustainable; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: May 2, 2022
Aggrieved Telefonaktiebolaget LM Ericsson investors only have until May 2, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-telefonaktiebolaget-lm-ericsson-investors-lead-plaintiff-deadline-may-2-2022/ | 2022-05-02T10:16:51Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Vertiv Holdings Co ("Vertiv") (NYSE: VRT) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 28, 2021 and February 23, 2022.
If you suffered a loss on your investment in Vertiv, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/vertiv-holdings-co-loss-submission-form?prid=26527&wire=4
ABOUT THE ACTION: The class action against Vertiv includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv's earnings would be adversely impacted; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: May 23, 2022
Aggrieved Vertiv investors only have until May 23, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-vertiv-investors-lead-plaintiff-deadline-may-23-2022/ | 2022-05-02T10:16:57Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Attention Volta Inc. ("Volta") (NYSE: VLTA) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 2, 2021 and March 28, 2022.
If you suffered a loss on your investment in Volta, contact us about potential recovery by using the link below. There is no cost or obligation to you.
ABOUT THE ACTION: The class action against Volta includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Volta had improperly accounted for restricted stock units issued in connection with the business combination of Volta Industries, Inc. ("Legacy Volta") and Tortoise Acquisition Corp. II; (2) as a result, the Company had understated its net loss for third quarter 2021; (3) there were material weaknesses in the Company's internal control over financial reporting that resulted in a material error; (4) as a result of the foregoing, the Company would restate its financial statements; (5) as a result of the foregoing, Legacy Volta's founders would imminently exit the Company; (6) as a result, the Company's financial results would be adversely impacted; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
DEADLINE: May 31, 2022
Aggrieved Volta investors only have until May 31, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:
SOURCE The Law Offices of Vincent Wong | https://www.whsv.com/prnewswire/2022/05/02/class-action-alert-law-offices-vincent-wong-remind-volta-investors-lead-plaintiff-deadline-may-31-2022/ | 2022-05-02T10:17:03Z |
- Net income was $313 million versus $312 million in the prior year quarter, core income was up 20% to $316 million versus $263 million in the prior year quarter.
- The P&C combined ratio was 91.9%, the lowest in over five years, compared with 98.1% in the prior year quarter, including 1.0 point of catastrophe loss impact compared with 6.8 points in the prior year quarter.
- The underlying combined ratio was 91.4% compared with 91.9% in the prior year quarter. The underlying loss ratio was 60.1% and the expense ratio was 31.0%.
- P&C segments, excluding third party captives, generated gross written premium growth of 8%. Net written premium growth was 4% in the quarter.
- P&C written rate of +7% and earned rate of +9% for the quarter.
- Net investment income of $448 million pretax includes $8 million of income from limited partnerships and common stock compared with $504 million of pretax net investment income which included $61 million of income from limited partnerships and common stock in the prior year quarter.
- Book value per share excluding AOCI of $44.67, a 2% increase from year-end 2021 adjusting for $2.40 of dividends per share; book value per share of $39.87 was also impacted by a decrease in AOCI reflecting the effect of higher interest rates on fixed income net unrealized gains and losses.
- Board of Directors declares regular quarterly cash dividend of $0.40 per share.
CHICAGO, May 2, 2022 /PRNewswire/ -- CNA Financial Corporation (NYSE: CNA) today announced first quarter 2022 net income of $313 million, or $1.15 per share, versus $312 million, or $1.14 per share, in the prior year quarter. Core income for the quarter was $316 million, or $1.16 per share, versus $263 million, or $0.96 per share, in the prior year quarter. Net investment losses for the quarter were $3 million, versus net investment gains of $49 million in the prior year quarter.
Our Property & Casualty segments produced core income of $321 million for the first quarter of 2022, an increase of $58 million, or 22%, compared to the prior year quarter due to lower catastrophe losses and improved non-catastrophe current accident year underwriting results partially offset by lower net investment income driven by limited partnership and common stock returns. Property & Casualty segments, excluding third party captives, generated gross written premium growth of 8% and net written premium growth of 4%, driven by written rate of +7% for the quarter and new business growth of 14%.
Our Life & Group and Corporate & Other segments produced core income (loss) for the first quarter of 2022 of $23 million and $(28) million, respectively.
CNA Financial declared a quarterly dividend of $0.40 per share, payable June 2, 2022 to stockholders of record on May 16, 2022.
"We are off to a good start in 2022 with a 20% increase in core income resulting from improved underlying P&C underwriting income and lower catastrophe losses. Our combined ratio of 91.9% was the lowest quarterly combined ratio in over five years. Gross written premium growth ex captives was 8% in the quarter. Earned rate increase of 9% remains comfortably above loss cost trends and a positive gap should persist through year-end as written rate increases, which were 7% in the quarter, are moderating at a measured pace and remain robust where needed most. With significant rate achievement over the last several years and improved terms and conditions, we remain optimistic about the market conditions and our growth opportunities for the remainder of 2022," said Dino E. Robusto, Chairman & Chief Executive Officer of CNA Financial Corporation.
Property & Casualty Operations
- The underlying combined ratio improved 0.5 points as compared with the prior year quarter due to an improvement in the expense ratio primarily driven by net earned premium growth of 5% and lower acquisition costs.
- The combined ratio improved 6.2 points as compared with the prior year quarter. Catastrophe losses were $19 million, or 1.0 point of the loss ratio in the quarter compared with $125 million, or 6.8 points of the loss ratio, for the prior year quarter. Favorable net prior period development improved the loss ratio by 0.5 points in the current quarter compared with 0.6 points of improvement in the prior year quarter.
- P&C segments, excluding third party captives, generated gross written premium growth of 8% and net written premium growth of 4%.
Business Operating Highlights
Specialty
- The underlying combined ratio improved 0.2 points as compared with the prior year quarter, driven by improvement in the underlying loss ratio.
- The combined ratio improved 0.1 point as compared with the prior year quarter. There were no catastrophe losses in the first quarter of 2022 compared with $5 million, or 0.7 points of the loss ratio, for the prior year quarter. Favorable net prior period development improved the loss ratio by 1.3 points in the quarter compared with 2.1 points of improvement in the prior year quarter.
- Gross written premiums, excluding third party captives, grew 8% and net written premiums grew 4% for the first quarter of 2022.
Commercial
- The underlying combined ratio improved 0.1 point as compared with the prior year quarter. The expense ratio improved 0.7 points driven by net earned premium growth of 6% and lower acquisition costs. The underlying loss ratio increased 0.7 points due to a shift in mix of business associated with the property quota share treaty purchased during June of 2021. Our property coverages, which have a lower underlying loss ratio than most other commercial coverages, now represent a smaller proportion of net earned premiums. On a mix adjusted basis, there was no change in the underlying loss ratio.
- The combined ratio improved 12.2 points as compared with the prior year quarter, reflecting the lowest combined ratio since 2008. Catastrophe losses were $16 million, or 1.8 points of the loss ratio in the first quarter of 2022 compared with $115 million, or 13.4 points of the loss ratio, for the prior year quarter.
- Gross written premiums, excluding third party captives, grew 9% and net written premiums grew 4% for the first quarter of 2022.
International
- The underlying combined ratio improved 2.8 points as compared with the prior year quarter. The expense ratio improved 1.8 points driven by lower acquisition costs and net earned premium growth of 5%. The underlying loss ratio improved 1.0 point.
- The combined ratio improved 3.5 points as compared with the prior year quarter. Catastrophe losses were $3 million, or 1.2 points of the loss ratio in the first quarter of 2022, compared with $5 million, or 2.0 points of the loss ratio, for the prior year quarter.
- Gross written premiums grew 6%, or 9% excluding currency fluctuations, and net written premiums grew 7%, or 11% excluding currency fluctuations, for the first quarter of 2022.
Life & Group
Core income decreased $13 million for the first quarter of 2022 as compared with the same period in 2021 primarily due to lower net investment income and higher expenses.
Corporate & Other
Core loss improved $8 million for the first quarter of 2022 as compared with the prior year quarter. The prior year quarter included the recognition of a $12 million after-tax loss resulting from the cession of a legacy portfolio of excess workers' compensation policies under a retroactive reinsurance agreement.
Net Investment Income
Net investment income decreased $56 million as compared with the prior year quarter. The decrease was driven by limited partnership and common stock investments, which returned 0.4%, or $8 million for the first quarter of 2022 compared with 3.4%, or $61 million in the prior year quarter.
Stockholders' Equity
Stockholders' equity of $10.8 billion decreased 16% from year-end 2021, primarily due to a decrease in net unrealized investment gains as a result of higher interest rates and dividends paid to stockholders, partially offset by net income. Net unrealized investment gains decreased $1.6 billion after-tax driven by a decrease in unrealized investment gains of $3.4 billion, partially offset by Shadow Adjustments of $1.4 billion and tax of $0.4 billion. Book value per share of $39.87 likewise decreased 16% from year-end 2021.
Book value per share ex AOCI of $44.67 increased 2% from year-end 2021 adjusting for $2.40 of dividends per share.
About the Company
CNA is one of the largest U.S. commercial property and casualty insurance companies. Backed by more than 120 years of experience, CNA provides a broad range of standard and specialized insurance products and services for businesses and professionals in the U.S., Canada and Europe. For more information, please visit CNA at www.cna.com.
Contact
Conference Call and Webcast/Presentation Information
A conference call for investors and the professional investment community will be held at 8:00 a.m. (CT) today. On the conference call will be Dino E. Robusto, Chairman and Chief Executive Officer of CNA Financial Corporation, Scott R. Lindquist, Executive Vice President and Chief Financial Officer of CNA Financial Corporation and other members of senior management. Participants can access the call by dialing (800) 289-0571, or for international callers, +1 (720) 543-0206. The call will also be broadcast live on the internet and may be accessed from the Investor Relations page of the CNA website (www.cna.com). A presentation will be posted and available on the CNA website and will provide additional insight into the results.
The call is available to the media, but questions will be restricted to investors and the professional investment community. An online replay will be available on CNA's website following the call. Financial supplement information related to the results is available on the investor relations pages of the CNA website or by contacting investor.relations@cna.com.
Definition of Reported Segments
- Specialty provides management and professional liability and other coverages through property and casualty products and services using a network of brokers, independent agencies and managing general underwriters.
- Commercial works with a network of brokers and independent agents to market a broad range of property and casualty insurance products to all types of insureds targeting small business, construction, middle markets and other commercial customers.
- International underwrites property and casualty coverages on a global basis through a branch operation in Canada, a European business consisting of insurance companies based in the U.K and Luxembourg and Hardy, our Lloyd's Syndicate.
- Life & Group primarily includes the results of the individual and group long term care businesses that are in run off.
- Corporate & Other primarily includes certain corporate expenses, including interest on corporate debt, and the results of certain property and casualty business in run-off, including CNA Re, asbestos and environmental pollution (A&EP), excess workers' compensation (EWC) and legacy mass tort.
Financial Measures
Management utilizes the following metrics in their evaluation of the Property & Casualty Operations. These ratios are calculated using financial results prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).
- Loss ratio is the percentage of net incurred claim and claim adjustment expenses to net earned premiums.
- Underlying loss ratio represents the loss ratio excluding catastrophes and development.
- Expense ratio is the percentage of insurance underwriting and acquisition expenses, including the amortization of deferred acquisition costs, to net earned premiums.
- Dividend ratio is the ratio of policyholders' dividends incurred to net earned premiums.
- Combined ratio is the sum of the loss, expense and dividend ratios.
- Underlying combined ratio is the sum of the underlying loss, expense and dividend ratios.
- Renewal premium change represents the estimated change in average premium on policies that renew, including rate and exposure changes.
- Rate represents the average change in price on policies that renew excluding exposure change. For certain products within Small Business, where quantifiable, rate includes the influence of new business as well.
- Retention represents the percentage of premium dollars renewed in comparison to the expiring premium dollars from policies available to renew.
- New business represents premiums from policies written with new customers and additional policies written with existing customers.
Gross written premiums ex. 3rd party captives represents gross written premiums excluding business which is ceded to third party captives, including business related to large warranty programs.
The Company's investment portfolio is monitored by management through analysis of various factors including unrealized gains and losses on securities, portfolio duration and exposure to market and credit risk.
To the extent that unrealized gains on fixed income securities supporting certain products within the Life & Group segment would result in a premium deficiency, or would impact the reserve balance if realized, a related increase in Insurance reserves is recorded, net of tax, as a reduction of net unrealized gains through Other comprehensive income (loss) (Shadow Adjustments).
Reconciliation of GAAP Measures to Non-GAAP Measures
This press release also contains financial measures that are not in accordance with GAAP. Management utilizes these financial measures to monitor the Company's insurance operations and investment portfolio. The Company believes the presentation of these measures provides investors with a better understanding of the significant factors that comprise the Company's operating performance. Reconciliations of these measures to the most comparable GAAP measures follow below.
Reconciliation of Net Income (Loss) to Core Income (Loss)
Core income (loss) is calculated by excluding from net income (loss) the after-tax effects of net investment gains or losses and any cumulative effects of changes in accounting guidance. The calculation of core income (loss) excludes net investment gains or losses because net investment gains or losses are generally driven by economic factors that are not necessarily reflective of our primary operations. Management monitors core income (loss) for each business segment to assess segment performance. Presentation of consolidated core income (loss) is deemed to be a non-GAAP financial measure.
Reconciliation of Net Income (Loss) per Diluted Share to Core Income (Loss) per Diluted Share
Core income (loss) per diluted share provides management and investors with a valuable measure of the Company's operating performance for the same reasons applicable to its underlying measure, core income (loss). Core income (loss) per diluted share is core income (loss) on a per diluted share basis.
Reconciliation of Book Value per Share to Book Value per Share Excluding AOCI
Book value per share excluding AOCI allows management and investors to analyze the amount of the Company's net worth primarily attributable to the Company's business operations. The Company believes this measurement is useful as it reduces the effect of items that can fluctuate significantly from period to period, primarily based on changes in interest rates.
Calculation of Return on Equity and Core Return on Equity
Core return on equity provides management and investors with a measure of how effectively the Company is investing the portion of the Company's net worth that is primarily attributable to its business operations.
For additional information, please refer to CNA's most recent 10-K on file with the Securities and Exchange Commission, as well as the financial supplement, available at www.cna.com.
Forward-Looking Statements
This press release includes statements that relate to anticipated future events (forward-looking statements) rather than actual present conditions or historical events. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and generally include words such as "believes," "expects," "intends," "anticipates," "estimates" and similar expressions. Forward-looking statements, by their nature, are subject to a variety of inherent risks and uncertainties that could cause actual results to differ materially from the results projected. Many of these risks and uncertainties cannot be controlled by CNA. For a detailed description of these risks and uncertainties please refer to CNA's filings with the Securities and Exchange Commission, available at www.cna.com.
Any forward-looking statements made in this press release are made by CNA as of the date of this press release. Further, CNA does not have any obligation to update or revise any forward-looking statement contained in this press release, even if CNA's expectations or any related events, conditions or circumstances change.
Any descriptions of coverage under CNA policies or programs in this press release are provided for convenience only and are not to be relied upon with respect to questions of coverage, exclusions or limitations. With regard to all such matters, the terms and provisions of relevant insurance policies are primary and controlling. In addition, please note that all coverages may not be available in all states.
"CNA" is a registered trademark of CNA Financial Corporation. Certain CNA Financial Corporation subsidiaries use the "CNA" trademark in connection with insurance underwriting and claims activities. Copyright © 2022 CNA. All rights reserved.
View original content to download multimedia:
SOURCE CNA | https://www.whsv.com/prnewswire/2022/05/02/cna-financial-announces-first-quarter-2022-net-income-115-per-share-core-income-116-per-share/ | 2022-05-02T10:17:10Z |
Leading C-UAS provider's flagship product EnforceAir recognized as top product in Unmanned Aerial Solutions (Drones) category
RA'ANANA, Israel and MCLEAN, Va., May 2, 2022 /PRNewswire/ -- D-Fend Solutions – the leader in counter-drone, radio frequency cyber-based takeover technology – today announced that its flagship product, EnforceAir won the Security Today "Govies Government Security Award" in the Unmanned Aerial Solutions (Drones) category. D-Fend Solutions was the only C-UAS provider recognized for their product in this category, achieving platinum award status.
EnforceAir, D-Fend Solutions' counter unmanned aerial system (C-UAS) solution is based on non-jamming, non-kinetic counter-drone, cyber, radio frequency (RF)-based takeover technology. D-Fend's system, in either autonomous or manual mode, detects, locates and identifies rogue drones in defined airspace and then neutralizes the threat by providing full control over the rogue drone and landing it safely in a predefined zone without the operational disruption or collateral damage risks associated with legacy counter-drone technologies.
"The Govies Security Award for Unmanned Aerial Solutions represents a rare source of objective third party validation in the C-UAS space. We are gratified by this prestigious recognition, more so by being the only counter-drone provider awarded in this prize category," said Jeffrey Starr, D-Fend Solutions' Chief Marketing Officer.
D-Fend Solutions was selected as a winner by an independent panel of judges recognizing providers for their Features, Innovation, User Friendliness, Interoperability, Quality, Design, Market Opportunity, Technical Advances, and Scalability and Impact in the security industry.
About D-Fend Solutions
D-Fend Solutions is the leading counter-drone, cyber-takeover technology provider, enabling full control, safety and continuity during rogue drone incidents across complex and sensitive environments, to overcome both current and emerging drone threats. With hundreds of deployments worldwide, EnforceAir, the company's flagship offering, focuses on the most dangerous drone threats in military, public safety, airport, prison, major event and critical infrastructure environments. D-Fend Solutions' technology has been chosen as best-in-class and is in deployment at top-tier U.S. government agencies – including with U.S. military, federal law enforcement and homeland security – as well as major international airports globally. EnforceAir autonomously executes RF, cyber-takeovers of rogue drones for a safe landing and outcome, ensuring the smooth flow of communications, commerce, transportation and everyday life.
For more information: D-FendSolutions.com
Media Inquiries
Paul Bilardo
PR@D-FendSolutions.com
View original content:
SOURCE D-Fend Solutions | https://www.whsv.com/prnewswire/2022/05/02/d-fend-solutions-wins-security-todays-2022-govies-government-security-award/ | 2022-05-02T10:17:16Z |
SHANGHAI, May 2, 2022 /PRNewswire/ -- Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy", the "Company" or "we"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced that its subsidiary, Xinjiang Daqo New Energy ("Xinjiang Daqo"), had obtained approval from the Shanghai Stock Exchange for its planned private offering in China's A-share market.
Xinjiang Daqo intends to raise up to RMB11 billion from this private offering, including approximately RMB8 billion of the gross proceeds to be used for its 100,000 metric tons of polysilicon expansion project in Baotou City, Inner Mongolia, China, and the rest of the proceeds for its working capital purposes. This transaction is subject to market conditions and further approval from the China Securities Regulatory Commission.
About Daqo New Energy Corp.
Daqo New Energy Corp. (NYSE: DQ) ("Daqo" or the "Company") is a leading manufacturer of high-purity polysilicon for the global solar PV industry. Founded in 2007, the Company manufactures and sells high-purity polysilicon to photovoltaic product manufactures, who further process the polysilicon into ingots, wafers, cells and modules for solar power solutions. The Company has a total polysilicon nameplate capacity of 105,000 metric tons and is one of the world's lowest-cost producers of high-purity polysilicon.
For more information, please visit www.dqsolar.com
Daqo New Energy Corp.
Investor Relations
Email: dqir@daqo.com
Christensen
In China
Mr. Rene Vanguestaine
Phone: +86 178 1749 0483
rvanguestaine@christensenir.com
In the U.S.
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@Christensenir.com
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Among other things, Xinjiang Daqo's private offering and project expansion plans contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the demand for photovoltaic products and the development of photovoltaic technologies; global supply and demand for polysilicon; alternative technologies in cell manufacturing; the Company's ability to significantly expand its polysilicon production capacity and output; the reduction in or elimination of government subsidies and economic incentives for solar energy applications; the Company's ability to lower its production costs; changes in the political and regulatory environment; and the duration of COVID-19 outbreaks in China and many other countries and the impact of the outbreaks and the quarantines and travel restrictions instituted by relevant governments on economic and market conditions, including potentially weaker global demand for solar PV installations that could adversely affect the Company's business and financial performance. Further information regarding these and other risks is included in the reports or documents the Company has filed with, or furnished to, the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date hereof, and the Company undertakes no duty to update such information or any forward-looking statement, except as required under applicable law.
View original content:
SOURCE Daqo New Energy Corp. | https://www.whsv.com/prnewswire/2022/05/02/daqo-new-energys-subsidiary-xinjiang-daqo-obtained-approval-shanghai-stock-exchange-its-planned-private-offering-chinas-a-share-market/ | 2022-05-02T10:17:22Z |
Expansion Meets Increased Demand for Descriptive Domains that Lets Businesses Authentically Express Who They Are and What They Do
BELLEVUE, Wash., May 2, 2022 /PRNewswire/ -- To meet the growing demand for descriptive domains, domain registry Donuts Inc. announced it expanded its portfolio offering to total nearly 300 top-level domains (TLDs). The announcement takes place in conjunction with National Small Business Week, which honors and celebrates America's entrepreneurs and innovative startups, a group that benefits from more choices in creative TLDs. Some of the most recent new descriptive TLDs like .games, .finance, .vacations, and .coach reflect the need for memorable options that help these businesses build a brand that expresses their authentic self and stands out from competitors.
Founded in 2010, Donuts is behind more new TLD extensions than any other registry. Donuts' brand TrueName® Domains is the world's largest operator of new-world domain extensions, an increasingly popular option next to the legacy .com, .net, and .org domain extensions. Learn more about TrueName domain options here.
Many forward-thinking companies are moving towards industry-specific, short, descriptive domain extensions that can help them define an authentic digital identity and positively impact SEO with domain extensions like .studio, .solutions, or .life. Descriptive domains also allow businesses to creatively use both the left and right of the dot to tell the world who they are and what they do. For instance, the domains builders.studio, armoire.style, and xbox.games are not only striking and concise, but they clearly express what these companies are about. In addition, when businesses utilize every letter of their domain name, they make it easier for customers to remember their website and find their business again in the future.
"Companies across industries increasingly embrace descriptive domains, and our continued expansion in the domain space helps meet this demand," said Akram J. Atallah, Donuts' CEO. "We are thrilled to see so many of our customers use short domain names that are authentic, to the point, and tell their stories with a strong impression from the start."
Domain names that contain meaningful keywords can boost SEO. For example, Jeff Pike uses thailandmotorcycle.tours for his company. He comments, "Thailand Motorcycle Tours is a series of high-ranking keywords and having 'tours' in the URL describes the focus of our business. It has put us at the top of the first page in Google search results."
All TrueName domains include free, robust security technology that blocks domain imposters before they strike. When people purchase a domain, Donuts automatically identifies and prevents the registration of many potentially malicious variations of their domain name. This proprietary blocking technology helps protect them and their users from phishing schemes by preventing hackers from registering false look-alike domain names.
For instance, by choosing the domain switchboard.live with the TrueName extension .live, the company is actively protected from 431 malicious variations of their domain name containing homographs, which are similar looking characters based on the letters in their URL and often used in phishing scams. Visit TrueName's Homograph Spinner to see how many homographic variations of a name they can block.
About Donuts Inc.
Donuts Inc. simplifies and connects the online world with domain names and related technologies that allow people to build, market and own their digital identities. Donuts owns the world's largest portfolio of top-level domains, branded TrueName Domains, and operates hundreds of others for registry partners on its innovative registry services platform. Together, Donuts' top-level domains have nearly 25 million domains under management. Beyond its domain name registry and innovative registry services platform, Donuts enables customers to discover, register, support, and use high-quality domain names with its registrar, Name.com. Donuts, which ranked on Inc.'s 5000 list as one of the fastest-growing U.S private companies in 2021, is a global company with hundreds of employees. It is headquartered in Bellevue, Washington, with international offices across four continents. For more information, please visit www.donuts.domains.
Contact
Sacha Arts
Bella Vista Communications
(408) 458.6316
sacha@bellavista.agency
View original content to download multimedia:
SOURCE Donuts Inc. | https://www.whsv.com/prnewswire/2022/05/02/donuts-inc-expands-domain-names-giving-small-businesses-startups-more-choices-stand-out-online/ | 2022-05-02T10:17:29Z |
MADISON, Wis., May 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conference and invited investors to participate by webcast.
- BofA Securities Healthcare Conference, Las Vegas
Fireside Chat on Wednesday, May 11, 2022 at 5:00 p.m. ET
The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.
Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download multimedia:
SOURCE Exact Sciences Corporation | https://www.whsv.com/prnewswire/2022/05/02/exact-sciences-participate-may-investor-conference/ | 2022-05-02T10:17:35Z |
- Total facility limit is increased from $30 million to $34 million
- Certain mandatory prepayments removed
- Amendment provides additional working capital to support continued revenue growth
TORONTO, May 2, 2022 /PRNewswire/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (CSE: TGOD) (OTC: TGODF), a sustainable global cannabis company is pleased to announce that it has agreed to amend the terms of the amended and restated credit agreement dated September 29, 2021, as amended (the "Credit Agreement"), between The Green Organic Dutchman Ltd. (the "Borrower"), a wholly-owned subsidiary of TGOD, and its Canadian lender (the "Agent").
The Agent and the Borrower have agreed to enter into the third amendment to the Credit Agreement (the "Amendment") to, amongst other things: (i) increase the term portion of the credit facility by $4,000,000 to $24,000,000; (ii) amend the EBITDA financial covenant to take effect June 30, 2022; (iii) remove the required $6,000,000 prepayment via funds raised by public issuance of equity securities in the Company.; (iv) remove the required $4,000,000 prepayment via funds raised by the sale of HemPoland Sp. Z o.o.; and (v) introduce certain prepayment fees in the combined amount of 2% of any prepayments; subject to the satisfaction of the various conditions set out therein. All other terms of the credit facility will remain the same as before, including the maturity date of June 30, 2023.
"As we continue to grow our market share in the Canadian retail cannabis market, we are seeing opportunities to accelerate our revenue growth profile," said Sean Bovingdon, CEO of TGOD. "Having immediate access to an additional $4 million in the term facility will allow us the flexibility to explore potential cultivation expansion in B.C. and Quebec and meet consumer demand for TGOD, Highly Dutch and Cruuzy products across the country. Additionally, the relaxation of covenants provides us the ability to hit profitability while maximizing shareholder value." added Bovingdon.
The Green Organic Dutchman Holdings Ltd. (CSE: TGOD) (US–OTC: TGODF) is a sustainable cannabis company with a focus on innovation, quality, consistency, integrity and transparency. The Company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. In Canada, the Company serves the recreational market with a brand portfolio including The Green Organic Dutchman, Highly Dutch Organics, Ripple by TGOD and Cruuzy, and the medical markets in Canada, South Africa, Australia, and Germany. All cannabis utilized in products for The Green Organic Dutchman and Highly Dutch Organics brands is grown through a certified organic process, which includes living soil, filtered rainwater, sunlight, and natural inputs.
The Company's common shares and certain warrants issued under the indentures dated December 19, 2019, June 12, 2020, October 23, 2020, and December 10, 2020, trade on the CSE under the symbol "TGOD", "TGOD.WS", "TGOD.WR", "TGOD.WA", and "TGOD.WB" respectively. The Company's common shares trade in the U.S. on the OTCQX under the symbol "TGODF". For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
This news release includes statements containing certain "forward–looking information" within the meaning of applicable securities law ("forward–looking statements"). Forward looking statements in this release include, but are not limited to statements about future revenues, acceleration of the revenue growth profile of the Company, profitability of the Company, cultivation expansion of the Company and maximization of the Company's shareholder value. Forward–looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "should", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in the Company's most recent Annual Information Form filed with Canadian securities regulators and available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the CSE nor the CSE's Regulation Services Provider (as that term is defined in the policies of CSE) accept responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:
SOURCE The Green Organic Dutchman Holdings Ltd. | https://www.whsv.com/prnewswire/2022/05/02/green-organic-dutchman-secures-additional-4-million-increase-term-portion-credit-facility/ | 2022-05-02T10:17:41Z |
Dr. Jack Kessler of Northwestern University will present "New Concept for Neuropathic Pain Relief with Regenerative Medicine Potential Based on Plasmid DNA Encoding Human Hepatocyte Growth Factor, VM202: Scientific Basis and Results from Clinical Studies"
LA JOLLA, Calif., May 2, 2022 /PRNewswire/ -- Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced today an upcoming presentation on their lead plasmid DNA product, Engensis (VM202) at the NYAS (New York Academy of Sciences) Advances in Pain Meeting on May 3, 2022. Dr. Jack Kessler, professor of neurology at Northwestern University, will discuss the scientific basis for VM202, recent clinical trial data, and Helixmith's ongoing Phase 3 clinical trial for painful diabetic peripheral neuropathy.
VM202 is a new concept regenerative gene medicine that has been developed for neuropathic pain. VM202 is a plasmid DNA product designed to produce two isoforms of Hepatocyte Growth Factor (HGF). Encouraged by efficacy and safety data from Phase 1 and Phase 2 studies for painful diabetic peripheral neuropathy (DPN), Helixmith's first Phase 3 double-blind, placebo-controlled, study was conducted in two parts; one for 9 months (DPN 3-1; N=500 subjects) and the other with a 3-month extension for late-enrolling subjects (DPN 3-1b; N=101) who were followed for a total of 12 months. Two cycles of treatments with VM202 or placebo were administered to the calf muscles of both legs at 3 month-intervals, one at Days 0 and 14 and another at Days 90 and 104. VM202 showed an excellent safety profile.
As discussed in a recent publication (Kessler et al., 2021), operational problems associated with the initial CRO hampered the analysis of the first part of the DPN 3-1 study, but there was no such issue with the DPN 3-1b extension trial that recruited subjects during the last third of the study. Subjects in this double-bind placebo-controlled extension study showed significant and high levels of pain reduction at 6, 9, and 12 months (p<0.05 at all points). The magnitude of pain reduction was even greater in subjects not receiving pregabalin and/or gabapentin, which was a preplanned analysis based on stratification criteria to recruit subjects who either were or were not continuing use of gabapentinoids as part of standard of care. The data showed that the analgesic effect of VM202 was maintained for more than 8 months without additional VM202 treatments beyond Day 104. Taken together with preclinical data showing that VM202 produces restoration of damaged nerves and blood vessels, VM202 appears to provide a fundamentally new treatment method for patients with DPN by regenerating damaged nerves.
Based on cumulative evidence of efficacy and safety from the Phase 3-1b study and earlier clinical studies, Helixmith is currently conducting a second Phase 3 clinical trial in DPN subjects with assessments of efficacy and safety for 12 months.
This 2-day conference will bring together international academic and industry researchers from diverse disciplines that include neuroscience/neurobiology, pharmacology, physiology, genetics/genomics, anesthesiology, psychology, and more, to explore the novel mechanisms underlining pain conditions and recent diagnostic/treatment progress. The conference features plenary lectures, poster presentations, and keynotes addresses by David Bennet of Oxford University and by Nobel Prize laureate David Julius of the University of California San Francisco who was awarded the 2021 Nobel prize in Physiology or Medicine for his pioneering work on pain receptors.
Painful DPN is a common and debilitating complication of diabetes mellitus that has a profound negative impact on quality of life, sleep, and mood. Current therapies are palliative and do not target the mechanisms underlying painful DPN. Moreover, symptomatic relief is often limited, and many patients with painful DPN still use opioids.
Helixmith is a clinical-stage gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to address previously untreated diseases, and is listed on the KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), the most advanced pipeline candidate, is a plasmid DNA therapy being studied for painful diabetic peripheral neuropathy, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis, coronary artery disease, and Charcot-Marie-Tooth disease.
View original content:
SOURCE Helixmith USA Inc. | https://www.whsv.com/prnewswire/2022/05/02/helixmith-announces-vm202-engensis-presentation-new-york-academy-sciences-advances-pain-meeting-may-3-2022/ | 2022-05-02T10:17:47Z |
- Darovasertib designated as an Orphan Drug by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, and potential statutory marketing exclusivity
- Targeting a clinical data update for darovasertib and crizotinib combination and FDA regulatory guidance for a potential registration-enabling trial design in mid-2022
SOUTH SAN FRANCISCO, Calif., May 2, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the treatment of uveal melanoma.
IDEAYA is currently evaluating the synthetic lethal combination of darovasertib, a PKC inhibitor, and crizotinib, a cMET inhibitor, in patients with metastatic uveal melanoma (MUM) and in patients with GNAQ or GNA11 mutant solid tumors, in an ongoing Phase 1/2 clinical trial (NCT03947385) pursuant to a clinical trial collaboration and supply agreement with Pfizer.
"We are excited to advance darovasertib towards a potential registration-enabling trial in metastatic uveal melanoma, and the orphan-drug designation is an important step towards our goal to bring this novel therapy to patients," said Matthew Maurer, M.D., Vice President, Head of Clinical Oncology and Medical Affairs, at IDEAYA Biosciences.
Orphan-drug designation (ODD) is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the U.S. Under the ODD, IDEAYA may be entitled to certain tax credits, exemption from user fees, and seven years of statutory marketing exclusivity, subject to FDA approval of a marketing application for darovasertib as a designated orphan-drug product.
As of May 1, 2022, Darovasertib has been evaluated in over 200 patients, including 74 patients in combination with crizotinib. The company is targeting a clinical data update for darovasertib and crizotinib combination in mid-2022, including tolerability and clinical efficacy. IDEAYA is also planning to seek FDA regulatory guidance for a potential registration-enabling trial design to evaluate the darovasertib and crizotinib combination in MUM in mid-2022. IDEAYA is preclinically evaluating potential expansion opportunities for darovasertib in other oncology indications, including in additional cMET-driven tumors, such as hepatocellular carcinoma and non-small cell lung cancer, and in KRAS G12C non-small cell lung cancer.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of an additional clinical data update for the darovasertib and crizotinib combination and (ii)the timing of obtaining FDA guidance for potential registration-enabling trial design to evaluate the darovasertib and crizotinib combination. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K filed on March 18, 2022, and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc. | https://www.whsv.com/prnewswire/2022/05/02/ideaya-biosciences-receives-orphan-drug-designation-darovasertib-pkc-inhibitor-treatment-uveal-melanoma/ | 2022-05-02T10:17:53Z |
Inspire Investing has announced fee reductions on seven of its biblically responsible, faith-based ESG ETFs
BOISE, Idaho, May 2, 2022 /PRNewswire/ -- Inspire Investing, the world's largest provider of biblically responsible ESG ETFs, reported fee reductions on seven of its eight exchange traded funds. This reduction in fees is due mostly to the rapid growth that Inspire has achieved and covers a broad range of investment solutions, from global and U.S. equity to fixed income, momentum, and tactical strategies.
The change allows for greater investor return potential as the total annual operating cost of the fund shrinks in relation to asset growth and represents $568K in net savings for investors.1 The firm's current lineup of eight ETFs added $397 million in new assets during 2021.
"God has greatly blessed our work, and as our assets under management have grown over the years, we have passed on those savings to the shareholders of our ETFs," said Robert Netzly, CEO of Inspire. "These fee reductions are great news for our investors, as they make our already competitively priced offerings even more attractive to institutions and individuals around the globe seeking to invest in a biblically responsible manner."
Inspire ETF fee reductions are detailed in the table below.
About Inspire Investing
Inspire is a leading provider of biblically responsible, faith-based ESG2 investments managing over $1.98 billion in assets under management (as of 3/31/2022), and creator of the globally recognized Inspire Impact Score™ which is used by investors around the world to measure the biblical alignment of their investments according to Biblically Responsible Investing (BRI) principles.
Inspire ranked #3 in the "Top 50 fastest growing RIA firms" by FA Magazine two years in a row (2020 & 2021 report) and was recognized in The Financial Times "Americas' Fastest Growing Companies" (2021 & 2022 report). Inspire also donates 50% or more of its net corporate profits to support impactful ministry projects around the globe through its Give50 Program. To learn more, visit https://www.inspireinvesting.com/give50.
1 Estimated savings for the identified funds is the difference between prior and current expense ratios multiplied by the average assets under management (AUM). Average AUM calculation is based on the average of the month-end total fund assets over the 12 months ending 3/31/2022.
2 ESG stands for environmental, social and governance. Environmental criteria considers how a company performs as a steward of nature. Social criteria examine how it manages relationships with employees, suppliers, customers, and the communities where it operates. Governance deals with a company's leadership, executive pay, audits, internal controls, and shareholder rights.
Each Fund invests its assets in companies with Inspire Impact Score® of zero and higher. As a result of its strategy, the Fund's exclusion of securities of certain issuers for non-financial reasons may cause the Fund to forgo some market opportunities available to funds that do not use these criteria. The value of investments in larger companies may not rise as much as smaller companies, or larger companies may be unable to respond quickly to competitive challenges, such as changes in technology and consumer tastes. The Sub-Adviser's judgments about the growth, value, or potential appreciation of an investment may prove to be incorrect or fail to have the intended results, which could adversely impact the Fund's performance and cause it to underperform relative to other funds with similar investment goals or relative to its benchmark, or not to achieve its investment goal. Fluctuations in the value of equity securities held by the Fund will cause the net asset value ("NAV") of the Fund and the price of its shares ("Shares") to fluctuate
There is no guarantee that the Funds will achieve their objective, generate positive returns, or avoid losses. Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus which contains this and other information, visit www.inspireetf.com. Read it carefully. The Inspire ETFs are distributed by Foreside Financial Services LLC., Member FINRA.
Inspire and Foreside Financial Services LLC are not affiliated. Investment advisory services offered through Inspire Investing, LLC, a Registered Investment Advisor with the SEC.
View original content to download multimedia:
SOURCE Inspire Investing | https://www.whsv.com/prnewswire/2022/05/02/inspire-etfs-reports-expense-ratio-reductions-7-funds/ | 2022-05-02T10:17:59Z |
Concert Calls for Peace and Solidarity Worldwide, Capping Daylong Celebrations in More than 180 Countries
NEW YORK, May 2, 2022 /PRNewswire/ -- With more than 180 countries participating, the International Jazz Day 2022 celebration concluded with a moving All-Star Global Concert reaching millions around the world. Hosted by UNESCO Goodwill Ambassador Herbie Hancock, the concert featured artists from all corners of the globe joining together to affirm the unifying power of jazz and issue a heartfelt call for peace and solidarity to the world.
Presented from the very center of international diplomacy – the United Nations – the 2022 Global Concert showcased jazz's unparalleled ability to build bridges and forge consensus through dialogue. The opening performance set the pace, with blues vocal phenom Shemekia Copeland performing her social justice tribute "Walk Until I Ride" alongside Marcus Miller, Brian Blade, John Beasley (Musical Director) and Mark Whitfield. Other highlights included GRAMMY Award-winning vocalist Gregory Porter joining musicians from Australia, Brazil, Japan and the United States for a soulful rendition of his acclaimed original "No Love Dying;" jazz legend David Sanborn performing "Georgia On My Mind" with a band including Linda May Han Oh and Terri Lyne Carrington; and an extraordinary interpretation of Herbie Hancock's "Maiden Voyage," led by Hancock himself, with Ravi Coltrane, James Genus, Zakir Hussain, Brian Blade and Randy Brecker.
Addressing a host of global crises, including the conflicts in Ukraine and other locations throughout the world, as well as the ongoing impacts of the COVID-19 pandemic, the 2022 Global Concert recognized music as a powerful tool for healing and positive change. "The music shows up when we need it most," host Herbie Hancock noted, "to ease our burdens and boost our spirits."
The 2022 Global Concert crowned a day of worldwide International Jazz Day celebrations, including performances, education programs and community outreach activities organized by UNESCO, the Herbie Hancock Institute of Jazz and thousands of partners across the globe.
Major support for International Jazz Day is provided by the Doris Duke Charitable Foundation. Air transportation and additional support for artists and educators is provided by United Airlines, the airline partner of International Jazz Day.
Each year on April 30, International Jazz Day brings together countries and communities on all continents to honor the international art form of jazz, highlighting its important role in encouraging dialogue, combating discrimination and promoting human dignity.
View original content to download multimedia:
SOURCE Herbie Hancock Institute of Jazz | https://www.whsv.com/prnewswire/2022/05/02/international-jazz-day-2022-concludes-with-spectacular-all-star-global-concert-united-nations/ | 2022-05-02T10:18:06Z |
Seventh Consecutive Quarter of Core Revenue Growth, Including Core Revenue Growth in Each Segment
CHARLOTTE, N.C., May 2, 2022 /PRNewswire/ -- JELD-WEN Holding, Inc. (NYSE:JELD) today announced results for the three months ended March 26, 2022, including first quarter net revenue of $1,171.0 million, net loss of $0.5 million, adjusted EBITDA of $80.2 million, cash flow used in operations of $186.9 million, net loss per share of $0.01, and adjusted earnings per share (EPS) of $0.16. Comparability is to the same period in the prior year, unless otherwise noted. References to "core" financial results exclude the impact of foreign exchange and acquisitions completed in the last twelve months.
- Net revenue increased 7.2% for the first quarter driven by 10% core revenue growth
- Seven consecutive quarters of core revenue growth, including core revenue growth in each segment
- Realized 12% pricing to mitigate raw material and freight inflation
- Adjusted EBITDA decreased 18.0% for the first quarter to $80.2 million
- Significant increase in raw material, freight and labor inflation negatively impacted results
- Repurchased 1.8 million shares in the quarter or approximately 2% of total shares outstanding at year-end 2021
"I am proud of our dedicated associates who delivered another solid quarter of core revenue growth across each of our segments," said Gary S. Michel, chair and chief executive officer. "Our improved execution and customer-centric solutions enabled us to capitalize on solid customer demand. Despite our strong core revenue growth, material increases in raw material, freight and labor inflation had a significant impact on our earnings. As we head into the second quarter, we remain laser-focused on driving above market growth through the introduction of innovative and margin accretive new products and services and additional strategic margin expansion opportunities. Given our strong order books, end market demand and initiatives in progress to drive profitable growth, we remain confident in our ability to deliver our 2022 and long-term financial commitments."
Net revenue for the three months ended March 26, 2022 increased $78.6 million, or 7.2%, to $1,171.0 million, compared to $1,092.4 million for the same period last year. The increase in net revenue was driven by 10% core revenue growth, partially offset by a 3% adverse impact from foreign exchange. Core revenue growth was driven by price realization (+12%), partially offset by lower volume/mix of (2%).
Net loss was $0.5 million in the first quarter, compared to net income of $25.5 million in the same period last year, a decrease of $26.0 million. The decrease in net income was largely from lower gross profit due to raw material, freight and labor inflation. Adjusted net income for the first quarter decreased $13.7 million, or 49.1%, to $14.2 million, compared to $27.9 million in the same period last year.
Net loss per share for the first quarter was $0.01, compared to earnings per share of $0.25 for the same quarter last year. Adjusted EPS decreased 40.7% to $0.16, compared to $0.27 a year ago.
Adjusted EBITDA decreased $17.7 million, or 18.0%, to $80.2 million, compared to the same quarter last year. Adjusted EBITDA margin declined due to higher raw material, freight and labor inflation, partially offset by higher price realization.
On a segment basis for the first quarter of 2022, compared to the same period last year:
- North America - Net revenue increased $82.7 million, or 12.9%, to $722.3 million, due to a 13% increase in core revenue. Core revenue increased due to price (+14%), partially offset by lower volume/mix (1%). Adjusted EBITDA margin was 9.3%.
- Europe - Net revenue increased $2.8 million, or 0.9%, to $323.3 million, due to an 8% increase in core revenue, partially offset by a 7% adverse impact from foreign exchange. Core revenue increased due to price (+11%), partially offset by lower volume/mix (3%). Adjusted EBITDA margin was 4.5%.
- Australasia - Net revenue decreased $6.8 million, or 5.2%, to $125.4 million, due to a 6% adverse impact from foreign exchange, partially offset by a 1% increase in core revenue. Core revenue increased due to price (+6%), partially offset by lower volume/mix (5%). Adjusted EBITDA margin was 8.3%.
Net cash flow used in operations was $186.9 million in the first quarter 2022, compared to net cash flow used in operations of $64.9 million during the same period a year ago. The increase in net cash flow used in operations was due to higher working capital investment and lower net income. Free cash flow used was $203.2 million in the first quarter 2022, compared to free cash flow used of $85.9 million during the same period a year ago. The increase in free cash flow used was due to higher net cash flow used in operations, partially offset by lower capital expenditures.
The company repurchased 1,777,266 shares in the first quarter for $40.2 million.
Total liquidity, including cash and cash equivalents and undrawn committed credit facilities, was $584.7 million as of March 26, 2022, compared to total liquidity of $837.8 million as of December 31, 2021.
JELD-WEN management will host a conference call on May 2, 2022, at 8 a.m. ET, to discuss the company's financial results. Interested investors and other parties can access the call either via webcast by visiting the Investor Relations section of the company's website at http://investors.jeld-wen.com, or by dialing (888) 330-2446 and using ID 1285715. A slide presentation highlighting the company's results will also be available on the Investor Relations section of the company's website.
For those unable to listen to the live event, a webcast replay will be available approximately two hours following completion of the call. To learn more about JELD-WEN, please visit the company's website at http://investors.jeld-wen.com.
Headquartered in Charlotte, N.C., JELD-WEN is a leading global manufacturer of high-performance interior and exterior building products, offering one of the broadest selections of windows, interior and exterior doors, and wall systems. JELD-WEN delivers a differentiated customer experience, providing construction professionals with durable, energy-efficient products and labor-saving services that help them maximize productivity and create beautiful, secure spaces for all to enjoy. The JELD-WEN team is driven by innovation and committed to creating safe, sustainable environments for customers, associates, and local communities. The JELD-WEN family of brands includes JELD-WEN® worldwide; LaCantina™ and VPI™ in North America; Swedoor® and DANA® in Europe; and Corinthian®, Stegbar®, and Breezway® in Australia. Visit jeld-wen.com for more information.
Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements by our CEO and statements regarding our business strategies and ability to execute on our plans, market potential, future financial performance, customer demand, the potential of our categories, brands and innovations, the impact of our footprint rationalization and modernization program, the impact of acquisitions and divestitures on our business and our ability to maximize value and integrate operations, our pipeline of productivity projects, the estimated impact of tax reform on our results, litigation outcomes, and our expectations, beliefs, plans, objectives, prospects, assumptions, or other future events. Forward-looking statements are generally identified by our use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "potential", "predict", "seek", or "should", or the negative thereof or other variations thereon or comparable terminology. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, such expectation or belief is based on the current plans, expectations, assumptions, estimates, and projections of our management. Although we believe that these statements are based on reasonable expectations, assumptions, estimates and projections, they are only predictions and involve known and unknown risks, many of which are beyond our control that could cause actual outcomes and results to be materially different from those indicated in such statements.
The assumptions underlying the guidance provided for 2022 include revenue growth from the acceleration in housing demand in our primary markets; improved product mix; increased pricing; impact from foreign exchange; and margin expansion from volume, pricing, and productivity, partially offset by higher expenses related to material and freight inflation and SG&A. Additionally, the outlook does not include the impact of potential acquisitions or divestitures and assumes no new COVID-19 lockdowns or restrictions, which could unfavorably impact our operations, labor availability, and supply chain continuity.
Risks and uncertainties that could cause actual results to differ materially from such statements include risks associated with the impact of the COVID-19 pandemic on the company and our employees, customers, and suppliers, and other factors, including the factors discussed in our Annual Reports on Form 10-K and our other filings with the Securities and Exchange Commission.
The forward-looking statements included in this release are made as of the date hereof, and except as required by law, we undertake no obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this release.
This press release presents certain "non-GAAP" financial measures. The components of these non-GAAP measures are computed by using amounts that are determined in accordance with accounting principles generally accepted in the United States of America ("GAAP"). A reconciliation of non-GAAP financial measures used in this press release to their nearest comparable GAAP financial measures is included in the tables at the end of this press release. The company provides certain guidance solely on a non-GAAP basis because the company cannot predict certain elements that are included in certain reported GAAP results, including the variables and individual adjustments necessary for a reconciliation to GAAP. While management is not able to specifically quantify the reconciliation items for forward-looking non-GAAP measures without unreasonable effort, management bases the estimated ranges of non-GAAP measures for future periods on its reasonable estimates of such factors as assumed effective tax rate, assumed interest expense, and other assumptions about capital requirements for future periods. The variability of these items may have a significant impact on our future GAAP results.
We use adjusted EBITDA, adjusted EBITDA margin, adjusted net income, and adjusted EPS because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes adjusted EBITDA and adjusted EBITDA margin are helpful in highlighting trends because they exclude the results of decisions that are outside the control of management, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. We use adjusted EBITDA and adjusted EBITDA margin to measure our financial performance and also to report our results to our board of directors. Further, our executive incentive compensation is based in part on adjusted EBITDA. In addition, we use adjusted EBITDA for purposes of calculating compliance with our debt covenants in certain of our debt facilities. adjusted EBITDA should not be considered as an alternative to net income as a measure of financial performance or to cash flows from operations as a liquidity measure.
We define adjusted EBITDA as net income (loss), adjusted for the following items: loss from discontinued operations, net of tax; equity earnings of non-consolidated entities; income tax (benefit) expense; depreciation and amortization; interest expense, net; impairment and restructuring charges; gain on previously held shares of equity investment; (gain) loss on sale of property and equipment; share-based compensation expense; non-cash foreign exchange transaction/translation (income) loss; other non-cash items; other items; and costs related to debt restructuring and debt refinancing. Adjusted EBITDA margin is defined as adjusted EBITDA divided by net revenues.
We present several financial metrics in "core" terms, which exclude the impact of foreign exchange and acquisitions completed in the last twelve months. We use core adjusted EBITDA, which we define as adjusted EBITDA excluding the impact of foreign exchange and acquisitions completed in the last twelve months. We define core revenue as net revenue excluding the impact of foreign exchange and acquisitions completed in the last twelve months. Our use of core margin is defined as core adjusted EBITDA divided by core revenue. These "core" metrics assist management, investors, and analysts in understanding the organic performance of the operations.
We present free cash flow because we believe it assists investors and analysts in determining the quality of our earnings. We also use free cash flow to measure our financial performance and to report to our board of directors. In addition, our executive incentive compensation is based in part on free cash flow. We define free cash flow as cash flow from operations less capital expenditures (including purchases of intangible assets). Free cash flow should not be considered as an alternative to cash flows from operations as a liquidity measure. We also present net debt leverage because it is a key financial metric that is used by management to assess the balance sheet risk of the company. We define net debt leverage as net debt (total principal debt outstanding less unrestricted cash) divided by adjusted EBITDA for the last twelve month period.
Adjusted net income represents net income adjusted for certain items as presented in our reconciliation of non-GAAP, including the after-tax impact of i) non-cash foreign currency (gains) losses, ii) impairment and restructuring charges, iii) one-time non-cash gains, and iv) other non-recurring expenses associated with mergers and acquisitions and litigation. Adjusted EPS represents net income per diluted share adjusted to exclude the estimated per share impact of the same specifically identified items used to calculate adjusted net income as described above. Where applicable, such items are tax-effected at our estimated annual adjusted effective tax rate.
Other companies may compute these measures differently. Non-GAAP metrics should not be considered as alternatives to any other measures derived in accordance with GAAP.
Due to rounding, numbers presented throughout this release may not sum precisely to the totals provided and percentages may not precisely reflect the absolute figures.
View original content:
SOURCE JELD-WEN Holding, Inc. | https://www.whsv.com/prnewswire/2022/05/02/jeld-wen-reports-first-quarter-2022-results/ | 2022-05-02T10:18:12Z |
HOUSTON, May 2, 2022 /PRNewswire/ -- KBR (NYSE: KBR) today announced that it has embarked on a series of electric aircraft test flights for the UK Ministry of Defence (MoD) to assess the feasibility of environmentally friendly alternatives to current military aircraft, through its Affinity Capital Works Limited Joint Venture with Elbit Systems UK.
The concept of trialing zero emissions aircraft was brought to the MoD through Affinity – demonstrating its commitment to providing innovative solutions for the UK Armed Forces and addressing the needs of the future to help realize net-zero ambitions in line with the MoD's green transformation.
The test flights will help the Royal Air Force (RAF) assess the technology of electric aircraft, determine its effectiveness as an impactful pilot training capability, and explore the implications on functional areas like aircraft and airfield operations on the ground and while flying, logistics support and infrastructure, as well as safety.
The flights will use a fully certified two-seater pilot training aircraft, the Velis Electro. Flight and safety assurances were developed during the summer of 2021, which was organized and delivered through Affinity, in partnership with the UK Civil Aviation Authority.
The program began with test flights in December 2021 ahead of the aircraft joining Affinity's existing fleet at RAF Cranwell, where up to twenty additional pilots will fly the sustainable, eco-friendly aircraft in the months ahead.
"We are tremendously proud to support this initiative. The project builds on KBR's proud history of pioneering new technologies and aligns with our vision to deliver solutions that help customers accomplish their most critical objectives in a safer and more sustainable way," said Andrew Barrie, President, KBR Government Solutions EMEA.
KBR has been instrumental to the UK military flying training program since 2016, helping procure nearly 50 aircraft and supporting over 100 staff across three RAF bases in the UK through its Affinity Joint Venture with Elbit Systems UK.
About KBR
We deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 28,000 people performing diverse, complex and mission critical roles in 34 countries.
KBR is proud to work with its customers across the globe to provide technology, value-added services, and long- term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.
Visit www.kbr.com
Forward Looking Statement
The statements in this press release that are not historical statements, including statements regarding future financial performance, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond the company's control that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the significant adverse impacts on economic and market conditions of the COVID-19 pandemic and the company's ability to respond to the resulting challenges and business disruption; the recent dislocation of the global energy market; the company's ability to manage its liquidity; the outcome of and the publicity surrounding audits and investigations by domestic and foreign government agencies and legislative bodies; potential adverse proceedings by such agencies and potential adverse results and consequences from such proceedings; changes in capital spending by the company's customers; the company's ability to obtain contracts from existing and new customers and perform under those contracts; structural changes in the industries in which the company operates; escalating costs associated with and the performance of fixed-fee projects and the company's ability to control its cost under its contracts; claims negotiations and contract disputes with the company's customers; changes in the demand for or price of oil and/or natural gas; protection of intellectual property rights; compliance with environmental laws; changes in government regulations and regulatory requirements; compliance with laws related to income taxes; unsettled political conditions, war and the effects of terrorism; foreign operations and foreign exchange rates and controls; the development and installation of financial systems; the possibility of cyber and malware attacks; increased competition for employees; the ability to successfully complete and integrate acquisitions; and operations of joint ventures, including joint ventures that are not controlled by the company.
The company's most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks, and other U.S. Securities and Exchange Commission filings discuss some of the important risk factors that the company has identified that may affect its business, results of operations and financial condition. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
View original content to download multimedia:
SOURCE KBR, Inc. | https://www.whsv.com/prnewswire/2022/05/02/kbr-joint-venture-introduces-sustainable-aviation-options-uk-ministry-defence/ | 2022-05-02T10:18:19Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Loews Corporation (NYSE:L) today reported net income of $338 million, or $1.36 per share, for the first quarter of 2022 compared to net income of $261 million, or $0.97 per share, in the first quarter of 2021.
Net income for the first quarter of 2022 increased compared to the comparable prior year period as CNA Financial, Boardwalk Pipelines, and Loews Hotels & Co all generated strong operating results. CNA experienced higher property & casualty non-catastrophe underwriting results and lower catastrophe losses, offset by lower net investment income and net investment losses compared to net investment gains in the comparable prior year period. Loews Hotels' results improved significantly as the company continues its recovery from reduced travel during the COVID-19 pandemic, and Boardwalk Pipelines' earnings increased due to higher revenues from growth projects recently placed into service. The parent company generated lower net investment income than in the comparable prior year period.
"Loews is off to a tremendous start in 2022, with an almost 30% increase in net income over the prior year's quarter. Each of our consolidated subsidiaries -- CNA Financial, Boardwalk Pipelines, and Loews Hotels -- produced excellent results in the first quarter," said James S. Tisch, President and CEO of Loews Corporation.
Book value per share as of March 31, 2022 was $67.27 compared to $71.84 as of December 31, 2021, reflecting lower net unrealized investment gains due to the rise in interest rates. Book value per share excluding accumulated other comprehensive income (AOCI) increased to $72.34 as of March 31, 2022 from $71.09 as of December 31, 2021.
Three Months Ended March 31, 2022 Compared to Three Months Ended March 31, 2021
CNA's earnings were consistent with the prior year. Property & casualty underwriting results increased, with lower catastrophe losses and higher non-catastrophe underwriting income. Net investment income declined, driven by lower returns from limited partnership and common stock investments. CNA swung from net investment gains last year to net investment losses, attributable to declines in the fair value of non-redeemable preferred stock and lower gains on sales of fixed maturity securities.
Boardwalk Pipelines' earnings increased due primarily to higher revenues from growth projects recently placed into service, partially offset by higher employee-related costs and higher expenses due to an increased asset base from growth projects.
Loews Hotels' results improved significantly, driven by increased occupancy rates due to the rebound in travel, especially at resort destinations, and higher average daily room rates. The hotel properties at the Universal Orlando Resort contributed meaningfully to the period-over-period improvement, as all 9,000 rooms were open for the entire quarter. Although results were significantly better in 2022 compared to 2021, occupancy levels have not rebounded to pre-pandemic levels at some Loews Hotels properties, particularly those located in city centers.
The parent company investment portfolio recorded a loss for the quarter as compared to income in the comparable prior year period primarily due to losses generated by investments in equity securities.
The Corporate & other segment benefited from the absence of unusual items recorded in 2021 related to the recapitalization and sale of 47% of Altium Packaging, including a $35 million deferred tax liability and a $14 million ($10 million after tax) debt extinguishment charge. Additionally, overhead costs at the parent company were lower in 2022 than in the comparable prior year period.
SHARE REPURCHASES
At March 31, 2022, there were 246.4 million shares of Loews common stock outstanding. For the three months ended March 31, 2022, the Company repurchased 2.15 million shares of its common stock at an aggregate cost of $129 million. From April 1, 2022 to April 29, 2022, the Company repurchased an additional 0.3 million shares of its common stock at an aggregate cost of $19 million. Depending on market conditions, the Company may from time-to-time purchase shares of its and its subsidiaries' outstanding common stock in the open market, in privately negotiated transactions or otherwise.
CONFERENCE CALLS
A conference call to discuss the first quarter results of Loews Corporation has been scheduled for today at 10:00 a.m. ET. A live webcast will be available via the Investors/Media section of www.loews.com. Those interested in participating should dial (866) 342-8591, or for international callers, (203) 518-9797. The conference ID number is L1Q22. An online replay will also be available at www.loews.com following the call.
A conference call to discuss the first quarter results of CNA has been scheduled for today at 9:00 a.m. ET. A live webcast will be available via the Investor Relations section of www.cna.com. Those interested in participating should dial (800) 289-0571, or for international callers, (720) 543-0206.
ABOUT LOEWS CORPORATION
Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries. For more information please visit www.loews.com.
FORWARD-LOOKING STATEMENTS
Statements contained in this press release which are not historical facts are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are inherently uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by management of the Company. A discussion of the important risk factors and other considerations that could materially impact these matters as well as the Company's overall business and financial performance can be found in the Company's reports filed with the Securities and Exchange Commission and readers of this release are urged to review those reports carefully when considering these forward-looking statements. Copies of these reports are available through the Company's website (www.loews.com). Given these risk factors, investors and analysts should not place undue reliance on forward-looking statements. Any such forward-looking statements speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any forward-looking statement is based.
View original content:
SOURCE Loews Corporation | https://www.whsv.com/prnewswire/2022/05/02/loews-corporation-reports-net-income-338-million-first-quarter-2022/ | 2022-05-02T10:18:25Z |
SUN VALLEY, Calif., May 2, 2022 /PRNewswire/ -- Mission Valley Bancorp (OTCQX: MVLY, "Mission Valley", or the "Company") announced today net income of $1.3 million, or $0.39 per diluted share, for the first quarter of 2022, compared to net income of $822 thousand, or $0.25 per diluted share, for the first quarter of 2021.
First Quarter 2022 Highlights
- Net Income was $1.3 million for the first quarter of 2022, an increase of $451 thousand, or 54.93%, compared to the first quarter of 2021. Diluted earnings per share was $0.39 for the first quarter of 2022, an increase of $0.14 per share, or 56.00%, compared to the first quarter of 2021.
- Non-Interest Income was $2.8 million for the first quarter of 2022, an increase of $1.9 million, or 219.10%, compared to $869 thousand for the first quarter of 2021.
- $23.9 million in Small Business Administration ("SBA") loans were sold in the first quarter of 2022 resulting in gain on sale of $1.6 million.
- Total Assets were $557.4 million as of March 31, 2022, compared to $444.4 million as of March 31, 2021 and $576.5 million as of December 31, 2021.
- Gross Loans, excluding SBA Paycheck Protection Program ("PPP") loans, were $309.3 million as of March 31, 2022, an increase of $54.7 million, or 21.49% compared to March 31, 2021, and a decrease of $4.6 million, or 1.47%, compared to December 31, 2021.
- Total Deposits were $497.3 million as of March 31, 2022, an increase of $116.6 million, or 30.63%, compared to March 31, 2021, which was primarily driven by one large customer relationship.
- No Provision for Loan Losses and $15 thousand in net recoveries from previously charged-off loans in the first quarter of 2022.
- No Non-Accrual and no Past Due Loans as of March 31, 2022.
- Classified Loans were $648 thousand as of March 31, 2022, a decrease of $4.6 million, or 78.19%, compared to March 31, 2021, and a decrease of $22 thousand, or 1.40%, compared to December 31, 2021.
- Strong capital position, which is reflected by Total Leverage Ratio of 9.18%, Common Equity Tier 1 Capital Ratio of 13.48%, Tier 1 Capital Ratio of 15.22%, and Total Risk Based Capital of 16.47% as of March 31, 2022.
President and Chief Executive Officer Tamara Gurney commented, "We were able to carry the momentum from a stellar 2021 into the first quarter of 2022 and we are proud to report strong operating results for the quarter highlighted by net income of $1.3 million, strong loan originations, and continued solid credit quality.
About Mission Valley Bancorp
Mission Valley Bancorp is a bank holding company headquartered in Sun Valley, California with two wholly owned subsidiaries Mission Valley Bank (the "Bank") and Mission SBA Loan Servicing LLC ("Mission SBA"). The Bank was founded in 2001 and is a full-service, independent, commercial bank specializing in the banking needs of small to medium businesses with full service branches in the San Fernando & Santa Clarita Valleys. Mission SBA is a de novo SBA lender service provider ("LSP") established in March 2021 that provides SBA lending services to other financial institutions.
Forward-looking statements:
Certain matters discussed in this news release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon current management expectations and, therefore, are subject to certain risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed, suggested, or implied by the forward-looking statements. Forward-looking statements are effective only as of the date that they are made and the Company assumes no obligation to update this information.www.MissionValleyBank.com.
View original content to download multimedia:
SOURCE Mission Valley Bancorp | https://www.whsv.com/prnewswire/2022/05/02/mission-valley-bancorp-reports-first-quarter-2022-results/ | 2022-05-02T10:18:32Z |
- 79 Properties Acquired Year-to-Date for $1.1 Billion -
- Two Properties Representing Approximately $200 Million Expected to Close Upon Completion of Loan Assumptions by End of Second Quarter -
NEW YORK, May 2, 2022 /PRNewswire/ -- The Necessity Retail REIT, Inc. (Nasdaq: RTL) ("RTL" or the "Company") announced today that the Company, through its operating partnership, completed the acquisition of 23 open-air shopping centers for a $277.8 Million, excluding closing costs. The closing is the fourth and fifth tranche from the previously announced agreement to acquire a portfolio of 81 Power, Anchored and Grocery Centers1 from certain subsidiaries of CIM Real Estate Finance Trust, Inc. for $1.3 billion. To date, 79 of the 81 properties have closed.
"This acquisition, paired with our targeted asset sales over the past few years, has significantly transformed RTL into a pure-play necessity-based retail REIT," said Michael Weil, CEO of RTL. "Bringing these properties onto our platform and integrating with new tenants, managers and communities has been handled seamlessly by our team. We are energized by what we think is the significant embedded upside in this portfolio and look forward to the cash flow contributions that will be derived from these properties for years to come."
Footnote 1 Portfolio includes 79 Power, Anchored and Grocery Centers and two single tenant properties.
About The Necessity Retail REIT Where America Shops
The Necessity Retail REIT (Nasdaq: RTL) is the preeminent publicly traded real estate investment trust (REIT) focused "Where America Shops". RTL acquires and manages a diversified portfolio of primarily necessity-based retail single tenant and open-air shopping center properties in the U.S. Additional information about RTL can be found on its website at www.necessityretailreit.com.
Important Notice
The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results or events to be materially different. The words "anticipates," "believes," "expects," "estimates," "projects," "plans," "intends," "may," "will," "seek," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the potential adverse effects of the ongoing global COVID-19 pandemic, including actions taken to contain or treat COVID-19, on the Company, the Company's tenants, any assets under contract to be acquired including their respective tenants and uncertainty and volatility in the global economy and financial markets from, among other things, COVID-19 and the ongoing war in Ukraine, all of which may adversely affect market conditions and capital availability as well as those risks and uncertainties set forth in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 24, 2022 and all other filings with the SEC after that date as such risks, uncertainties and other important factors may be updated from time to time in the Company's subsequent reports Forward looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results, unless required to do so by law.
Contacts:
Investor Relations
ir@rtlreit.com
(866) 902-0063
View original content to download multimedia:
SOURCE The Necessity Retail REIT, Inc. | https://www.whsv.com/prnewswire/2022/05/02/necessity-retail-reit-closes-23-properties-representing-278-million-previously-announced-13-billion-open-air-shopping-center-acquisition/ | 2022-05-02T10:18:38Z |
PHOENIX, May 2, 2022 /PRNewswire/ -- Renren Inc. (NYSE: RENN) ("Renren" or the "Company"), announces today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 (the "2021 20-F") with the Securities and Exchange Commission (the "SEC") on April 29, 2022. The 2021 20-F can be accessed on the Company's investor relations website at http://ir.renren-inc.com and on the SEC's website at www.sec.gov. The Company will provide a hard copy of its audited consolidated financial statements contained in the 2021 20-F, free of charge, to its shareholders and ADS holders upon request. Requests can be directed to Renren Inc., 2828 N. Central Avenue Fl 7, Phoenix, Arizona, 85004 USA.
About Renren Inc.
Renren Inc. (NYSE: RENN) operates several U.S.-based SaaS businesses including Chime, an all-in-one CRM and sales acceleration platform designed to help real estate professionals close more deals faster, and Trucker Path, a suite of applications and dispatch services commercial truck drivers use to plan trips, navigate, and operate their business. Renren's ADSs, each currently representing 45 Class A ordinary shares of the Company, are traded on NYSE under the symbol "RENN".
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Renren may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Renren's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The forward-looking statements included in this press release are not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Further information regarding these and other risks is included in our annual report on Form 20-F and other documents filed with the SEC. All information provided in this press release is as of the date of this press release, and Renren does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
View original content:
SOURCE Renren Inc. | https://www.whsv.com/prnewswire/2022/05/02/renren-inc-filed-2021-annual-report-form-20-f/ | 2022-05-02T10:18:45Z |
BEIJING, May 2, 2022 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE: RLX), a leading branded e-vapor company in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (the "SEC") on April 29, 2022. The Company also published its second Environmental, Social and Governance Report (ESG report) on April 30, 2022.
The annual report on Form 20-F can be accessed on the SEC's website at https://www.sec.gov and on the Company's investor relations website at http://ir.relxtech.com. The Company will provide a hard copy of its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. The ESG report can also be accessed on the Company's investor relations website at http://ir.relxtech.com.
About RLX Technology Inc.
RLX Technology Inc. (NYSE: RLX) is a leading branded e-vapor company in China. The Company leverages its strong in-house technology and product development capabilities and in-depth insights into adult smokers' needs to develop superior e-vapor products. RLX Technology Inc. sells its products through an integrated offline distribution and retail model tailored to China's e-vapor market.
For more information, please visit: http://ir.relxtech.com.
Contacts
In China:
RLX Technology Inc.
Head of Investor Relations
Sam Tsang
Email: ir@relxtech.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86-10-6508-0677
Email: RLX@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
Email: RLX@tpg-ir.com
View original content:
SOURCE RLX Technology Inc. | https://www.whsv.com/prnewswire/2022/05/02/rlx-technology-filed-2021-annual-report-form-20-f-published-esg-report/ | 2022-05-02T10:18:51Z |
BOCA RATON, Fla., May 2, 2022 /PRNewswire/ -- Terran Orbital Corporation (NYSE: LLAP), a global leader in satellite solutions, primarily serving the United States aerospace and defense industry, today announced it shipped two next-generation satellites from GeoOptics, a global leader in remote Earth observation. Terran shipped the vehicles to Cape Canaveral for launch on SpaceX's Transporter-5 mission.
The spacecraft are the first phase of GeoOptics's CICERO-2 constellation, which form a unified Earth observatory allowing governments, industry, and individual stakeholders to monitor and prepare for the many impacts of climate change.
GeoOptics's first generation satellites were designed and developed by Tyvak Nano-Satellite Systems, a Terran Orbital Corporation. These new satellites have been fully developed by Terran Orbital's international arm, Tyvak International. The spacecrafts are 6U XXL and based on the Phoenix Avionics, entirely designed and developed in Italy. GeoOptics's payload is a Global Navigation Satellite System (GNSS) Radio Occultation (RO) system, which is a miniaturized version of the NASA/JPL developed "TriG" payload, named Cion.
"Terran Orbital is delighted to provide the satellites enabling GeoOptics to observe the Earth's atmosphere, surface, and subsurface," said Terran Orbital Co-Founder, Chairman, and Chief Executive Officer Marc Bell. "There is an increasingly urgent need for actionable information about the state of our planet and the impacts of human activity on our climate. Terran Orbital looks forward to working with GeoOptics to continue providing this data."
"The CICERO-2 satellites will provide new accurate, sustainable Earth monitoring on a significantly faster cadence so that governments, companies, and individuals can prepare for the impact of climate change," said GeoOptics Chief Executive Officer Alex Saltman. "Our expanded partnership with Terran Orbital is critical in delivering these advanced capabilities to customers across the globe."
About Terran Orbital
Terran Orbital is the leading manufacturer of small satellites primarily serving the United States aerospace and defense industry. Terran Orbital provides end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and in-orbit support to meet the needs of the most demanding military, civil, and commercial customers. Learn more at www.terranorbital.com.
Media Contacts:
pr@terranorbital.com
949-508-6404
View original content to download multimedia:
SOURCE Terran Orbital | https://www.whsv.com/prnewswire/2022/05/02/terran-orbital-ships-two-geooptics-satellites-cape-canaveral-integration-ahead-spacexs-transporter-5-mission/ | 2022-05-02T10:18:58Z |
DUBLIN, May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
Conference Call Information
To participate in the live call by telephone, please dial (800) 225-9448 from the US or (203) 518-9783 for international callers, using the conference code TBPH0505. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Presentations and Events.
A replay of the conference call will be available on Theravance Biopharma's website for 30 days through June 4, 2022. An audio replay will also be available through 11:59 pm ET on May 12, 2022 by dialing (800) 839-1337 from the US, or (402) 220-0489 for international callers.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.
In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download multimedia:
SOURCE Theravance Biopharma, Inc. | https://www.whsv.com/prnewswire/2022/05/02/theravance-biopharma-report-first-quarter-2022-financial-results-may-5-2022/ | 2022-05-02T10:19:04Z |
NEW YORK, May 2, 2022 /PRNewswire/ -- Total spending on financial market data and cloud-based software continued its decade-long growth trend in the second quarter of 2022. A new report from TradeAlgo estimates total financial data spending will surpass $37 billion in 2022, marking a new record.
Real-time data is dominated by Bloomberg with over one-third of the total market share. Fintech upstarts like TradeAlgo and global players like IRESS, IHS Markit, Refinitiv and S&P Global have contributed to a record $35.6 billion in 2021.
"Bloomberg ranks 1st in global revenue in all user groups we tracked," says Jon Stone, founder of TradeAlgo. "We seek to serve the 100+ million users who can't afford to pay tens of thousands per year for high quality, low latency market data and algorithms."
"We hear from underserved people every day that they wish they had access to the same kind of data that hedge funds on Wall Street have," added Stone.
Post pandemic growth has been consistent across all global regions TradeAlgo tracked, with market data spending in the Americas increasing by approximately 8.2% in 2021, outpacing the 6.7% rate in Europe and 6.6% in Asia.
The United States leads market data spending with 55.1% of the global's total number. Europe and Asia accounted for 26.2% and 18.7% of the total, respectively.
The investing landscape has changed radically as retail investors' power and influence grew exponentially and showed no signs of abating. "Public companies can no longer operate under the former conventional wisdom that retail investors have no impact," noted a report by S&P Global.
Public participation in the market remains higher than it was prior to the pandemic, which has contributed to TradeAlgo's forecast of $37 billion in global market data spending by 2022.
TradeAlgo combines cost-saving engineering innovations with access to institutional-grade data APIs to help both seasoned investors and novices make better, more informed decisions.
"Access to data isn't just valuable for investors, it's indispensable. Today's high-frequency-driven trading environment, enhanced by artificial intelligence and Virtual Reality, continues to infiltrate our markets. TradeAlgo seeks to open up these emerging technologies for everyone to accelerate transparency and fair markets for all," said Mr. Stone.
Although the industry demand is expected to reach new heights this year and surpass $37B, many traders surveyed expect traditional market data providers to face greater threats from incumbents and blockchains.
In a recent TradeAlgo survey, 50% of respondents said the biggest challenge facing market data providers in the next two years will be adapting to the growing popularity of data platforms, cloud marketplaces, and third-party application suites.
With scalable cloud-based solutions, underserved customers are able to consume and purchase data more conveniently while at the same time maintaining fewer direct vendor relationships, which respondents believe will force legacy vendors like Bloomberg, Refinitiv and others to adapt.
About TradeAlgo.com
TradeAlgo is on a mission to make high quality, low latency market data available for the 100 million + underserved customers in capital markets. TradeAlgo has refined its technology through best-in-class cloud-based applications, APIs, and algorithms by sponsoring The Harvard Computer Society alongside Citadel, Microsoft, and Huawei. TradeAlgo seeks to help traders, fintech startups and financial institutions get the maximum value from their data with its algorithms and market data application suite solutions. Today, thousands of clients have access to over 500 market APIs and leverage a suite of specialized applications to accelerate efficient and cost-effective trading solutions. Visit TradeAlgo.com for more information.
View original content to download multimedia:
SOURCE Trade Algo | https://www.whsv.com/prnewswire/2022/05/02/total-spending-financial-market-data-set-break-new-record-37-billion-2022-according-trade-algo/ | 2022-05-02T10:19:10Z |
Airbnb’s COVID refund policy is ending
Published: May. 2, 2022 at 6:06 AM EDT|Updated: 55 minutes ago
(CNN) - Airbnb has announced its popular COVID-19 refund policy is ending as of May 31.
After that date, guests will have to cover short-term rental costs, even if their reason for canceling was due to the coronavirus.
For much of the pandemic, guests who had to cancel an Airbnb reservation could do so without a penalty.
Starting at the end of May, cancellation policies will return to the discretion of the individual host property. Some Airbnb rentals only require 24 hours of advance notice, while others may require cancellation five days in advance for a full refund.
Airbnb is promising to offer guests travel insurance in the near future, which will provide another refund option for customers.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.wvva.com/2022/05/02/airbnbs-covid-refund-policy-is-ending/ | 2022-05-02T11:01:54Z |
Sunny skies with highs in the 70s today; growing unsettled again this week
Multiple storm systems will bring back the chance of rain later this week
It’s a mild morning and we will stay that way throughout the rest of the day. Temperatures will rise into the 70s this afternoon with mainly sunny skies. Breezy conditions are expected today behind a cold front that moved through last night.
Winds will be calmer tonight out of the southwest which will keep us mild with lows in the 50s. We will stay dry with partly cloudy skies.
Rain chances return tomorrow as a warm front lifts through the region. Some pop-up showers and thunderstorms are possible mainly during the afternoon hours as we heat up. High temperatures will reach the upper 70s and 80s tomorrow afternoon.
A cold front will pass through Wednesday morning bringing some more rain and possibly a thunderstorm. Since it will move through in the morning, we luckily won’t see anything in the way of severe weather. Temperatures will be cooler but above average with highs in the 70s for most.
Most should dry up on Thursday, however, a few isolated showers are possible. That’s before some more widespread rain moves in for the rest of the week. Make sure to stay tuned and catch the latest on WVVA.
Copyright 2022 WVVA. All rights reserved. | https://www.wvva.com/2022/05/02/sunny-skies-with-highs-70s-today-growing-unsettled-again-this-week/ | 2022-05-02T11:02:01Z |
US pediatricians’ group moves to abandon race-based guidance
(AP) - For years, pediatricians have followed flawed guidelines linking race to risks for urinary infections and newborn jaundice. In a new policy announced Monday, the American Academy of Pediatrics said it is putting all its guidance under the microscope to eliminate “race-based” medicine and resulting health disparities.
A re-examination of AAP treatment recommendations that began before George Floyd’s 2020 death and intensified after it has doctors concerned that Black youngsters have been undertreated and overlooked, said Dr. Joseph Wright, lead author of the new policy and chief health equity officer at the University of Maryland’s medical system.
The influential academy has begun purging outdated advice. It is committing to scrutinizing its “entire catalog,” including guidelines, educational materials, textbooks and newsletter articles, Wright said.
“We are really being much more rigorous about the ways in which we assess risk for disease and health outcomes,” Wright said. “We do have to hold ourselves accountable in that way. It’s going to require a heavy lift.”
Dr. Brittani James, a family medicine doctor and medical director for a Chicago health center, said the academy is making a pivotal move.
“What makes this so monumental is the fact that this is a medical institution and it’s not just words. They’re acting,” James said.
In recent years, other major doctor groups including the American Medical Association have made similar pledges. They are spurred in part by civil rights and social justice movements, but also by science showing the strong roles that social conditions, genetics and other biological factors play in determining health.
Last year, the academy retired a guideline calculation based on the unproven idea that Black children faced lower risks than white kids for urinary infections. A review had shown that the strongest risk factors were prior urinary infections and fevers lasting more than 48 hours, not race, Wright said.
A revision to its newborn jaundice guidance — which currently suggests certain races have higher and lower risks — is planned for this summer, Wright said.
Dr. Nia Heard-Garris, head of an academy group on minority health and equity and a pediatrician at Chicago’s Lurie Children’s Hospital, noted that the new policy includes a brief history “of how some of our frequently used clinical aids have come to be — via pseudoscience and racism.”
Whatever the intent, these aids have harmed patients, she said.
“This violates our oath as physicians — to do no harm — and as such should not be used,” Heard-Garris said.
Dr. Valerie Walker, a specialist in newborn care and health equity at Nationwide Children’s Hospital in Columbus, Ohio, called the new policy “a critical step” toward reducing racial health disparities.
The academy is urging other medical institutions and specialty groups to take a similar approach in working to eliminate racism in medicine.
“We can’t just plug up one leak in a pipe full of holes and expect it to be remedied,” said Heard-Garris. “This statement shines a light for pediatricians and other healthcare providers to find and patch those holes.”
___
Follow AP Medical Writer Lindsey Tanner at @LindseyTanner.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Copyright 2022 The Associated Press. All rights reserved. | https://www.wvva.com/2022/05/02/us-pediatricians-group-moves-abandon-race-based-guidance/ | 2022-05-02T11:02:07Z |
15 injured in pedal pub crash in Atlanta; driver charged with DUI
ATLANTA (WGCL/Gray News) - The driver of a pedal pub that crashed on Saturday night has been arrested and charged with driving under the influence, the Atlanta Police Department said Sunday morning.
The pedal pub, which is a mobile bar, tipped over while making a turn at West Peachtree Street and 14th Street NE in downtown Atlanta, authorities said.
It happened around 6:30 p.m. According to the Atlanta Police Department, the pedal pub was apparently going too fast while trying to make the turn.
Atlanta Fire Rescue said 15 people were injured and taken to hospitals. Ten sustained minor injuries, three had serious injuries, and two had critical injuries.
“The Atlanta Fire Rescue Department has a mobile ambulance. We call it MAV-1. ... We utilized that to transport 10 and Grady facilitated the transportation of the other five patients,” said Jason McLain, battalion chief for Atlanta Fire Rescue Department.
No other vehicles were involved.
In addition to the DUI, the driver was also charged with a business permit violation, WGCL reported.
Copyright 2022 WGCL via Gray Media Group, Inc. All rights reserved. | https://www.whsv.com/2022/05/02/15-injured-pedal-pub-crash-atlanta-driver-charged-with-dui/ | 2022-05-02T11:46:44Z |
Greyhound racing nearing its end in the US after long slide
DUBUQUE, Iowa (AP) — Vera Rasnake laughed as she led a trio of barking, jostling dogs into the Iowa Greyhound Park, but her smile faded when she acknowledged that after 41 years of being around the sleek animals, her sport was teetering on extinction.
After the end of a truncated season in Dubuque in May, the track here will close. By the end of the year there will only be two tracks left in the country.
“It’s very hard for me to see this,” Rasnake said.
It’s been a long slide for greyhound racing, which reached its peak in the 1980s when there were more than 50 tracks across 19 states. Since then, increased concerns about how the dogs are treated along with an explosion of gambling options has nearly killed a sport that gained widespread appeal about a century ago.
A racing association found that betting on greyhounds plunged from $3.5 billion in 1991 to about $500 million in 2014. Since then, many more tracks have closed.
In some states like the dog-racing mecca of Florida in 2021, it was voter initiatives that ended the sport at the state’s dozen tracks. In others like Iowa, state officials allowed casinos to end subsidies that had kept greyhound racing alive as interest declined.
“Do I think the industry is dying? Yes,” said Gwyneth Anne Thayer, who has written a history of greyhound racing. But “it’s happening way faster than I thought it would.”
The Dubuque track closure and the end of racing in West Memphis, Arkansas, this December will leave racing only in West Virginia, where tracks in Wheeling and near Charleston operate with subsidies from casino revenue.
For some animal welfare groups, the industry’s collapse is the culmination of decades of work to publicize allegations of greyhound mistreatment. The group GREY2K was formed in 2001 and Carey Theil, the organization’s executive director, said he feels a sense of accomplishment now that the sport’s end seems within reach.
“This has become one of the signature animal welfare debates of our time,” Theil said.
GREY2K, the Humane Society and other groups have long argued that greyhound racing was cruel, including its longtime practice of killing dogs that weren’t deemed top racers, using drugs to enhance their performance, confining them for long periods and subjecting animals to the risk of injury on the racetrack.
Industry supporters note there now is a huge demand to adopt retired racers and deny that the other problems are widespread. They also contend that some don’t understand the love greyhounds have for running.
On opening day at the Iowa Greyhound Park in Dubuque, spectators packed into a spacious room that overlooked the track, sipping beers and mixed drinks as they pored over racing statistics before placing bets at kiosks or with attendants. They expressed disappointment that the track would close, lamenting the loss of an entertainment option in Dubuque, a city of about 60,000 known for its stately brick buildings and church steeples built on hills overlooking the Mississippi River.
Peggy Janiszewski and her friend Robin Hannan have for years been driving about three hours from the Chicago area to Dubuque to watch the racing. They typically bet only a few dollars on each race but are more interested in watching the dogs than counting their winnings.
“They’re beautiful. Like works of art,” Janiszewski said.
Bruce Krueger said he has been making the 170-mile (274-kilometer) drive from Milwaukee to Dubuque. He doesn’t believe the dogs are mistreated.
“I know some trainers, and they treat them like kings and queens,” Krueger said.
General Manager Brian Carpenter was 16 when he started working at the track in its second year and has remained 36 seasons until this, its final year.
He recalls the excitement when the track opened in 1985, a time when Iowa was mired in farm bankruptcies and much of Dubuque was struggling. Back then, thousands of people would attend the races, with buses of gamblers arriving every weekend from Chicago and Milwaukee.
“It was an exciting time and the track offered good jobs,” he said.
Opening day this year drew at least 1,000 people but smaller crowds are typical, especially on weeknights.
The Dubuque track was helped along by city and state funding, and after Iowa and other states began allowing casinos, the Dubuque operation was expanded to include its own casino.
Thayer’s book, “Going to the Dogs,” describes a sport with a colorful and often tumultuous history. From its beginning in the 1920s following development of the mechanical lure, the industry was continually pushing to allow for legalized betting state-by-state and to attract attention, with help from Hollywood celebrities, athletes and beauty pageant competitors.
At times, the sport drew more spectators than its more prominent rival horse racing. While considered seedy by some, it was mainstream entertainment for decades, Thayer said.
“People don’t realize how normalized it was in American culture for a long time,” she said.
Greyhound racing also is held in other countries, including Australia, Great Britain, Ireland, Mexico and Vietnam, but it is facing some of the same problems apparent in the U.S.
Although greyhound racing in the U.S. will be confined only to West Virginia, that state seems intent on retaining the sport, said Steve Sarras, president of the West Virginia Kennel Owners Association. The state’s two tracks run races five-days a week year-round.
Sarras said West Virginia legislators made repeated visits to his kennel and others to inspect conditions, and ultimately were confident the dogs are well treated.
“When you see it firsthand, you cannot fake how happy a dog is,” he said.
___
Follow Scott McFetridge on Twitter: https://twitter.com/smcfetridge
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/05/02/greyhound-racing-nearing-its-end-us-after-long-slide/ | 2022-05-02T11:46:50Z |
US pediatricians’ group moves to abandon race-based guidance
(AP) - For years, pediatricians have followed flawed guidelines linking race to risks for urinary infections and newborn jaundice. In a new policy announced Monday, the American Academy of Pediatrics said it is putting all its guidance under the microscope to eliminate “race-based” medicine and resulting health disparities.
A re-examination of AAP treatment recommendations that began before George Floyd’s 2020 death and intensified after it has doctors concerned that Black youngsters have been undertreated and overlooked, said Dr. Joseph Wright, lead author of the new policy and chief health equity officer at the University of Maryland’s medical system.
The influential academy has begun purging outdated advice. It is committing to scrutinizing its “entire catalog,” including guidelines, educational materials, textbooks and newsletter articles, Wright said.
“We are really being much more rigorous about the ways in which we assess risk for disease and health outcomes,” Wright said. “We do have to hold ourselves accountable in that way. It’s going to require a heavy lift.”
Dr. Brittani James, a family medicine doctor and medical director for a Chicago health center, said the academy is making a pivotal move.
“What makes this so monumental is the fact that this is a medical institution and it’s not just words. They’re acting,” James said.
In recent years, other major doctor groups including the American Medical Association have made similar pledges. They are spurred in part by civil rights and social justice movements, but also by science showing the strong roles that social conditions, genetics and other biological factors play in determining health.
Last year, the academy retired a guideline calculation based on the unproven idea that Black children faced lower risks than white kids for urinary infections. A review had shown that the strongest risk factors were prior urinary infections and fevers lasting more than 48 hours, not race, Wright said.
A revision to its newborn jaundice guidance — which currently suggests certain races have higher and lower risks — is planned for this summer, Wright said.
Dr. Nia Heard-Garris, head of an academy group on minority health and equity and a pediatrician at Chicago’s Lurie Children’s Hospital, noted that the new policy includes a brief history “of how some of our frequently used clinical aids have come to be — via pseudoscience and racism.”
Whatever the intent, these aids have harmed patients, she said.
“This violates our oath as physicians — to do no harm — and as such should not be used,” Heard-Garris said.
Dr. Valerie Walker, a specialist in newborn care and health equity at Nationwide Children’s Hospital in Columbus, Ohio, called the new policy “a critical step” toward reducing racial health disparities.
The academy is urging other medical institutions and specialty groups to take a similar approach in working to eliminate racism in medicine.
“We can’t just plug up one leak in a pipe full of holes and expect it to be remedied,” said Heard-Garris. “This statement shines a light for pediatricians and other healthcare providers to find and patch those holes.”
___
Follow AP Medical Writer Lindsey Tanner at @LindseyTanner.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/05/02/us-pediatricians-group-moves-abandon-race-based-guidance/ | 2022-05-02T11:46:57Z |
As Rising Inflation Makes Paying Bills and Building Savings Increasingly Difficult, More Consumers of All Income Brackets Join Their Ranks
Paycheck-to-Paycheck Consumers are Three Times More Likely to Revolve Credit Card Debt and Carry Higher Monthly Balances
SAN FRANCISCO, May 2, 2022 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from its ninth edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS.com.
The Credit Edition examines the growing shares of U.S. consumers in all economic brackets living paycheck to paycheck, and the impact on their ability to access credit and other expense management tools.
Key takeaway: Living paycheck to paycheck has become the dominant way people manage their cashflow in the United States, with close to two-thirds of the U.S. population, 64% or about 166 million adults, doing so in March 2022.
Living paycheck to paycheck means devoting all of one's salary to expenses with little to nothing left over at the end of the month, yet many of these consumers remain credit worthy, actively managing their cash flows in real time. In fact, close to one-quarter of consumers living paycheck to paycheck report a credit score higher than the FICO average of 750.
"The number of people living paycheck to paycheck today is reminiscent of the early days of the pandemic and it has become the dominant lifestyle across income brackets," said Anuj Nayar, Financial Health Officer at LendingClub. "As inflation we have not seen in a generation takes more of our paychecks for everyday needs, Americans across incomes and credit scores are increasingly relying on credit products just to get by. That is why the financial services industry must offer better tools to help bridge the gap."
A Deeper Look at Credit Scores
PYMNTS' research finds that paycheck-to-paycheck consumers without issues paying their bills have an about average credit score of 694, while those struggling to pay bills each month have a below average credit score of 613. The average credit score for all paycheck-to-paycheck consumers is 664, more than 90 points below the average for consumers not living paycheck to paycheck. Meanwhile, the gap between the average credit scores of low- and high-income consumers is less than 90 points. Consumers who earn less than $50,000 report a below average credit score of 648, while those earning more than $100,000 report an above average credit score of 734.
The data also finds that consumers who are financially struggling tend to check their credit scores more frequently. Of those consumers who live paycheck to paycheck with issues paying their bills, 20% checked their credit scores in the 24 hours before PYMNTS' survey compared to only 9% of consumers who live paycheck to paycheck without issues paying their bills.
Credit And Living Paycheck to Paycheck
The report continues to find that credit card ownership remains high, with 63% of respondents of all financial lifestyles saying they have made a credit card payment in the last 90 days.
Paycheck-to-paycheck consumers are three times as likely to revolve credit card debt and carry higher monthly balances overall. Those consumers who never pay their credit balances in full also tend to hold more credit cards than average. PYMNTS' research finds that 29% of credit card holders "always" or "usually" revolve their balances.
On average, credit card holders have approximately two credit cards, which rises to three credit cards among those not likely to pay their credit card in full (i.e., those who "always" or "usually" have a revolving balance). Moreover, the data finds that the average sum of monthly balances over the last six months for those who always revolve balances on their credit cards is triple the average of those who always pay in full.
Struggling consumers also tend to nearly saturate the average credit card spending limit of $4,700, declaring an average balance of $3,800. Paycheck-to-paycheck consumers not struggling to pay their bills report an average spending of $3,100 and a limit of $6,500. Consumers not living paycheck to paycheck report an average spending of $2,100 and a $9,000 limit.Many paycheck-to-paycheck consumers remain creditworthy, maintain good credit scores, and are apt to tap into consumer loans, credit cards and other payment options such as personal loans to manage their cash flows.
"As the Fed looks to curb inflation by raising interest rates, consider looking at any credit you have with a variable interest rate," continued Nayar. "Many of LendingClub's 4 million members have already refinanced their variable interest rate credit card balance into a lower cost fixed rate loan so they can responsibly manage their debt obligations."
To view the full report, visit: http://www.pymnts.com/study/reality-check-paycheck-to-paycheck-credit-scores-consumer-card-debt-inflation/
Methodology
New Reality Check: The Paycheck-To-Paycheck Report is based on a census-balanced survey of 2,326 U.S. consumers conducted from March 9 to March 11. The Paycheck-To-Paycheck series expands on existing data published by state agencies such as the Federal Reserve System and the Bureau of Labor Statistics to provide a deep look into the elements that lie at the backbone of the American consumer's financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 52% of respondents identified as females, 32% were college-educated and 36% declared incomes of over $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $70 billion in loans, our artificial intelligence-driven credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members, while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
CONTACT:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.whsv.com/prnewswire/2022/05/02/23-us-population-now-lives-paycheck-paycheck/ | 2022-05-02T11:47:04Z |
Flexible benefits cover changing needs of workers in post-pandemic environment
COLUMBUS, Ga., May 2, 2022 /PRNewswire/ -- Aflac Incorporated, a leading provider of supplemental insurance products in the U.S., today announced the launch of its newly redesigned Aflac Group Critical Illness Insurance to help employers better support the changing needs of their valued workers in a post-pandemic environment. The newly designed product includes more standard and optional benefits, giving employers greater flexibility to design the coverage plan that meets the unique needs of their workforce. This has become increasingly important as critical illness insurance is one of the five fastest-growing benefits employers offer.1
Aflac's redesigned Group Critical Illness Insurance is a next-generation product, offering coverage for a growing list of acute and chronic conditions. In addition to benefits for serious health events and illnesses — like heart attacks, stroke and cancer — that are traditionally part of a critical illness plan, the redesigned product now gives employers the option to include coverage for infectious diseases, including the flu, pneumonia, human coronavirus and chronic conditions like diabetes.
Aflac's new Group Critical Illness Insurance product also offers a mental illness rider that covers serious mental illnesses, including bipolar disorder, post-traumatic stress disorder, substance use disorder, major depressive disorder and schizophrenia. This benefit helps address alarming survey data that shows 80% of workers are worried about their mental health,2 particularly as studies show that chronic illnesses, such as cancer, heart disease or diabetes, may increase the likelihood of having or developing a mental health condition.3 Health screenings, including mental health exams that can help detect potential problems before they become more harmful to a covered individual's health, are also available in the plan.
"The past two years have taught us that being prepared for potential medical challenge is essential for employers to maintain a safe and healthy workforce," said Bob Ruff, senior vice president, Aflac Group Voluntary Benefits. "Aflac's new Group Critical Illness Insurance, including new mental health and infectious disease coverage, allows employers to keep their benefits program robust in a way that is meaningful and relevant for today's workforce, while not impacting budget and cost constraints."
"Employees bring their whole selves to work. That includes everything they're dealing with physically, mentally and financially, and the last two years have been especially challenging," said Kim Rudeen, vice president, Aflac Product Development and Management. "Aflac's Group Critical Illness Insurance products were designed to meet today's rapidly changing benefits environment with flexible coverage that helps take care of expenses health insurance doesn't cover. Insured individuals can use their benefits to help with medical co-pays, deductibles and prescriptions or everyday living expenses like rent, utilities or child care."
Highlights of Aflac's strengthened Critical Illness Insurance product include:
- Hospitalization benefit for treatment of a covered infectious disease that is payable on day one of intensive care unit confinement or day four of hospital confinement, whichever is the highest applicable benefit.
- Expanded tests and screenings: New health screening benefits encourage people to seek care that can help detect health concerns, including annual vision exams, testing for certain human coronaviruses, biopsies, immunizations, genetic screening tests and mental health screenings.
- Customizable coverage: Modular expansions cover more chronic and serious illnesses that can be expensive to treat and could possibly lead to higher health insurance costs. The progressive disease rider provides optional coverage for conditions like COPD, Crohn's disease, advanced Parkinson's disease and advanced Alzheimer's disease, while the specified disease rider now covers human coronavirus, pneumonia, influenza, bird flu and Ebola.
- Cancer treatment rider: Rarely seen on a critical illness plan, this new rider provides benefits for therapy, hospitalization, inpatient and outpatient surgery, blood and plasma.
Learn more about this new plan at Aflac.com/critical.
Products and benefits vary by state and are not currently available in all states.
Aflac Group products are underwritten by Continental American Insurance Company (CAIC), a proud member of the Aflac family of insurers. CAIC is not licensed to solicit business in New York, Guam, Puerto Rico, or the Virgin Islands. For groups sitused in California, group coverage is underwritten by Continental American Life Insurance Company.
About Aflac Incorporated
Aflac Incorporated (NYSE: AFL) is a Fortune 500 company helping provide protection to more than 50 million people through its subsidiaries in Japan and the U.S., where it is a leading supplemental insurer by paying cash fast when insured individuals get sick or injured. For more than six decades, insurance policies of Aflac Incorporated's subsidiaries have given insured individuals the opportunity to focus on recovery, not financial stress. In the U.S., Aflac is the number one provider of voluntary/worksite insurance products. Aflac Life Insurance Japan is the leading provider of medical and cancer insurance in Japan, where it insures 1 in 4 households. In 2021, Aflac Incorporated was proud to be included as one of the World's Most Ethical Companies by Ethisphere for the 16th consecutive year. Also in 2021, the company was included in the Dow Jones Sustainability North America Index and became a signatory of the Principles for Responsible Investment (PRI). In 2022, Aflac Incorporated was included on Fortune's list of World's Most Admired Companies for the 21st time and Bloomberg's Gender-Equality Index for the third consecutive year. To find out how to get help with expenses health insurance doesn't cover, get to know us at aflac.com or aflac.com/español. Investors may learn more about Aflac Incorporated and its commitment to ESG and social responsibility at investors.aflac.com under "Sustainability."
Aflac herein means American Family Life Assurance Company of Columbus and American Family Life Assurance Company of New York.
1 Willis Towers Watson. Pandemic accelerates employer voluntary benefit offerings. May 13, 2021. Accessed 10.7.2021.
2 The Conference Board. Survey: Workers Say Job Pressures Take Bigger Mental Toll than COVID-19 Fears. October 7, 2021. Accessed 10.28.2021.
3 Centers for Disease Control and Prevention. Chronic Illness and Mental Health: Recognizing and Treating Depression. Accessed 11.15.21.
For interviews, contact: Jon Sullivan, 706-763-4813 or jsullivan@aflac.com
Analyst and investor contact: David A. Young, 706-596-3264, 800-235-2667 or dyoung@aflac.com
View original content to download multimedia:
SOURCE Aflac Incorporated | https://www.whsv.com/prnewswire/2022/05/02/aflac-enhances-group-critical-illness-insurance-include-serious-mental-illnesses-infectious-diseases-like-covid-19/ | 2022-05-02T11:47:14Z |
VANCOUVER, BC, May 2, 2022 /PRNewswire/ - Alexco Resource Corp. (NYSE American: AXU) (TSX: AXU) ("Alexco" or the "Company") today announced that it will release its first quarter 2022 financial results on Thursday, May 12, 2022 after market close. Management will discuss the results during an audio webcast conference call on Friday, May 13, 2022 at 1:00 pm Eastern Time (10:00 am Pacific Time).
To participate in the live call, please use one of the following methods:
Participants should connect five to ten minutes before the call. The conference call will be recorded, and an archived audio webcast will be available at www.alexcoresource.com shortly after the call.
Alexco is a Canadian primary silver company that owns and operates the majority of the historic Keno Hill Silver District, in Canada's Yukon Territory, one of the highest-grade silver mines in the world. Alexco started concentrate production and shipments in 2021 and is currently advancing Keno Hill toward steady state production. Upon reaching commercial production, Keno Hill is expected to produce an average of approximately 4.4 million ounces of silver per year contained in high quality lead/silver and zinc concentrates. Keno Hill retains significant potential to grow and Alexco has a long history of expanding the operation's mineral resources through successful exploration.
Please visit the Alexco website at www.alexcoresource.com
Some statements ("forward-looking statements") in this news release contain forward-looking information concerning the Company's anticipated results and developments in the Company's operations in future periods, made as of the date of this news release. Forward-looking statements may include, but are not limited to, statements with respect to the timing of activities and reports. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Forward-looking statements are based on certain assumptions that management believes are reasonable at the time they are made. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
View original content:
SOURCE Alexco Resource Corp. | https://www.whsv.com/prnewswire/2022/05/02/alexco-release-first-quarter-2022-results-may-12-2022/ | 2022-05-02T11:47:21Z |
...SMALL CRAFT ADVISORY NOW IN EFFECT UNTIL 6 PM HST MONDAY...
* WHAT...East to northeast winds 20 to 25 knots.
* WHERE...All Hawaiian Coastal Waters.
* WHEN...Until 6 PM HST Monday.
* IMPACTS...Conditions will be hazardous to small craft.
PRECAUTIONARY/PREPAREDNESS ACTIONS...
Inexperienced mariners, especially those operating smaller
vessels, should avoid navigating in these conditions.
&&
HONOLULU (KITV)- An apartment building fire forced eight residents from their homes, sent one man to the hospital, and a woman who lived next door is recovering from smoke inhalation. Residents of that building tell us they've lost what cannot be replaced.
"My uncle passed away. We had one photo of him. He just passed away 2 years ago. And we always had the photo by the door. And we always like blessed his photo, watching him as we left. I didn't even remember about it until a minute ago. Like oh my god I lost that," said Sarah Hickey who is a resident who was displaced by the fire.
Hours after a fire ripped through the second floor of apartment complex on Varsity Place, Sarah Hickey is still brought to tears. The Honolulu Fire Department says the call came in at 10:53 am. "The first unit arrived at 11:01 am to find smoke and flames coming from the second story," said Honolulu Fire Department Captain Randall Lindsey.
Only 9 minutes later, the second story started to collapse. So too did the hearts of those who once lived there. Two dogs did not make it out alive. "I think what really hurts is the loss of our fur family. That's what is really difficult. But I'm glad everyone is safe," said displaced resident Don farmer.
Hickey herself had a scare when she was notified of the fire. A neighbor was concerned her brother was inside at the time. "It was scary because I didn't know where he was. And I didn't know if he was a sleep at the time. So at the moment I was devastated thinking he might have been home. But luckily he wasn't," said Hickey.
No human fatalities. That's the good news. The bad news is the second floor is gutted by the fire, the first floor has water damage, and 4 families need a new place to sleep. They don't know what tomorrow brings. " I'm just going to try and find a new apartment to live in. Luck I have the support of neighbors and friends here, as well as my boyfriend. We're going to be OK for a few days as we try to get it together," said Hickey.
Meanwhile the Red Cross, a local church, and neighbors have stepped up to offer different kinds of support whether it was something to drink or a chair to sit and recover. But it's going to be an uphill battle after losing all their things, and pets. We're told a Gofundme account is being set up for the victims.
The Honolulu fire departments tells us an electrical arc from an outlet on the second floor caused this accidental fire, which caused an estimated $620,000 in damage. | https://www.kitv.com/news/local/update-and-reaction-to-varsity-circle-apartment-fire/article_453f94f4-c9f8-11ec-9648-cf3e2c567f0f.html | 2022-05-02T11:47:26Z |
̶ Clinical, Epidemiology and Health Economics and Outcomes Research to Advance Understanding of Treatment Patterns and Patient Experiences ̶
DUBLIN, May 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present research related to its psychiatry portfolio at four scientific conferences during Mental Health Awareness Month in May. The meetings include:
- American Telemedicine Association (ATA) Annual Conference, May 1-3, Boston
- International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, May 15-18, National Harbor, Md.
- American Psychiatric Association (APA) Annual Meeting, May 21-25, New Orleans
- American Society of Clinical Psychopharmacology (ASCP) Annual Conference, May 31-June 3, Scottsdale, Ariz.
"This year, we're excited to once again take part in scientific discourse and engage with leaders and members of the medical, mental health and health economics communities," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes. "May is Mental Health Awareness Month, and it's an important reminder of the tremendous unmet need that still exists for people living with mental health conditions. We are committed to conducting and sharing research that contributes to the understanding of these diseases, and that may help inform future study into new treatment options."
Highlights of the upcoming presentations include:
- Methodology and qualitative data from LATITUDE, a noninterventional study designed to assess knowledge of, attitudes toward and perceived barriers to utilizing long-acting injectable (LAI) antipsychotics for schizophrenia in telepsychiatry;
- Findings from post-hoc analyses evaluating daily and social functioning in adults with schizophrenia who were switched from a prior LAI antipsychotic to ARISTADA® (aripiprazole lauroxil);
- Findings from a budget impact model estimating the cost of adding LYBALVI® (olanzapine and samidorphan) to formulary from Commercial, Medicaid and Medicare perspectives in the United States;
- Detailed results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of LYBALVI compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.
The full list of Alkermes' presentations by meeting includes:
ATA
- Use of Long-Acting Antipsychotic Treatments in Community Telepsychiatry: Study to Assess Knowledge, Attitudes, and Perceived Barriers from Patients', Caregivers', and Providers' Perspectives in South Carolina (LATITUDE Study)
ISPOR
- Poster EE158: Budget Impact of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective
- Poster CO58: Long-term Health Outcomes in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for 1 Year
- Poster CO122: Patient Versus Caregiver and Clinician Reports of Cognitive Difficulties in Patients with Schizophrenia Switching to Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: A Post Hoc Analysis
- Poster HPR1: Does Specialty Drug Coverage Vary Between Health Plans' Medical and Pharmacy Benefit Policies?
APA
- Poster P8-090: Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics Since COVID-19 Pandemic Onset, Including the Role of Telepsychiatry
- Poster P6-082: Opioid Prescription Dispensing Patterns Among Patients with Schizophrenia or Bipolar Disorder
ASCP
Oral Presentation:
- Title: Olanzapine/Samidorphan in Young Adults with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the ENLIGHTEN-Early Study
- Presenter: John Kane, M.D., Chairman of the Department of Psychiatry at The Zucker Hillside Hospital and Professor and Chairman of Psychiatry at Hofstra Northwell School of Medicine
- Presentation Date: The oral presentation will take place during the Individual Research Report session on Tuesday, May 31, 2022 at 5:05 p.m. MT.
Posters:
- W37: Opioid Prescription Dispensing Patterns Among Patients with Schizophrenia or Bipolar Disorder
- W38: Patient Versus Caregiver and Clinician Reports of Cognitive Difficulties in Patients with Schizophrenia Switching to Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: A Post Hoc Analysis
- Th36: Metabolic Parameters, Vital Signs, and Weight Change in Patients with Schizophrenia Switched to Treatment with Aripiprazole Lauroxil
- Th53: Daily and Social Functioning in Patients with Schizophrenia After Switching to Treatment with Aripiprazole Lauroxil
About LYBALVI® (olanzapine and samidorphan)
LYBALVI® (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet. LYBALVI is available in fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 mg, 15 mg or 20 mg of olanzapine.
INDICATIONS and IMPORTANT SAFETY INFORMATION FOR LYBALVI® (olanzapine and samidorphan)
INDICATIONS
LYBALVI is indicated for the treatment of:
- Schizophrenia in adults
- Bipolar I disorder in adults
- Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate
- Maintenance monotherapy treatment
IMPORTANT SAFETY INFORMATION
Contraindications: LYBALVI is contraindicated in patients who are using opioids or are undergoing acute opioid withdrawal. If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products.
Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke, transient ischemia attack, and fatalities. See Boxed Warning above.
Precipitation of Severe Opioid Withdrawal in Patients who are Physiologically Dependent on Opioids: LYBALVI can precipitate opioid withdrawal in patients who are dependent on opioids, which can lead to an opioid withdrawal syndrome, sometimes requiring hospitalization. LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal. Prior to initiating LYBALVI, there should be at least a 7-day opioid-free interval from last use of short-acting opioids, and at least a 14-day opioid-free interval from the last use of long-acting opioids. Explain the risks associated with precipitated withdrawal and the importance of giving an accurate account of last opioid use to patients and caregivers.
Vulnerability to Life-Threatening Opioid Overdose: Attempting to overcome opioid blockade with high or repeated doses of exogenous opioids could lead to life-threatening or fatal opioid intoxication, particularly if LYBALVI therapy is interrupted or discontinued subjecting the patient to high levels of unopposed opioid agonist as the samidorphan blockade wanes. Inform patients of the potential consequences of trying to overcome the opioid blockade and the serious risks of taking opioids concurrently with LYBALVI or while transitioning off LYBALVI. In emergency situations, if a LYBALVI-treated patient requires opioid treatment as part of anesthesia or analgesia, discontinue LYBALVI. Opioids should be administered by properly trained individual(s) and patient should be continuously monitored in a setting equipped and staffed for cardiopulmonary resuscitation. Patients with a history of chronic opioid use prior to treatment with LYBALVI may have decreased opioid tolerance if LYBALVI therapy is interrupted or discontinued. Advise patients that this decreased tolerance may increase the risk of opioid overdose if opioids are resumed at the previously tolerated dosage.
Neuroleptic Malignant Syndrome, a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation, intensive symptomatic treatment, and close monitoring.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a potentially fatal condition reported with exposure to olanzapine, a component of LYBALVI. Symptoms include a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. Discontinue if DRESS is suspected.
Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Any patient treated with LYBALVI should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required anti-diabetic treatment despite discontinuation of the suspect drug. Measure weight and assess fasting glucose and lipids when initiating LYBALVI and monitor periodically.
Tardive Dyskinesia (TD): Risk of developing TD (a syndrome of potentially irreversible, involuntary, dyskinetic movements) and the likelihood it will become irreversible increases with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief treatment period, even at low doses, or after discontinuation. Given these considerations, LYBALVI should be prescribed in a manner that is most likely to reduce the risk of tardive dyskinesia. If signs and symptoms of TD appear, drug discontinuation should be considered.
Orthostatic Hypotension and Syncope: Monitor orthostatic vital signs in patients who are vulnerable to hypotension, patients with known cardiovascular disease, and patients with cerebrovascular disease.
Falls: LYBALVI may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls, and consequently, fractures or other injuries. Assess patients for risk when using LYBALVI.
Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases): Perform complete blood counts in patients with a history of a clinically significant low white blood cell (WBC) count or history of leukopenia or neutropenia. Discontinue LYBALVI if clinically significant decline in WBC occurs in the absence of other causative factors.
Dysphagia: Use LYBALVI with caution in patients at risk for aspiration.
Seizures: Use LYBALVI with caution in patients with a history of seizures or with conditions that lower the seizure threshold.
Potential for Cognitive and Motor Impairment: Because LYBALVI may cause somnolence, impair judgment, thinking, or motor skills, caution patients about operating hazardous machinery, including motor vehicles, until they are certain that LYBALVI does not affect them adversely.
Body Temperature Dysregulation: Use LYBALVI with caution in patients who may experience conditions that increase core body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).
Anticholinergic (Antimuscarinic) Effects: Olanzapine, a component of LYBALVI, was associated with constipation, dry mouth, and tachycardia. Use LYBALVI with caution with other anticholinergic medications and in patients with urinary retention, prostatic hypertrophy, constipation, paralytic ileus or related conditions. In postmarketing experience, the risk for severe adverse reactions (including fatalities) was increased with concomitant use of anticholinergic medications.
Hyperprolactinemia: LYBALVI elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.
Risks Associated with Combination Treatment with Lithium or Valproate: If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for a description of the risks for these products.
Most common adverse reactions observed in clinical trials were:
- Schizophrenia (LYBALVI): weight increased, somnolence, dry mouth, and headache
- Bipolar I Disorder, Manic or Mixed Episodes (olanzapine): asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor
- Bipolar I Disorder, Manic or Mixed Episodes, adjunct to Lithium or Valproate (olanzapine): dry mouth, dyspepsia, weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, paresthesia
Concomitant Medication: LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal. Concomitant use of LYBALVI is not recommended with strong CYP3A4 inducers, levodopa and dopamine agonists. Reduce dosage of LYBALVI when using with strong CYP1A2 inhibitors. Increase dosage of LYBALVI with CYP1A2 inducers. Use caution with diazepam, alcohol, other CNS acting drugs, or in patients receiving anticholinergic (antimuscarinic) medications. Monitor blood pressure and reduce dosage of antihypertensive drug in accordance with its approved product labeling.
Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with LYBALVI. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to LYBALVI during pregnancy.
Renal Impairment: LYBALVI is not recommended for patients with end-stage renal disease (eGFR of <15 mL/minute/1.73 m2).
To report SUSPECTED ADVERSE REACTIONS, contact Alkermes at 1-888-235-8008 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see accompanying full Prescribing Information, including Boxed Warning, for LYBALVI.
About ARISTADA®
ARISTADA is an injectable atypical antipsychotic approved in four dose strengths and three dosing durations for the treatment of schizophrenia (441 mg, 662 mg or 882 mg monthly, 882 mg once every six weeks and 1064 mg once every two months). Once in the body, ARISTADA converts to aripiprazole.
About ARISTADA INITIO®
ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, can be used to initiate onto any dose of ARISTADA. The first ARISTADA dose may be administered on the same day as the ARISTADA INITIO regimen or up to 10 days thereafter.
INDICATION and IMPORTANT SAFETY INFORMATION for ARISTADA INITIO® (aripiprazole lauroxil) and ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use
INDICATION
ARISTADA INITIO, in combination with oral aripiprazole, is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults.
ARISTADA is indicated for the treatment of schizophrenia in adults.
IMPORTANT SAFETY INFORMATION
Contraindication: Known hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis.
Cerebrovascular Adverse Reactions, Including Stroke: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, have been reported in placebo-controlled trials of elderly patients with dementia-related psychosis treated with risperidone, aripiprazole, and olanzapine. ARISTADA INITIO and ARISTADA are not approved for the treatment of patients with dementia-related psychosis.
Potential for Dosing and Medication Errors: Medication errors, including substitution and dispensing errors, between ARISTADA INITIO and ARISTADA could occur. ARISTADA INITIO is intended for single administration in contrast to ARISTADA which is administered monthly, every 6 weeks, or every 8 weeks. Do not substitute ARISTADA INITIO for ARISTADA because of differing pharmacokinetic profiles.
Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex may occur with administration of antipsychotic drugs, including ARISTADA INITIO and ARISTADA. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.
Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal, involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing antipsychotics should be consistent with the need to minimize TD. Discontinue ARISTADA if clinically appropriate. TD may remit, partially or completely, if antipsychotic treatment is withdrawn.
Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include:
- Hyperglycemia/Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of antidiabetic treatment despite discontinuation of the suspect drug.
- Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
- Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.
Pathological Gambling and Other Compulsive Behaviors: Compulsive or uncontrollable urges to gamble have been reported with use of aripiprazole. Other compulsive urges less frequently reported include sexual urges, shopping, binge eating and other impulsive or compulsive behaviors which may result in harm for the patient and others if not recognized. Closely monitor patients and consider dose reduction or stopping aripiprazole if a patient develops such urges.
Orthostatic Hypotension: Aripiprazole may cause orthostatic hypotension which can be associated with dizziness, lightheadedness, and tachycardia. Monitor heart rate and blood pressure, and warn patients with known cardiovascular or cerebrovascular disease and risk of dehydration and syncope.
Falls: Antipsychotics including ARISTADA INITIO and ARISTADA may cause somnolence, postural hypotension or motor and sensory instability which may lead to falls and subsequent injury. Upon initiating treatment and recurrently, complete fall risk assessments as appropriate.
Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue ARISTADA INITIO and/or ARISTADA at the first sign of a clinically significant decline in WBC and in severely neutropenic patients.
Seizures: Use with caution in patients with a history of seizures or with conditions that lower the seizure threshold.
Potential for Cognitive and Motor Impairment: ARISTADA INITIO and ARISTADA may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are certain therapy with ARISTADA INITIO and/or ARISTADA does not affect them adversely.
Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Advise patients regarding appropriate care in avoiding overheating and dehydration. Appropriate care is advised for patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.
Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use; use caution in patients at risk for aspiration pneumonia.
Concomitant Medication: ARISTADA INITIO is only available at a single strength as a single-dose pre-filled syringe, so dosage adjustments are not possible. Avoid use in patients who are known CYP2D6 poor metabolizers or taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers, antihypertensive drugs or benzodiazepines.
Depending on the ARISTADA dose, adjustments may be recommended if patients are 1) known as CYP2D6 poor metabolizers and/or 2) taking strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, or strong CYP3A4 inducers for greater than 2 weeks. Avoid use of ARISTADA 662 mg, 882 mg, or 1064 mg for patients taking both strong CYP3A4 inhibitors and strong CYP2D6 inhibitors. (See Table 4 in the ARISTADA full Prescribing Information.)
Commonly Observed Adverse Reactions: In pharmacokinetic studies the safety profile of ARISTADA INITIO was generally consistent with that observed for ARISTADA. The most common adverse reaction (≥5% incidence and at least twice the rate of placebo reported by patients treated with ARISTADA 441 mg and 882 mg monthly) was akathisia.
Injection-Site Reactions: In pharmacokinetic studies evaluating ARISTADA INITIO, the incidences of injection site reactions with ARISTADA INITIO were similar to the incidence observed with ARISTADA. Injection-site reactions were reported by 4%, 5%, and 2% of patients treated with 441 mg ARISTADA (monthly), 882 mg ARISTADA (monthly), and placebo, respectively. Most of these were injection-site pain and associated with the first injection and decreased with each subsequent injection. Other injection-site reactions (induration, swelling, and redness) occurred at less than 1%.
Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first days of treatment and at low doses.
Pregnancy/Nursing: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider of a known or suspected pregnancy. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA INITIO and/or ARISTADA during pregnancy. Aripiprazole is present in human breast milk. The benefits of breastfeeding should be considered along with the mother's clinical need for ARISTADA INITIO and/or ARISTADA and any potential adverse effects on the infant from ARISTADA INITIO and/or ARISTADA or from the underlying maternal condition.
Please see full Prescribing Information, including Boxed Warning for ARISTADA INITIO and ARISTADA.
About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
LYBALVI®, ARISTADA® and ARISTADA INITIO® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license.
Alkermes Contacts:
For Investors: Alex Braun +1 781 296 8493
For Media: Marisa Borgasano +1 781 609 6659
View original content to download multimedia:
SOURCE Alkermes plc | https://www.whsv.com/prnewswire/2022/05/02/alkermes-highlight-data-related-psychiatry-portfolio-upcoming-scientific-conferences-during-mental-health-awareness-month/ | 2022-05-02T11:47:28Z |
Country
United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary
People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe | https://www.kitv.com/weather/forecast/monday-weather-forecast/article_859f6ffa-c9fe-11ec-b25f-53f1848a367b.html | 2022-05-02T11:47:32Z |
− Unique and simplified digital experience will enable PayPal's small business customers in the U.S. to explore and obtain their insurance in the same ecosystem they use to manage their payments
CHICAGO, May 2, 2022 /PRNewswire/ -- Aon plc (NYSE: AON) and PayPal Holdings, Inc. (NASDAQ: PYPL) today announced an initiative to help millions of PayPal's small business customers in the U.S. access insurance simply and quickly.
The unique digital insurance program will enable PayPal's small business customers in the U.S. to shop for, purchase and manage insurance coverage through Aon's CoverWallet solution on the PayPal Commerce Platform, online and in minutes. Customers can also obtain personalized advice and guidance from Aon's licensed insurance advisors.
PayPal already offers a range of solutions to help small businesses manage risk, like Seller Protection, Fraud Protection and Chargeback Protection (Terms apply. Fees may apply). By working with Aon, PayPal will be able to provide its small business customers with streamlined access to small business insurance via Aon's CoverWallet solution on the PayPal Commerce Platform. Small business owners in the U.S. are confronted with the challenge of selecting the most appropriate insurance for their business, and they may not have the time to research, shop for and purchase insurance. As a result, many of these businesses are underinsured, meaning they do not have the proper insurance coverage to fully protect their business. This new initiative is designed to address some of the most persistent challenges small businesses face with their insurance decisions — time, effort, choice and cost.
"We share PayPal's culture of innovating on behalf of clients and this initiative is one way we are addressing our clients' most pressing needs," said Roberto Pinto, president of Digital Client Solutions at Aon. "We are uniquely positioned to develop and deliver a digital solution to PayPal that will expand access to insurance for small businesses, which is often an underserved market, and ultimately help them make better decisions to grow and protect their business. By bringing together CoverWallet's digital capabilities and integrating it into PayPal's existing offering for small businesses, we have created a unique experience that simplifies accessing and obtaining insurance for millions of merchants."
PayPal's small business customers in the U.S. will benefit from real-time visibility into the typical coverage and average costs for their insurance needs, a breadth of online quotes and coverage options from top carriers, and the convenience of purchasing insurance with their PayPal accounts via Aon's CoverWallet solution.
"This is a challenging time for small businesses and this initiative can help make it easier for PayPal's small business customers to access a range of insurance solutions to help keep their businesses protected," said Jim Magats, SVP, Payments and SMB Solutions, PayPal. "The program moves forward PayPal's mission to democratize access to the digital payments and commerce solutions small businesses need to manage their end-to-end business, including managing risk and protecting their finances. Aon's digital capabilities, risk expertise, insurance carrier relationships and ability to deliver new solutions tailored to our specific small business customers is key to delivering this program."
The insurance program is live in the U.S. as of April 4, 2022. More information is available here.
Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business.
Follow Aon on Twitter and LinkedIn. Stay up-to-date by visiting the Aon Newsroom and sign up for News Alerts here.
PayPal has remained at the forefront of the digital payment revolution for more than 20 years. By leveraging technology to make financial services and commerce more convenient, affordable, and secure, the PayPal platform is empowering 429 million consumers and merchants in more than 200 markets to join and thrive in the global economy. For more information, visit paypal.com.
Media Contacts
Aon – Nadine Youssef, mediainquiries@aon.com, +1 833 751 8114
PayPal – Grace Nasri, gnasri@paypal.com, +1 408 750 4290
View original content to download multimedia:
SOURCE Aon plc | https://www.whsv.com/prnewswire/2022/05/02/aon-paypal-expand-access-insurance-small-businesses/ | 2022-05-02T11:47:34Z |
TSX Venture Exchange (TSX-V): LIT
Frankfurt Stock Exchange (FSE): OAY3
OTCQB Venture Market (OTC): PNXLF
VANCOUVER, BC, May 2, 2022 /PRNewswire/ - Argentina Lithium & Energy Corp. (TSXV: LIT) (FSE: OAY3) (OTC: PNXLF), ("Argentina Lithium" or the "Company") announces the completion of geophysical surveys at its Rincon West lithium project in Salta Province, Argentina. The results of these deep-seeking geophysical studies expand the potential extent of conductive brine aquifers at the project and will be used to target drilling at the property, due to begin in May 2022.
The Rincon West project covers 2470 hectares of the salar basin, located west of the adjacent Rincon Project owned by Rio Tinto. A total of 36.4 line-kilometres of Transient Electromagnetic (TEM) soundings surveys were completed at Rincon West. The surveys provide electrical resistivity data capable of detecting and delineating conductive strata potentially associated with concentrated lithium brines. TEM soundings are an advanced reconnaissance technique frequently employed in the exploration of lithium salars.
"The TEM surveys suggest that interpreted brine aquifers extend substantially further west and south than indicated by earlier electrical surveys, demonstrating greater potential than expected by the previous owners. We plan to begin drilling in May to test these targets. These new geophysical data allow us to assess potential aquifer quality and depth prior to drilling, which is extremely advantageous for targeting." stated Miles Rideout, V.P. of Exploration.
The TEM surveys, data modeling and presentation were completed by the Argentinean subsidiary of Toronto-based Quantec Geoscience Ltd., ("Quantec"). Quantec is a recognized leader in the industry, with experience spanning over 40 countries with over 5,000 geophysical projects. Quantec has considerable experience in the provision of qeophysical services for the evaluation of salars in the Puna Region of Argentina.
A total of 190 soundings were completed at 200 metre intervals along six east-west lines and two transecting lines, with a north-south line spacing of between 1400 and 1900 metres (see Figure 1). Data were acquired with a Geonics Ltd. PROTEM System operated in centre-loop sounding mode with 200m transmitter loops. The sounding data were recorded at 2.5 and 25 Hz. repetition rates. The data were modelled with 1-D resistivity-depth inversions, which were compiled as 2D resistivity transects of the project. The maximum depth of investigation varied from 200 metres to as much as 1700 metres below surface.
Figure 1 (https://bit.ly/3y6UPWH) presents a map showing the extent of highly conductive subsurface strata at the project (shaded yellow), interpreted from the TEM to represent the potential extent of concentrated brine aquifer. The prospective ground defined by the TEM survey covers 1,570 hectares or approximately 64% of the project.
Figure 2 (https://bit.ly/3MIgpVp) presents a sequence of TEM sections overlaid on the interpretation map. The upper bound of each section represents the topography of the terrain at surface. The lower extent of each section represents the maximum depth of investigation, not the limit of the conductive targets. In this presentation, warm colours shading red-to-purple designate electrically-conductive strata consistent with brine aquifers in a salar setting. Cold colours (blue-white) represent resistive units interpreted to lack lithium brine potential. The presented resistivity unit is Ohm-m.
Based on published drill data and geophysics from similar salar projects, the Company expects prospective aquifer zones to exhibit resistivities below approximately 5 Ohm-m. Brine-rich porous units are expected to produce resistivities on the order of 1 Ohm-m.
David Terry, Ph.D., P.Geo. is the Company's Qualified Person as defined in National Instrument 43-101. Dr. Terry is responsible for oversight of the Company's early-stage exploration at the Rincon West property. The disclosure in this news release has been reviewed and approved by Dr. Terry.
Argentina Lithium & Energy Corp is focused on acquiring high quality lithium projects in Argentina, and advancing them towards production in order to meet the growing global demand from the battery sector. The management group has a long history of success in the resource sector of Argentina, and has assembled a first rate team of experts to acquire and advance the best lithium properties in the world renowned "Lithium Triangle". The Company is a member of the Grosso Group, a resource management group that has pioneered exploration in Argentina since 1993.
ON BEHALF OF THE BOARD
"Nikolaos Cacos"
_________________________________
Nikolaos Cacos, President, CEO and Director
Facebook, Twitter, LinkedIn, Google+
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. All statements, other than statements of historical fact, that address activities, events or developments the Company believes, expects or anticipates will or may occur in the future, including, without limitation, statements about the Company's plans for its mineral properties; the Company's business strategy, plans and outlooks; the future financial or operating performance of the Company; and future exploration and operating plans are forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things: the impact of COVID-19; risks and uncertainties related to the ability to obtain, amend, or maintain licenses, permits, or surface rights; risks associated with technical difficulties in connection with mining activities; and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations. Actual results may differ materially from those currently anticipated in such statements. Readers are encouraged to refer to the Company's public disclosure documents for a more detailed discussion of factors that may impact expected future results. The Company undertakes no obligation to publicly update or revise any forward-looking statements, unless required pursuant to applicable laws. We advise U.S. investors that the SEC's mining guidelines strictly prohibit information of this type in documents filed with the SEC. U.S. investors are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on our properties.
View original content to download multimedia:
SOURCE Argentina Lithium & Energy Corp. | https://www.whsv.com/prnewswire/2022/05/02/argentina-lithium-geophysics-delineates-potential-extent-conductive-brine-aquifers-rincon-west/ | 2022-05-02T11:47:42Z |
NEW YORK, May 2, 2022 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH" or the "Company") (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator focused on bettering lives through cannabis, today announced its participation in the following upcoming conferences:
- 6th Annual Canaccord Genuity Cannabis Conference: CEO and Founder, Abner Kurtin, will participate in a virtual fireside chat on Wednesday, May 11th at 8:00 am ET. The webcast can be accessed here and will be available for 90 days.
- Wolfe Research Virtual Consumer Conference: CEO and Founder, Abner Kurtin, will participate in a virtual panel alongside Curaleaf, Verano, and Ayr on Friday, May 13th at 12:55 pm ET. The team will also participate in 1x1 meetings throughout the day. Contact your Wolfe representative for more information at sales@wolferesearch.com
AWH is a vertically integrated multistate cannabis operator with licenses and assets in Illinois, Michigan, Ohio, Massachusetts, New Jersey, and Pennsylvania. AWH owns and operates state-of-the-art cultivation facilities, growing award-winning strains and producing a curated selection of products for retail and wholesale customers. AWH produces and distributes its in-house Simply Herb, Ozone, and Ozone Reserve branded products. For more information, visit www.awholdings.com.
View original content to download multimedia:
SOURCE Ascend Wellness Holdings, LLC | https://www.whsv.com/prnewswire/2022/05/02/awh-announces-participation-upcoming-conferences-may/ | 2022-05-02T11:47:49Z |
No clinical efficacy or safety issues raised and no additional clinical studies required by FDA to support approval
Company plans to engage with FDA toward expeditious resolution of outstanding items
NEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval of AXS-07.
The principal reasons given in the CRL relate to chemistry, manufacturing, and controls (CMC) considerations. The CRL identified the need for additional CMC data pertaining to the drug product and manufacturing process. Axsome believes that the issues raised in the CRL are addressable and intends to provide potential timing for a resubmission following consultation with the FDA.
"It is our goal to work with the FDA to fully understand and adequately address their comments, so that we can make this important new medicine available to patients with migraine as quickly as possible," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "The approval of AXS-07 would offer a much-needed new multi-mechanistic treatment option for the millions of people living with this debilitating neurological condition."
The NDA is supported by results from two Phase 3 randomized, double-blind, controlled trials of AXS-07 in the acute treatment of migraine, the MOMENTUM and INTERCEPT trials, which demonstrated statistically significant elimination of migraine pain with AXS-07 compared to placebo and active controls.
About Migraine
Over 37 million Americans suffer from migraine according to the Centers for Disease Control, and it is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation. Migraine is characterized by recurrent attacks of pulsating, often severe and disabling head pain associated with nausea, and sensitivity to light and or sound. It is estimated that migraine accounts for $78 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) costs each year in the United States [1]. Published surveys of migraine sufferers indicate that more than 70% are not fully satisfied with their current treatment, that nearly 80% would try a new therapy, and that they desire treatments that work faster, more consistently, and result in less symptom recurrence [2,3].
About AXS-07
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan. Meloxicam is a new molecular entity for migraine enabled by Axsome's MoSEIC™ (Molecular Solubility Enhanced Inclusion Complex) technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. Meloxicam is a COX-2 preferential non-steroidal anti-inflammatory drug and rizatriptan is a 5-HT1B/1D agonist. AXS-07 is designed to provide rapid, enhances and consistent relief of migraine, with reduced symptom recurrence. AXS-07 is covered by more than 80 issued U.S. and international patents which provide protection out to 2036. AXS-07 is not approved by the FDA.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company's website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.
References
- Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol. 2017 Apr; 81(4):479-484.
- Smelt AF, Louter MA, Kies DA, Blom JW, Terwindt GM, van der Heijden GJ, De Gucht V, Ferrari MD, Assendelft WJ. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS One. 2014 Jun 16;9(6):e98933.
- Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(suppl 2):S20-S26
Forward Looking Statements
Certain matters discussed in this press release are "forward-looking statements". We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application ("NDA") for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, whether potential filing issues or issues identified by FDA during the substantive review may impact the potential approvability of the Company's NDA submission for AXS-05 in MDD or the timing of such approval; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company's NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the Company's commercial launch of its product candidates, and the potential impact on the Company's anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Axsome Contact:
Mark Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
22 Cortlandt Street, 16th Floor
New York, NY 10007
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
View original content to download multimedia:
SOURCE Axsome Therapeutics Inc | https://www.whsv.com/prnewswire/2022/05/02/axsome-therapeutics-receives-fda-complete-response-letter-new-drug-application-axs-07-acute-treatment-migraine/ | 2022-05-02T11:47:55Z |
Company to host conference call today at 8:00 AM Eastern
NEW YORK, May 2, 2022 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2022.
"Axsome is poised to transform into a commercial entity potentially as early as this month, a direct result of our dedicated team's focused execution. Between pending FDA action on our NDA for AXS-05 in depression and the expected closing of our acquisition of Sunosi, Axsome is well-positioned to potentially make two important new medicines available to patients living with serious CNS disorders in the coming months," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "With regards to AXS-07 for migraine, we look forward to engaging with the FDA to address the issues in the recent complete response letter, with the goal of an expeditious resubmission of that NDA. The rest of our rich pipeline continues to progress with an NDA filing for AXS-14 in fibromyalgia, and topline results from our Phase 3 trials of AXS-12 in narcolepsy and AXS-05 in Alzheimer's disease agitation anticipated in 2023."
Business Update
Axsome is committed to developing medicines that meaningfully improve the lives of patients living with CNS disorders. The Company is advancing a portfolio of differentiated, patent-protected, CNS product candidates with four in active clinical development.
AXS-05
AXS-05 (dextromethorphan-bupropion) is Axsome's novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the following indications: major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designations for MDD and for AD agitation.
- Depression: Axsome's New Drug Application (NDA) for AXS-05 for the treatment of MDD was granted Priority Review and is currently under review by the FDA. The Company has received and agreed to Postmarketing Requirements/Commitments proposed by the FDA. Based on this interaction, the Company anticipates potential FDA action on the NDA in the second quarter of 2022.
- Alzheimer's Disease Agitation: Axsome is conducting the ACCORD study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial to evaluate the efficacy and safety of AXS-05 in the treatment of Alzheimer's disease (AD) agitation. The Company is evaluating the design of the study and will provide an update following consultation with the FDA.
- Smoking Cessation: Axsome plans to proceed to a pivotal Phase 2/3 trial in this indication. The Company intends to provide information on the timing of initiation of this study in 2022.
AXS-07
AXS-07 (MoSEIC™ meloxicam-rizatriptan) is Axsome's novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine.
- Migraine: Axsome received a Complete Response Letter (CRL) from the FDA regarding its NDA for AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA and the FDA did not request any new clinical trials to support the approval of AXS-07. The principal reasons given in the CRL relate to chemistry, manufacturing, and controls (CMC) considerations. The Company believes that the issues raised in the CRL are addressable, and intends to provide potential timing for a resubmission following consultation with the FDA.
AXS-12
AXS-12 (reboxetine) is Axsome's novel, oral, potent, and highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for the treatment of narcolepsy.
- Narcolepsy: Axsome is conducting the SYMPHONY study, a Phase 3 randomized, multicenter, double-blind, placebo-controlled, parallel-group trial of AXS-12 in the treatment of narcolepsy. Enrollment in the trial is progressing and topline results are anticipated in the first half of 2023.
AXS-14
AXS-14 (esreboxetine) is Axsome's novel, oral, potent, and highly selective norepinephrine reuptake inhibitor for the management of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.
- Fibromyalgia: Manufacturing and other activities related to the planned submission of an NDA for AXS-14 for the management of fibromyalgia are ongoing. The Company expects to submit the NDA in 2023. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the management of fibromyalgia.
Corporate
- In March 2022, Axsome announced that the Company entered into a definitive agreement to acquire Sunosi® (solriamfetol) from Jazz Pharmaceuticals (NASDAQ: JAZZ). Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA). Sunosi net sales were $57.9 million in 2021, representing year-over-year growth of 104%.
The waiting period applicable to the acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired. The transaction is structured to be completed in sequential closings for the U.S. and ex-U.S. territories. The Company expects the U.S. transaction to close in the second quarter of 2022, and the ex-U.S. transaction to close within 60 days following the U.S. transaction close.
Commercial and Launch-Readiness Activities
Axsome is prepared for a commercial launch of AXS-05 for the treatment of MDD, if approved, and is ready to assume commercialization of Sunosi upon closing of that acquisition:
- The AXS-05 field force team build is complete with all signed offers contingent upon approval. The Company anticipates having all field representatives for the product candidate on-board by launch.
- Activities are underway to ensure a timely and seamless transition of Sunosi into the Axsome infrastructure upon closing of the transaction.
- Axsome's first-in-class Digital Centric Commercialization™ (DCC) platform will be used to augment commercialization of both AXS-05 and Sunosi.
Anticipated Milestones
- Corporate:
- Regulatory and Commercial:
- Clinical Trial Readouts:
First Quarter 2022 Financial Results
- Research and development (R&D) expenses: R&D expenses were $12.6 million for the three months ended March 31, 2022 and $16.6 million for the comparable period in 2021. The decrease was driven by expenses related to the NDA filing which occurred in the prior comparable period.
- General and administrative (G&A) expenses: G&A expenses were $25.7 million for the three months ended March 31, 2022 and $11.2 million for the comparable period in 2021. The increase was primarily related to pre-commercial activities and personnel expense, along with an increase in non-cash stock compensation expense.
- Net loss: Net loss was $39.6 million, or $(1.03) per share, for the three months ended March 31, 2022 compared to a net loss of $29.3 million, or $(0.78) per share, for the comparable period in 2021. The net loss for the current period included $7.6 million of non-cash stock compensation expense compared to $3.7 million in the comparable period.
- Cash: At March 31, 2022, Axsome had $84.7 million of cash compared to $86.5 million at December 31, 2021.
- Shares outstanding: At March 31, 2022, Axsome had 38,883,445 shares of common stock outstanding.
Financial Guidance
- Axsome believes that its current cash, along with the remaining committed capital from the $300 million term loan facility, is sufficient to fund anticipated operations into 2024, based on the current operating plan, which includes the potential launch of AXS-05 in MDD, and the acquisition and commercialization of Sunosi.
- Axsome expects that its operating expenses will increase year over year as it continues to build out the commercial function and further advance its pipeline.
Conference Call Information
Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss first quarter 2022 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) and use the conference ID 152950. The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company's website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company's website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.
Forward Looking Statements
Certain matters discussed in this press release are "forward-looking statements". We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application ("NDA") for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, whether potential filing issues or issues identified by FDA during the substantive review may impact the potential approvability of the Company's NDA submission for AXS-05 in MDD or the timing of such approval; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company's NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the Company's commercial launch of its product candidates, and the potential impact on the Company's anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Axsome Contact:
Mark Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
22 Cortlandt Street, 16th Floor
New York, NY 10007
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
View original content to download multimedia:
SOURCE Axsome Therapeutics Inc | https://www.whsv.com/prnewswire/2022/05/02/axsome-therapeutics-reports-first-quarter-2022-financial-results-provides-business-update/ | 2022-05-02T11:48:02Z |
Scientific Advisory Board Will Review Company Innovation Pipeline and Advise on Emerging Trends in Health Care, Science and Technology
FRANKLIN LAKES, N.J., May 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the inaugural members of the BD Scientific Advisory Board (SAB), which is comprised of top external medical key opinion leaders, science and technology experts and experienced innovation leaders.
The SAB will advise BD on the company's technology capabilities, innovation pipeline, tuck-in M&A opportunities, early-stage investments and growth prioritization, along with emerging trends in health care, science and technology, and the potential implications for BD.
"Innovation is the driving force in our strategy to grow and deliver an even more significant impact toward improving outcomes for patients and providers," said Tom Polen, chairman, chief executive officer and president of BD. "Our vision is to actively lead in emerging science that will transform health care. The scientific advisory board brings leading experts to help pressure-test our portfolio and strategy, while also providing real-world practicality for future technologies."
Inaugural members of the SAB include:
- John DeFord, PhD: DeFord serves as an adviser to BD and co-chair of the BD SAB. He is a member of the Weldon School of Biomedical Engineering Advisory Board and executive faculty at Purdue University's Krannert School of Management and Weldon School of Biomedical Engineering. DeFord is also a member of the board of directors of Nordson Corporation and NuVasive.
- Claire Fraser, PhD: Fraser is the director of the Institute for Genome Sciences, a professor of Medicine, Microbiology and Immunology at the University of Maryland School of Medicine and a member of the BD board of directors. Fraser is also a member of the National Academy of Medicine and recent past chair of the board for the American Association for the Advancement of Science.
- Martha Gray, PhD: Gray is the J. W. Kieckhefer professor of Health Sciences and Technology at Massachusetts Institute of Technology (MIT) and professor of Electrical Engineering and Computer Science. She has spent the past two decades establishing a new paradigm for research in the academy that has proven to provide an innovation pipeline for biomedical technology.
- Eric Perakslis, PhD: Perakslis is the chief science and digital officer at the Duke Clinical Research Institute. His work focuses on collaborative efforts in data science that have spanned medicine, policy, engineering, computer science, information technology and security.
- Ken Sands, MD, PhD: Dr. Sands is the chief epidemiologist of HCA Healthcare, leading enterprise-wide initiatives for HCA Healthcare's 182 hospitals and approximately 2,300 ambulatory sites of care in the U.S. and U.K.
- Jay Schnitzer, MD, PhD: Dr. Schnitzer is senior vice president, chief technology officer and chief medical officer at the MITRE Corporation. In this role, he directs the organization's independent research and development program and manages development of corporate technology strategy, which spans MITRE's operating centers and sponsor community.
"We're at an inflection point where advances in science, technologies like data science and artificial intelligence, and new care models are opening up unprecedented opportunities to improve and reshape what health care looks like," said Joseph (Joe) Smith, MD, PhD, chief scientific officer at BD and co-chair of the SAB. "The board will help us build on our momentum by advising on evolving care pathways and emerging technologies that can enhance or disrupt our near- and long-term innovation pipelines to ensure we're creating the best solutions for the billions of patients we serve."
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
View original content to download multimedia:
SOURCE BD (Becton, Dickinson and Company) | https://www.whsv.com/prnewswire/2022/05/02/bd-announces-inaugural-members-scientific-advisory-board/ | 2022-05-02T11:48:09Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.